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 The human gut microbiome is one of the most biochemically rich ecosystems in nature, 
with approximately 1000 bacterial species, trillions of cells, and millions of genes, and is 
intimately connected to human health. One of the ways in which the gut microbiome impacts 
human health is through the action of bacterial β-glucuronidases (GUSs), glycoside hydrolases 
that metabolize a myriad of glucuronides including drugs and endobiotics. Here we show our 
efforts to characterize and inhibit gut bacterial GUSs. Using a panel of unique gut microbial 
GUS enzymes derived from the 279 mapped from the human gut microbiome, we found that 
only four were capable of processing the tyrosine kinase inhibitor used to treat colorectal cancer, 
regorafenib-glucuronide. A pilot screen identified the FDA-approved drug raloxifene as an 
inhibitor of regorafenib-reactivation. Using a similar panel, we provide the first in vitro analysis 
of the ability of GUS enzymes from the human gut microbiome to reactivate two distinct 
estrogen glucuronides, estrone-3-glucuronide and estradiol-17-glucuronide, to estrone and 
estradiol, respectively. These findings confirm that gut microbial GUS enzymes participate in the 
estrobolome but suggest that the estrobolome is a multidimensional set of ongoing processes 
within the mammalian gastrointestinal tract that likely involves many enzymes. Finally, we 
sought to characterize a family of enzymes known as sulfatases that similarly reverse the action 
of Phase II metabolism. Here we determined the crystal structures of two toward understanding 
iv 
unique structural motifs that may guide microbial sulfatase substrate specificities observed with 
distinct substrates and we show that these sulfatases exhibit differential activities with distinct 
sulfated endogenous substrates. Taken together, the work outlined in this dissertation charts the 
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CHAPTER 1: RELATIONSHIP BETWEEN THE GUT MICROBIOME 
AND SYSTEMIC CHEMOTHERAPY1 
 
Introduction 
 The human gastrointestinal (GI) tract is home to a complex microbial ecosystem that 
houses a microbial community (the gut microbiota), consisting of approximately 1013 microbial 
cells (1). Collectively, the aggregate genomes of the gut microbiota encode >100x more unique 
genes compared to the human genome (2).  Therefore, it is no surprise these genes and their 
encoded metabolic activities expand host metabolic capabilities and significantly influence 
neurology, immune response, endocrinology, disease states and clinical outcomes (3-11). In 
particular, this review focuses on the implications of the microbiota on chemotherapy-induced 
GI toxicity.  
 Chemotherapy induced GI toxicity (C-GIT) is a frequent complication of cancer 
treatment with a variety of symptoms including nausea, vomiting, diarrhea, and constipation 
(12). C-GITs are often serious adverse events that may significantly harm the patients’ prognosis 
since often, the primary treatments are dose reductions or treatment interruptions (13). The 
incidence of chemotherapy‐induced diarrhea has been reported as high as 50–80% in patients 
undergoing systemic chemotherapy. 31% of patients undergoing chemotherapy for colorectal 
cancer experience diarrhea severe enough to require dose delay/reduction, and patient 
hospitalization (14-16). Studies have shown that chemotherapeutic drugs increase intestinal 
permeability and modulate gut microbiota, which collectively contribute to C-GIT (13, 17) 
Recent advances suggest that gut microbiota may be used to predict C-GIT (18, 19). Hence, 
2 
characterizing the chemotherapy-induced changes in microbiota composition may reveal new 
insights into the development and management of C-GIT.  
 Here we define C-GIT, and catalog what is currently known about the role of individual 
microbes, their associated enzymes, and their small molecule products which may influence 
systemic chemotherapy-induced GI toxicity. Finally, we outline ways in which the GI microbiota 
can be modulated in response to chemotherapy and the implications on patient outcome. 
Chemotherapy Induced Gastrointestinal Toxicity  
Mucositis is the principal manifestation of oral toxicity in patients receiving 
chemotherapy. 20–40% of patients receiving conventional-dose cytotoxic chemotherapy develop 
oral mucositis of varying severity (20, 21). The focus of this review, gastrointestinal (GI) side-
effects following chemotherapy, is also a common problem in cancer management. Nausea, 
vomiting, ulceration, bloating, constipation, and diarrhea, cause dose-delays, dose-adjustments, 
and discontinuation of treatment whilst adversely impacting quality of life in many cancer 
patients.  
Chemotherapy induced nausea and vomiting (CINV) negatively impact patients’ quality 
of life, nutritional status, and day-to-day functioning (22). These side effects impact adherence to 
chemotherapy regimens leading to treatment delays, fewer treatments, or lower than 
recommended dosages, which in turn may result in suboptimal clinical outcomes, potentially 
increasing health care-related resource utilization and costs (23). CINV is categorized as acute, 
delayed, breakthrough, refractory, or anticipatory (Table 1.1), and these distinctions have 
important implications in management (24). 
Chemotherapy patients frequently also experience constipation, likely due to decreased 
oral intake, and drugs that slow intestinal transit time e.g. opioid analgesics and antiemetic 
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agents (25). Constipation is rarely a dose-limiting toxicity except with vincristine and other vinca 
alkaloids, which have pronounced neuropathic effects and increase gastrointestinal transit time 
(26). Laxatives are used both preventatively and prophylactically. Senna, docusate and bisacodyl 
are commonly used, and if ineffective, magnesium salts, polyethylene glycol, lactulose or 
sorbitol are considered (27). Opiod analgesic-associated constipation is managed with 
methylnaltrexone (28). 
Risk of gastrointestinal perforation (GIP) is increased with patients receiving anti-VEGF 
targeting agents (29), possibly due to intestinal wall disruption in areas of tumor necrosis, sub-
mucosal inflammation and resultant ulcers. GIP may be clinically asymptomatic or may present 
with abdominal pain and may be complicated by intra-abdominal abscess formation and can 
occasionally be fatal. To decrease this risk, >28 days should elapse between surgery and the last 
dose, except in emergency situations (30), with immediate and permanent discontinuation of the 
anti-VEGF agent following perforation. Unstable patients with confirmed or high possibility of 
GIP should be considered for immediate surgical repair. Less invasive management strategies 
like bowel rest and antibiotics with/without percutaneous intraabdominal abscess drainage are 
used in patients who are more stable (31, 32). 
Chemotherapy patients frequently experience constipation, likely due to decreased oral 
intake, and drugs that slow intestinal transit time e.g. opiod analgesics and antiemetic agents 
(25). Constipation is rarely a dose-limiting toxicity except with vincristine and other vinca 
alkaloids, which have pronounced neuropathic effects and increase gastrointestinal transit time 
(26). Vandetanib (33) and Belinostat (34) also cause constipation in patients. Laxatives are used 
both preventatively and prophylactically. Senna, docusate and bisacodyl are commonly used, and 
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if ineffective, magnesium salts, polyethylene glycol, lactulose or sorbitol are considered (27). 
Opiod analgesic-associated constipation is managed with methylnaltrexone (28).  
Finally, and perhaps most significantly, chemotherapy related diarrhea (CRD) is the most 
common dose-limiting side effect of chemotherapeutic intervention.  For example, regimens of 
fluoropyrimidines (5-fluorouracil, capecitabine) and irinotecan are associated with rates of CRD 
of up to 80% (35,36) with 1/3 patients experiencing severe diarrhea (37). Pemetrexed, 
cabazitaxel, bortezomib, vorinostat, and some targeted agents like sorafenib, sunitibib, afatinib, 
ceritinib, and other agents that target epidermal growth factor receptor (EGFR) have also been 
associated with CRD. Thus, CRD is a pervasive complication of chemotherapy and 
understanding its occurrence and mechanism is key to finding preventative treatment options. 
CRD occurs through three major different mechanisms: increased secretion of 
electrolytes caused by luminal secretagogues or reduced absorptive capacity (due to surgery or 
epithelial damage), called secretory diarrhea; increased intraluminal osmotic substances leading 
to osmotic diarrhea; or altered GI motility. CRD typically begins with an increasing frequency of 
bowel movements and/or a loosening of the stool consistency, with accompanying intestinal gas 
and/or excessive gas, and can progressively become severe, with frequent watery stools. CRD 
can be debilitating and, in some cases, life-threatening. Patients may present with volume 
depletion, acute kidney injury, and electrolyte disorders, such as hypokalemia, metabolic 
acidosis, and depending upon water intake, hyponatremia or hypernatremia. Loperamide is a 
synthetic opioid derivative and it is one of the few drugs for treating CRD. Given the risk for 
dehydration and infection, severe CRD (Table 1.2) frequently require hospital admission for 
adequate supportive care. 
5 
Certain chemotherapeutics also induce specific colitis syndromes including neutropenic 
enterocolitis, ischemic colitis, and Clostridioides difficile-associated colitis. Neutropenic colitis 
presents with fever, abdominal pain, watery or bloody diarrhea and frank hematochezia in 
patients with neutropenia; it is one of the most frequently observed GI complications in leukemic 
patients who are undergoing induction therapy (38). A small number of ischemic colitis cases 
have been reported with docetaxel-containing regimens in patients with metastatic breast cancer, 
which typically presents with abdominal pain and tenderness over affected bowel along with 
rectal bleeding and bloody diarrhea (39). C. difficile-associated colitis is a common problem in 
patients with cancer, mostly due to high rate of oral antibiotic use and hospitalization (40).  
Patients with grade 1 or 2 CRD, without complicating risk factors, discontinue cytotoxic 
chemotherapy; in-home supportive care consists of oral hydration, dietary modifications, and 
loperamide, which is dose escalated in case of non-response, with addition of octreotide if 
symptoms persist (35). However, hospitalization is required with persistent mild to moderate 
diarrhea, or progressive severe/complicated diarrhea necessitating intravenous hydration. Urgent 
abdominal and pelvic computerized tomography scans are required in patients with fever, 
peritoneal signs, or bloody diarrhea. Most chemotherapies are withheld for ≥grade 2 diarrhea, 
and restarted only after toxicity resolves; such interruption of treatment may reduce survival 
(41). 
To combat CRD, uridine triacetate may be considered in patients who develop diarrhea, 
mucositis, and myelosuppression during their first chemotherapy cycle containing 
fluoropyrimidine, if deficiency of one of the fluoropyrimidine metabolizing enzymes is 
suspected (42). Esophagogastroduodenoscopy with duodenal biopsy and aspirate, and 
colonoscopy can be considered in patients who are refractory to loperamide and octreotide to 
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rule out viral infections like CMV and small intestinal bacterial overgrowth (43). Ultimately, 
however, the most effective way to combat CRD is with dose-delays and dose-reductions. For 
this reason, examining the impact of the microbiota on drug metabolism is key in finding and 
validating new CRD treatments.  
Dietary Interventions to Reduce Chemotherapy-induced Toxicity 
The GI tract is directly exposed to the metabolism of nutrients, has a high rate of cell 
turnover, and shows plasticity in response to nutritional stimuli (5,6,44). As such, it is an 
attractive target to consider in the mitigation of toxic side effects of chemotherapy. One way the 
GI can be easily targeted is through dietary interventions; these dietary changes may lessen 
injury to normal tissues and alleviate GI toxicity associated with chemotherapy. 
Diverse dietary elements, including amino acids, fatty acids, oligosaccharides, minerals, 
vitamins, and antioxidants have been suggested to modulate GI toxicities related to cancer 
treatments (45). Dietary interventions interfere with the mechanisms of drug toxicity by 
modulating pharmacokinetics of anticancer drugs and altering key mechanisms of injury (17, 
45). Additionally, dietary interventions may mitigate injury to nontumor tissues by modulating 
immune responses, cytokine/hormone network, cellular protective and repair machinery, and 
signaling events involved in regulating the cell cycle and cell proliferation or death (45,46). 
Although preclinical findings suggest a beneficial role in the use of therapeutic nutritional 
supplements, more work is required to develop effective adjuvants during anticancer treatments. 
Microbial Changes During and Following Chemotherapy 
Several studies have investigated the effect of systemic cancer therapy on gut microbiota 
composition. These studies span different cancer types, as well as different chemotherapeutic 
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agents and treatment settings. Here we outline a few of these studies and their impact on patient 
prognosis and outcome.  
During a five-day high-dose chemotherapy regimen, Montassier et al. (47) observed a 
significant reduction in the microbial richness and diversity of the GI tract, indicating a 
significant reduction in diversity due to chemotherapy. Overall abundance of Bacteroidetes and 
Proteobacteria was increased, while Firmicutes and Actinobacteria were decreased (47). Thus, 
high-dose chemotherapy causes a marked decrease in overall microbial diversity and shifted the 
microbial community structure. Furthermore, there was a statistically significant shift from 
Gram-positive bacteria to Gram-negative bacteria during chemotherapy (47). A similar 
observation was described by Zwielehner et al. (48). 
  Using 16S rRNA sequencing, Galloway-Peña et al. identified a progressive decrease in 
overall microbial diversity in the microbiota of patients with acute myeloid leukemia during 
chemotherapy (49). More specifically, they noted a decreased abundance of the anaerobic genus 
Blautia and an increased abundance of Lactobacillus (49). Interestingly, chemotherapy also 
increased the occurrence of intestinal domination, where more than 30% of the intestinal bacteria 
belong to a single taxon. Most of the domination events were caused by opportunistic pathogenic 
bacteria, including Staphylococcus, Enterobacter, and Escherichia (49).  
Youssef et al. collected fecal samples of 13 healthy controls and 20 patients that had been 
treated for gastrointestinal neoplasms (50). Patients treated with chemotherapy and/or 
radiotherapy had a significantly higher relative abundance of Lactobacillaceae and Lactobacillus 
compared to untreated patients. In comparison to healthy controls, treated patients had a 
significantly lower relative abundance of Bifidobacteriaceae, Ruminiclostridium, 
Lachnoclosteridium, and Oscillibacter (50). Similarly, Deng et al. compared fecal microbiota 
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composition of 14 CRC patients treated with tegafur and oxaliplatin against 33 healthy controls 
(18). Compared to healthy controls, the species Veillonella dispar was only present in CRC 
patients. Additionally, Prevotella copri and Bacteroides plebeius were enriched in patients 
treated with chemotherapy compared to controls (18). Additionally, Stringer et al. demonstrated 
that cancer patients receiving chemotherapy for different cancer types were characterized by a 
decreased relative abundance of Lactobacillus spp., Bacteroides spp., Bifidobacterium spp., and 
Enterococcus spp. compared to healthy controls; Increased relative abundance was found for 
Escherichia coli and Staphylococcus spp. (19).  
Thus, gut dysbiosis following treatment seems ubiquitous over different types of cancer, 
and different treatments. However, recent studies have suggested that this dysbiosis may also be 
used to predict prognosis. Taur et al. divided patients into low-, intermediate- or high-diversity 
cohorts after allogenic hematopoietic stem cell transplantation (allo-HSCT); low microbial 
diversity was associated with a 31% reduction in 3-year survival compared to high diversity (51). 
Similarly, in a cohort of patients with metastatic renal cell carcinoma (RCC), patients could be 
clustered based on relative abundance at the genus level into low-risk and high-risk groups (52). 
The high-risk group had a high abundance of Bacteroides (42%) and a low level of Prevotella 
(3%) (52). In the low-risk group, the opposite pattern was apparent with 47% Prevotella and 
13% Bacteroides. Thus, the same may be true for predicting patient side effects; by identifying 
high-risk and low-risk groups before care, medical intervention can be taken before patients 
experience life-threatening side effects.  
Defining the distinct mechanisms that cause GI toxicity can guide treatments for GI 
adverse effects of chemotherapeutics. By uncovering the breadth of effects of chemotherapies on 
gut bacteria, we may be able to devise methods to control some of these effects. Attempts must 
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be made to understand the breadth of effects of chemotherapy on the gut microbiota, in order to 
determine how to control these effects. Furthermore, predicting patient outcomes based on 
species abundance and diversity of the microbiome could prove to be a powerful tool in 
combating chemotherapy-induced toxicity, but at present, efficient and facile techniques to attain 
this goal do not exist. Elucidating the functional significance of individual microbes and the 
collective microbiota may help achieve these goals, and thus, improve patient care.  
Probiotics to Reduce Chemotherapy-induced Toxicity 
The concept that bacteria or their products play a therapeutic role in cancer is not new; in 
1891, Coley used the toxins from Streptococcus erysipelas and Serratia maracens to treat 
sarcoma (53, 54) and Mycobacterium bovis is still used in the treatment of superficial bladder 
cancer (55). Furthermore, probiotics have been successfully used to treat diarrhea in patients 
with irritable bowel syndrome (56), ulcerative colitis (57), pouchitis, (58,59) and Crohn's disease 
(60). More recently, innovative possibilities for the genetic engineering of bacteria for delivery 
of chemotherapy, or as vectors for genetic therapy, are emerging (61). 
In a study by Yuvaraj et al, E.coli was genetically modified to enable excretion of a 
tumor suppressor, human bone morphogenic protein-2 (62). E. coli’s quorum sensing feedback 
loops were similarly manipulated to synchronously lyse E. coli engineered to express the 
antitumor toxin Hemolysin E. This resulted in  apoptosis in vitro, with tumor regression and 
increased mean survival in vivo when administered in combination with 5-FU (63).  Thus, 
manipulating E. coli may be a promising avenue in the development of probiotics to reduce 
chemotherapy induced toxicity.   
Despite these promising results, and multiple case studies where probiotics have been 
successfully delivered to alleviate chemotherapy-induced gut toxicity (64-66), the relationship 
between chemotherapy-induced diarrhea and the beneficial effects of probiotics administration is 
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extremely complex. Further research is necessary to understand the response and underlying 
mechanisms by which specific probiotics alleviate chemotherapy-induced diarrhea. Defining 
beneficial probiotics will facilitate developing targeted therapies and adjuvants that improve 
patient outcome. 
Drug Metabolism by the Gut Microbiota 
That gene polymorphisms contribute to differences in drug metabolism was first noted in 
1957, when it was found that atypical forms of serum cholinesterase led to fatal reactions with 
certain anesthetics (67). Adverse drug reactions are estimated to cost from 30 to 130 billion 
dollars in the USA annually and are primary contributors to drug failure and patient 
noncompliance (68). Cytochrome P450 oxidases (CYPs) are generally considered the primary 
drug metabolizers in the body, by altering the xenobiotic through oxidation, after which, 
transferases then conjugate the product with a glucuronic acid or sulfate, forming polar derivates 
that can be excreted via bile or urine. Distinct from host genomes, the gut microbiome encodes 
enzymes capable of metabolizing xenobiotics in unique and unappreciated ways. More than 60 
bioactive compounds are known to undergo direct and indirect gut microbial modifications (69-
74). These modifications inactivate and reactivate drug products, often resulting in detrimental 
side effects to the host. Some of the direct transformations include reduction, ring-opening, 
demethylation, deamination, deacylation, and decarboxylation (Figure 1.1). 
Direct Metabolism 
Direct forms of biotransformation have profound effects on drug metabolism, leading to 
drug inactivation, production of harmful byproducts, or reduced bioavailability, indicating the 
importance of elucidating chemical implications of the microbiome on drug efficacy and 
potential off-target effects.  
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To date, the most widely described incidences of metabolism by the gut microbiota are 
the in form of reduction reactions. The most striking example of this type of reduction is with the 
drug, digoxin, used to treat congestive heart failure. The intestinal microbe Eggerthella lenta 
reduces a single double bond leading to complete inactivation of digoxin (75) (Figure 1.1A). 
Reductive metabolism of a range of 5-aminosalicylic acid prodrugs (e.g. sulfasalazine, used in 
the treatment of inflammatory bowel diseases) by gut bacterial azoreductases releases the active 
agent, aminosalicylic acid (76). Similarly, gut microbial nitroreductases are also known to 
metabolize benzodiazepenes (77). Taken together, reduction reactions play key roles in 
xenobiotic metabolism within the gut. 
Gut bacteria undertake remarkably complex chemistry; for example, incubating 
Bacteroides and Clostridia with the anthelmintic drug, levamisole resulted in thiazole ring–
opened metabolites including levametabol I, which may possess antitumor activity (Figure 1.1B) 
(78). Such intricate chemistry underscores the complexity and diversity of gut microbial 
enzymes, and the importance of defining microbial metabolic products.  
The gut microbiota performs other biotransformations including demethylation, 
deacylation, and deamination. For example, in 1974 Smith et. al. demonstrated that bucetin, 
formanilide, and acetaminophen (Figure 1.1C) are deacylated when incubated with rat caecal 
microflora (79). The deacylation of acetaminophen results in the toxic product p-aminophenol 
(79). More recently, Zimmermann et al. measured the ability of 76 human gut bacteria to 
metabolize diverse drugs, and demonstrated bacterial deacylation of the blood pressure 
medication, diltiazem (80). The demethylation of imipramine (Figure 1.1D) (81), and 
demethylation of methamphetamine has also been shown to occur in bacterial species from the 
GI tract (82). Importantly, the deamination of 5-fluorocytosine to 5-fluorouracil (5-FU) (Figure 
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1.1E), and the associated toxicity of this chemotherapeutic has been linked to the gut 
microbiome (83,84). Taken together, deacylation, demethylation, and deamination reactions 
further implicate the gut microbes in the biotransformation of a host of different compounds, 
having effects on a wide variety of diseases and disorders.  
Finally, the decarboxylation reaction of L-dopa (levodopa) to dopamine is another 
example of a well-known metabolism by a gut microbial enzyme. Used in the treatment of 
Parkinson’s disease, L-DOPA crosses the blood-brain barrier where it is decarboxylated to 
dopamine; it has been shown that the gut microbiota is capable of this decarboxylation reaction, 
resulting in reduced bioavailability of L-DOPA (Figure 1.1F) (85-88). Eradication of H. pylori 
with antibiotics increases L-DOPA bioavailability in Parkinson patients, with a single antibiotic 
dose improving motor symptoms for 3 months or more (89). 
Zimmermann et al also elegantly combined experimental and computational approaches 
to unravel the complex metabolism of the antiviral, brivudine, and the anxiolytic, clonazepam 
(90); bacterial and host metabolism of both of these compounds generates chemically 
indistinguishable metabolites. This study demonstrates that cutting-edge, multidisciplinary 
approaches aid in dissecting the role of the microbiota in complex drug metabolism, with a view 
towards personalizing drug responses and mitigating side effects.  
Indirect Metabolism  
The gut microbiota influences the therapeutic response of immunotherapy; here we 
describe how the microbiota indirectly impacts drug metabolism and associated toxicity through 
diverse mechanisms e.g. altered host gene expression, competition for host enzymes, generating 
pathway intermediates, and enterohepatic recycling of xenobiotics (Figure 1.2).  
The first example of indirect metabolism is through the alteration of host gene 
expression. Several studies have shown that the hepatic expression of CYP450 genes differs 
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between conventional and germ-free (GF) states (91-93), and the latter have increased expression 
of constitutive androstane receptor (CAR), a key regulator of both endobiotic and xenobiotic 
metabolism (93) (Figure 1.2A). Elevated CAR levels result in increased rates of xenobiotic 
metabolism, resulting in GF mice recovering 35% faster from pentobarbital-induced anesthesia 
compared to conventional animals (93). Therefore, studies with GF animals help define host 
responses to pharmaceuticals including systemic chemotherapy, and their potential off-target 
effects.  
Gut bacterial enzymes can also interfere with xenobiotic metabolism by competing for 
host enzymes/receptors. This can be seen in the competition between gut produced p-cresol and 
acetaminophen. The toxicity of acetaminophen varies substantially across individuals, (94,95) 
and recent work implicates gut microbiota that produce p-cresol from tyrosine e.g. C. difficile 
(96). p-cresol is a substrate for the human liver enzyme sulfotransferase (SULT1A1), which also 
sulfonates acetaminophen (97). Thus microbially-derived p-cresol competes with acetaminophen 
for SULT1A1 binding sites (Figure 1.2B), reducing its capacity to bind acetaminophen. This 
likely diverts acetaminophen metabolism away from sulfonation, resulting in CYP metabolism of 
acetaminophen to the highly reactive N-acetyl-p-benzoquinone imine (NAPQI), a toxic 
metabolite primarily responsible for the hepatotoxicity of acetaminophen (98). Thus, by 
competing for host products, bacterial enzymes can likely impact the metabolism of a variety of 
other compounds; targeted inhibition of these bacterial enzymes may mitigate GI toxicity.  
A striking example of how interwoven host and bacterial metabolic pathways affect 
health is the metabolite trimethylamine N-oxide (TMAO), a gut microbiota-derived metabolite 
contributing to the pathogenesis of cardiovascular diseases via multiple mechanisms, including 
enhancing thrombotic potential and platelet activation (99). Notably, TMAO is known to predict 
14 
the risk of atherothrombotic events. Gut microbial glycyl radical enzymes encoded by the cut 
cluster convert dietary components e.g. red meat (100) into trimethylamine (TMA) subsequently 
oxidized by host flavin monooxygenases (101) to form TMAO (Figure 1.2C) (102-104). Roberts 
et al developed an oral microbiota-selective, cut cluster inhibitor that reduced plasma TMAO 
levels, reduced thrombus prevention, and maintained the viability of intestinal bacteria, further 
underscoring the utility of targeting gut bacterial enzymes to improve host health (105).  
Finally, the gut microbiota indirectly impacts drug metabolism by contributing to 
enterohepatic recycling. During phase II metabolism, sulfate and glucuronic acid moieties are 
appended to a variety of small molecule substrates to permit excretion. Sulfatase and β-
glucuronidase enzymes expressed by gut bacteria hydrolyze the water-soluble moieties 
reactivating the drug and/or endobiotic within the gut (106-108). This reactivation process, and 
deleterious effects are most evident in the administration of the colorectal cancer drug, irinotecan 
(Figure 1.2D). Plasma carboxylesterases convert irinotecan into its active metabolite SN-38, 
subsequently detoxified and inactivated by hepatic UDP-glucuronosyltransferase enzymes 
(UGTs) which attach a glucuronic acid to facilitate biliary excretion into the intestines. ß-
glucuronidases expressed by gut bacteria hydrolyze SN-38-G, causing its reactivation to SN-38, 
and bacterial scavenging of released glucuronic acid (109). Reactivated SN-38 is known to cause 
severe, dose-limiting GI toxicity (110-113). Broad-spectrum antibiotics (112,114) and dietary 
fiber consumption (115) have been proposed to alleviate these dose-limiting side effects, but 
both of these approaches impact the gut microbiota as a whole. 
  As an alternative, targeted approach, Wallace et al. identified small-molecule inhibitors 
of gut microbial β-glucuronidases (116,117) that prevented reactivation of SN-38-G to SN-38 in 
vitro. Co-administration with irinotecan substantially reduced irinotecan-induced toxicity in 
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mouse models, and did not inhibit the mammalian ortholog, or impact bacterial or host cell 
viability (118). Recently, it was proposed that ß-glucuronidase activity may serve as a biomarker 
to assign patients to full or adapted irinotecan regimens, to mitigate irinotecan-associated 
diarrhea (119). Furthermore, the specific ß-glucuronidases responsible for SN-38 reactivation 
have recently been identified in donor stool samples (120). ß-glucuronidase inhibitors also 
reduce the enteropathy observed with nonsteroidal anti-inflammatory drugs (NSAIDs) (107,108, 
121). Finally, bacterial ß-glucuronidases also reactivate glucuronide of the tyrosine kinase 
inhibitor regorafenib (122); this mechanism may contribute to regorafenib’s significant GIT 
observed in clinical trials. Thus, targeting specific microbial enzymes has been a uniquely 
successful approach in reducing drug-induced GI toxicity, which can be extended to a variety of 
other classes of bacterial enzymes.  
The biotransformations listed here represented only a limited understanding of the 
metabolic potential of the gut microbiota; other chemotherapeutics may possibly be metabolized 
by other gut bacterial enzymes carrying out unique, as yet undiscovered chemical reactions. As 
such, there is a fundamental need to incorporate enzyme discovery and characterization efforts 
into investigations of gut microbial xenobiotic metabolism from both a basic-science and 
clinician’s perspective.  
The Future of the Gut Microbiome and Medicine 
Advances in research and medical practices have made significant progress towards 
precise treatment of individual patients. Integrating an individual’s microbiome composition and 
its functional output into clinical decision making may enhance precision medicine, with the 
potential to reduce adverse effects, improve preventative care, and reduce health care costs by 
tailoring individual treatment based on predictive biomarkers (123-127). For example, Jariwala 
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et al. recently developed a cutting-edge technical and bioinformatics platform that may be used 
to predict GI side effects of certain drugs subject to glucuronidation, and their subsequent 
metabolism by microbiota (120). Further, as highlighted above, the gut microbiota possesses a 
plethora of currently undefined metabolic processes, which can contribute to interindividual 
variability in disease treatment. Thus, the microbiome is a potentially modifiable factor amenable 
to targeted intervention and is emerging as an integral part of precision medicine approaches to 
alleviate chemotherapy-induced GI toxicity.  
Recent advances in meta’omics and biochemistry have expanded our ability to 
characterize the activity, function, and metabolic products of the human microbiome, beyond 
cataloging the organisms and genes present in particular individuals or disease states. 
Collectively, these technologies can uncover the molecular bases of microbiota on host health, in 
the context of interindividual variation in microbiota composition. Pursuing a mechanistic 
understanding of the direct and indirect manipulation of xenobiotics by the gut microbiome, and 
their interactions with host and environmental factors, is critical in understanding and targeting 
the negative GI effects of systemic chemotherapy.  
Conclusion 
There is now ample evidence implicating the gut microbiota in defining both the efficacy 
and toxicity of chemotherapeutic agents, highlighting the need to include this factor for precision 
medicine. Targeting the microbiota at the compositional or functional level is a rational approach 





TABLE 1. 1: Chemotherapy induced nausea and vomiting grades 
Acute Nausea and/or vomiting occurring within 24 hours  
Delayed Nausea and/or vomiting occurring at least 24 hours; often peaks 
between 48-72 hours 
Breakthrough  Nausea and/or vomiting occurring within 5 days despite optimal 
antiemetic regimen; requires rescue therapy with other antiemetics 
Refractory  Nausea and/or vomiting that occurs in subsequent chemotherapy 
cycles despite maximum antiemetic protocol.  
Anticipatory  Nausea and/or vomiting that is triggered by sensory stimuli 
associated with chemotherapy administration.  
 
 
TABLE 1. 2: Severity of chemotherapy related diarrhea 
Grade Symptoms 
1 Increase of <4 stools per day over baseline; mild increase in ostomy output 
compared to baseline 
2 Increase of 4-6 stools per day over baseline; moderate increase in ostomy output 
compared to baseline; limiting instrumental activities of daily of living 
3 Increase of >= 7 stools per day over baseline; hospitalization indicated; severe 
increase in ostomy output compared to baseline; limiting self-care and activities of 
daily living 






Figure 1. 1: Direct Metabolism through the GI Microbiota.  
A. E. lenta within the GI, reduces a single double bond leading to the inactivation of the heart 
medicine, digoxin. B. Bacteroides and Clostridia species incubated with levamisole results in a 
thiazole-ring opening and the metabolite levametabol I, which may possess antitumor activity. C. 
Incubating acetaminophen with rat caecal microbiota results in deacylation and the toxic product, 
p-aminophenol. D. The demethylation of imipramine by the gut microbiota results in 
desipramine. E. The deamination of of 5-fluorocytosine to 5-fluorouracil (5-FU) by the gut 
microbiota results in toxicity. F. The decarboxylation of levodopa (L-dopa) by H. pylori in the 






Figure 1. 2: Indirect Metabolism of Drugs through the GI Microbiome.  
A. The gut microbiome may alter host gene expression. Germ-free mice have increased 
expression of constitutive androstane receptor (CAR) in comparison to conventional mice. 
Elevated levels of CAR result in increased rates of xenobiotic metabolism. B. The gut 
microbiome competes for host enzymes and receptors. The gut microbiota produces the 
metabolite p-cresol from tyrosine. This metabolite competes with acetaminophen for 
sulfotransferase binding sites, resulting in reduced capacity to bind acetaminophen. C. The gut 
microbiome generates pathway intermediates. Gut microbial glycyl radical enzymes convert 
choline and dietary components into trimethylamine (TMA). TMA is then oxidized by host 
flavin monooxygenases to form trimethylamine N-oxide (TMAO). TMAO is a contributing 
factor in heart disease. D. The gut microbiota influences enterohepatic recycling. During phase II 
metabolism, glucuronic acid is appended to small molecules like the anti-cancer drug, SN-38, 
creating SN-38-G, to facilitate excretion. β-glucuronidase enzymes within the GI hydrolyze the 
glucuronic acid, reactivating the drug within the gut. This allows the molecule to be recirculated 
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CHAPTER 2: TARGETING REGORAFENIB INDUCED TOXICITY THROUGH 
INHIBITION OF GUT MICROBIAL β-GLUCURONIDASES2 
 
Introduction 
 Regorafenib (Stivarga®) is an oral small molecule kinase inhibitor, whose anti-oncology 
effects are driven by inhibition of the tyrosine kinases VEGF and TIE2. It is indicated worldwide 
for patients with metastatic colorectal cancer (mCRC), hepatocellular carcinomas and 
gastrointestinal (GI) stromal tumors. In the US and Europe, it is most often designated for 
patients with mCRC who have failed previous therapies, or who are not candidates for other 
approaches. Although regorafenib is an effective anti-neoplastic compound, diarrhea is one of 
the most frequently observed adverse reactions (1-6). Regorafenib and its close structural 
homolog sorafenib, which is used for kidney, liver and thyroid cancer (and also causes diarrhea), 
are known to be glucuronidated in mice, rats and humans, and to reach the GI tract as inactivated 
glucuronide metabolites (7-10). Thus, one mechanism by which regorafenib may cause GI 
toxicity is the reactivation of the drug within the GI lumen by gut microbial β-glucuronidase 
enzymes (11-14). 
 Bacterial β-glucuronidase (GUS) proteins are gut microbial enzymes that have been 
shown to reverse compound inactivation catalyzed by host Phase II glucuronidation by removing 
the glucuronic acid added to a wide variety of drugs and endobiotics. Drug-glucuronide 
processing by GUS enzymes can lead to toxic levels of the reactivated drug in the GI tract. This 
process has been extensively studied for the colorectal and pancreas cancer drug irinotecan. 
Irinotecan’s active metabolite SN-38 is processed in the liver by Phase II uridine diphosphate 
33 
glucuronosyltransferase (UGT) enzymes to create the inactive metabolite SN-38-G, which is sent 
to the GI tract for excretion. In the gut, however, SN-38-G can serve as a substrate for microbial 
GUS enzymes that remove the glucuronide moiety to reactivate SN-38, which is toxic to 
intestinal epithelial cells and generates irinotecan’s dose-limiting diarrhea (15-18). A review of 
product package inserts has revealed that nearly 90% of oncology drugs known to be 
glucuronidated cause clinical gut toxicity. NSAIDs are also metabolized by glucuronidation, 
reach the gut as inactive glucuronides, and are reactivated in the small intestine by gut microbial 
GUS enzymes to cause intestinal perforations and bleeding ulcers (19-24). This reactivation and 
subsequent toxicity has not been formally established for regorafenib.  
 GUS enzymes are capable of hydrolyzing a diverse array of glucuronides, but limited 
information is available on the specific types of gut microbial GUS enzymes that are most 
efficient at processing distinct drug glucuronides. To gain insight into the structural and 
functional diversity of GUS enzymes, we recently reported an atlas of 279 unique human gut 
microbial GUS enzymes identified from the stool sample catalogue in the Human Microbiome 
Project (HMP), and showed that these proteins clustered into six structural groups based on their 
active site loop features (e.g., Loop 1, Loop 2, No Loop, etc.) (25). We have since created a 
representative panel of 31 of these enzymes for in vitro screening, and we have demonstrated 
that Loop 1 GUS enzymes are capable of processing the small standard glucuronide substrate p-
nitrophenol-β-D-glucuronide (pNPG) and small molecule glucuronides including those of 
NSAIDS and SN-38 faster than non-Loop1 GUS enzymes (15,25-27). However, this level of 
granularity has yet to be assigned to the other loop classes. 
 Here we investigate the role of a distinct subset of ‘No Loop’ GUS enzymes in 
regorafenib-glucuronide reactivation. Regorafenib-glucuronide is unique among the drug-
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glucuronides examined to date because it is a “central glucuronide” – its glucuronic acid moiety 
is linked to the middle of the regorafenib molecule (Figure 2.1A). In contrast, SN-38-G and 
NSAID-glucuronides have their glucuronic acid sugars appended “terminally” to their chemical 
structure (Figure 2.2). Additionally, regorafenib-glucuronide is an N-linked glucuronide; all 
other substrates examined to date, including the standard GUS reporter substrates pNPG and 4-
methylumbelliferyl glucuronide (4-MUG), have been O-linked. Thus, given these differences in 
chemical structure and glucuronide linkage, we hypothesized that a distinct set of gut microbial 
GUS enzymes would act on the central, N-linked regorafenib-glucuronide substrate compared to 
those that efficiently process compounds with terminal, O-linked glucuronides. To test this 
hypothesis, we screened our panel of 31 representative GUS enzymes using regorafenib-
glucuronide and, validating our hypothesis, found that only four distinct enzymes are capable of 
reactivating regorafenib-glucuronide to regorafenib. Taken together, our data provide new 
information on drug-glucuronide processing by gut microbial GUS enzymes, and suggest the 
need to discover new GUS inhibitors that have the potential to improve patient outcomes with 
regorafenib. 
Results and Discussion 
Identification of Regorafenib-Glucuronide Processing Gut Microbial GUS Enzymes 
  As members of the CAZy glycoside hydrolase 2 family, gut microbial GUS enzymes 
have been shown to share a common fold but exhibit unique active site structures and distinct 
substrate-processing functions (28,29). To gain greater insight into the specific sequence-
structure-function relationships among GUS proteins, we generated a sequence similarity 
network (SSN) using sequences of β-glucuronidase enzymes found within the Human 
Microbiome Project. Using an alignment score of 10-220, the resultant SSN clusters the 279 
unique protein sequences based on sequence identity and homology (30). We find that the human 
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gut microbial GUS enzymes largely cluster based on the six previously defined active site loop 
architectures: Loop1 (L1), mini-Loop1 (mL1), Loop2 (L2), mini-Loop2 (mL2), mini-Loop1,2 
(mL1,2), and No Loop (NL) (Figure 2.1B). Of the 279 unique GUS enzymes identified in the 
HMP, we have cloned, expressed, and purified 31 of these proteins for in vitro study. These 
enzymes were selected such that there is at least one representative enzyme from each major and 
minor clade in the SSN, as well as several singletons (Figure 2.1B). Enzymes were also chosen 
so that the prevalence of each loop category was comparable to what has been previously 
reported in the HMP (25). However, an exceptional to this is the Loop1 enzymes, which are 
over-represented in our panel of 31 proteins as these have been previously shown to efficiently 
reactivate small molecule drug substrates, a key focus of our work (27). All 31 of these purified 
enzymes have been shown to be active with the small molecule GUS reporter substrate 4-MUG 
(Table 2.1).  Of the 31 enzymes examined, crystal structures have been reported for 18 (Table 
2.1), and these structural data correlate with the family groupings present in the SSN. 
 While most glucuronides tested to date are terminal, O-linked glucuronides regorafenib-
glucuronide is unique in that it is a central N-linked glucuronide (Figure 2.2). For these reasons, 
we hypothesized that there would be a limited number of enzymes capable of processing this 
drug. To identify GUS enzymes capable of processing regorafenib-glucuronide, we incubated 
each of the 31 enzymes with 500 μM regorafenib-glucuronide to obtain a relative rate at one 
substrate concentration, a kcat
apparent (s-1). For 27 of the 31 enzymes tested, no activity was 
observed (Figure 2.1C). However, four of the enzymes exhibited the ability to convert 
regorafenib-glucuronide to regorafenib (Figure 2.1C). These enzymes were Ruminococcus 
gnavus GUS3 (Rg3GUS [GenBank accession ID: WP_118581144.1]), Roseburia hominis GUS2 
(Rh2GUS [GenBank accession ID: WP_118096903.1]), Faecalibacterium prausnitzii GUS L2-6 
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(FpL2-6 [GenBank accession ID: CBK98066.1]), and H11G11 GUS (identified from an 
uncultured taxon [GenBank accession ID: CBJ55484.1]). The four GUS enzymes that processed 
regorafenib-glucuronide are highlighted on the SSN (Figure 2.1B). Three of the four enzymes 
cluster in the same clade (H11G11, Rg3GUS, Rh2GUS) (Figure 2.1B) and the remaining 
enzyme (FpL2-6) is in an adjacent clade. These proteins are all NL enzymes, share between 42-
69% sequence identity, (31) and three have recently been shown to uniquely bind to the flavin 
cofactor FMN (FpL2-6, Rg3GUS, Rh2GUS) (32). Thus, only an exclusive and small group of 
related GUS enzymes are capable of processing regorafenib-glucuronide. 
 We then determined catalytic efficiency (s-1 M-1) values with regorafenib-glucuronide for 
the four enzymes identified. These rates range from 1.21 × 102 to 9.94 × 103 s-1 M-1 (Table 2.2). 
In comparison, the catalytic efficiencies were also determined for the four enzymes with a small 
molecule reporter substrate, 4-methylumbelliferyl glucuronide (4-MUG). The rates for 4-MUG 
range between 8.92 × 104 – 5.40 × 105 s-1 M-1, 10-100 times faster than their rates with 
regorafenib-glucuronide (Table 2.3). Previous studies have examined the rate of Loop1 GUS 
enzymes with the reporter substrate, pNPG (27). These rates range between 2.0 × 103 – 9.2 × 105 
s-1 M-1. Thus, the rates of regorafenib-glucuronide cleavage are significantly slower than what we 
have previously seen with other GUS enzymes and other GUS substrates. This is likely because 
the regorafenib-glucuronide substrate is significantly less accessible to the enzymes due to the 
steric hindrance a “central” glucuronide presents. Additionally, this is the first substrate 
examined that contains an N-linked glucuronide; the difference in electronic and structural 
characteristics of this linkage may contribute to the slower rates observed here. Despite their 
slower rates, though, we have identified the first microbiome-encoded enzymes from the GI tract 
capable of processing the inactive glucuronide conjugate of the anticancer drug regorafenib.   
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Structural Interrogation of Regorafenib-Glucuronide Processing 
 The crystal structures of three of the four enzymes discovered to process regorafenib-
glucuronide have been determined in their apo (unliganded) state; the exception to date is 
H11G11. Despite considerable effort, a regorafenib- or regorafenib-glucuronide-bound structure 
with the enzymes discovered has not been resolved. However, a model of regorafenib-
glucuronide docked within the active site of Rg3GUS, the fastest enzyme with this substrate, was 
created based on extant structures and our knowledge of gut microbial GUS structure and 
function (15, 29, 33) (Figure 2.3A). This model points towards key active site features that aid in 
the ability of these enzymes to process this substrate, including individual residues and the C-
terminal domain (Figures 2.3A, B).   
 To test the validity of this model and to probe our understanding of the processing of 
regorafenib-glucuronide, mutations were introduced at key residues predicted to contact the 
regorafenib-glucuronide substrate at the active site. The catalytic glutamate residues are 2.3-6.7 
Å from the residues examined by mutagenesis. Introduction of bulky tryptophan side chains at 
positions V415, G441 and S344 significantly reduced or eliminated regorafenib-glucuronide 
processing activity (Figure 2.3C).  Furthermore, while mutating M417 to alanine had no effect 
on activity, mutating the adjacent M382 significantly reduced substrate-processing activity 
(Figure 2.3C). Importantly, most of the corresponding mutations had little effect on the 
processing of the smaller, standard GUS activity substrate 4-MUG (Figure 2.4).  Specifically, 
V415W, M382A and especially G441W, which significantly impacted regorafenib-glucuronide 
processing, had no effect on 4-MUG processing by Rg3GUS. Taken together, these data support 
the validity of the modeling of regorafenib-glucuronide into the active site of Rg3GUS and 
demonstrate that this unique central glucuronide substrate makes contacts to regions of the active 
site involved in 4-MUG processing.  
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 The structures of Rg3GUS (PDB: 6MVG), Rh2GUS (PBD: 6MVH) and FpL2-6 (PDB: 
6MVF) have recently been reported by our group (32); these enzymes share high structural 
similarity, aligning with RMSD values of 1.6-1.8 Å over 624 equivalent Cα positions. However, 
they all contain roughly 150 residues of missing density at their C-termini, potentially 
influencing the ability to visualize the complete active site architecture of these enzymes. We 
therefore modeled the C-terminal domain of Rg3GUS based on a previously resolved GUS 
structure with an intact C-terminal region present in its structure (5UJ6, a GUS from the human 
gut commensal microbe Bacteroides uniformis) (Figure 2.5A). We hypothesized that this region 
may be able to rotate into the active site and impact substrate turnover. To test this hypothesis, 
we created a form of Rg3GUS in which the C-terminal domain was eliminated by placing a stop 
codon following residue 641 (STP641). This mutant enzyme exhibits no activity with 
regorafenib-glucuronide and significantly reduced activity with 4-MUG, yet the structural 
integrity of this protein and all the mutant proteins examined here remain intact (Figure 2.5B, 
Figure 2.6). These results indicate that the C-terminal domain of Rg3GUS is proximal to the 
active site and impacts substrate turnover. Although the exact role of this domain is unclear, 
recent work from our laboratory has demonstrated that similar C-terminal domains in other gut 
microbial GUS enzymes play roles in carbohydrate metabolism (27). Taken together, these data 
indicate that the C-terminal domains of the unique GUS enzymes identified here likely 
participate in the processing of both regorafenib-glucuronide and 4-MUG.  
 Because Rg3GUS was the fastest of the four enzymes, we next sought to unravel 
differences between it and FpL2-6, the slowest enzyme. The two enzymes have an RMSD of 1.6 
Ȧ (Cα=624) and thus have little difference in their overall secondary and tertiary structures. 
However, there is a unique and obvious difference in the individual residues at the active sites of 
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these proteins: the key methionine in Rg3GUS (M382), Rh2GUS and H11G11 is a glycine in 
FpL2-6 (G380) (Figure 2.7A). Note that mutation of M382 to alanine significantly reduced the 
regorafenib-glucuronide processing activity of Rg3GUS. Thus, we hypothesized that G380 in 
FpL2-6 plays a role in the low regorafenib-glucuronide processing by this enzyme. Indeed, a 
G380M variant of FpL2-6 created to test this hypothesis exhibits enhanced activity from 1.21 × 
102 to 4.56 × 103 s-1 M-1, a 40-fold increase in catalytic efficiency generated by a single point 
mutant (Figure 2.7B).  
 Finally, we examined the differences between the gut microbial enzymes capable of 
processing regorafenib-glucuronide and the many that were not able to catalyze the reactivation 
of this cancer drug. Using structural superpositions of the four enzymes discovered as active with 
regorafenib-glucuronide and the other orthologs of gut microbial GUS proteins (L1, mL1, L2, 
mL2, mL1,2 and other NL enzymes), we see that the active enzymes have considerably more 
open catalytic sites. Indeed, the inactive GUS enzymes form steric clashes with the regorafenib-
glucuronide docked into the active site of Rg3GUS (Figure 2.8). These observations likely 
explain why 27 of the 31 enzymes examined had no activity with this substrate, as steric 
occlusion prevents productive substrate binding. In contrast, the four active enzymes uniquely 
have a more open platform at their active sites that allows this central glucuronide substrate to 
bind productively for catalysis. Taken together, these structural, modeling, and mutagenesis data 
begin to explain the molecular basis for the processing of regorafenib-glucuronide by specific 
gut microbial GUS enzymes.  
Inhibition of Gut Microbial GUS Enzymes that Process Regorafenib-Glucuronide  
 We have previously developed selective, potent and non-lethal inhibitors of gut microbial 
GUS enzymes that block the GI toxicity of irinotecan and poor outcomes with NSAIDs 
(15,16,18). However, to date, these inhibitors, which were discovered by high-throughput 
40 
screening (HTS) using the Loop 1 GUS from E. coli, have been found to only be effective 
against Loop 1 gut microbial GUS enzymes (15,26). Thus, we sought to screen for inhibitors of 
the unique microbial GUS enzymes identified here that can process regorafenib-glucuronide. To 
accomplish this goal, we developed and validated an HTS-compatible assay using the Rg3GUS 
enzyme, the fastest with regorafenib-glucuronide. The assay contains three components: 
Rg3GUS, 4-MUG as the substrate, and compound (inhibitor) and exhibits a high-quality Z-prime 
(Z’) of >0.8. Using this assay, we conducted a preliminary screen with the Library of 
Pharmacologically Active Compounds (LOPAC®1280; Sigma) to further validate the assay and 
identify potential inhibitor chemotypes of these NL GUS enzymes capable of reactivating 
regorafenib-glucuronide. Encouragingly, this initial proof-of-concept screen produced an 
excellent Z’ of 0.89  0.02 and excellent correlation between duplicate runs (R2 = 0.98; Figure 
2.9). Additionally, we obtained an initial hit, raloxifene, which inhibited Rg3GUS with an IC50 = 
12.5 μM in follow-up dose-response studies (Table 2.4). This compound, which is a synthetic 
ligand for the estrogen receptor (ER) used in the treatment of osteoporosis, stood out to us 
because it is FDA approved, has been well-characterized, and related compounds could be 
purchased commercially (34-38). Additionally, by the calculations proposed in Maier et al. (39), 
the luminal concentration of raloxifene is roughly 40 μM in patients administered a low dose (60 
mg/day) of the drug. This is above what is necessary to inhibit Rg3GUS in vitro. Most side 
effects associated with administration of raloxifene HCl, including flu syndrome and hot flashes, 
are relatively minor (40). Furthermore, because the structure-activity relationship (SAR) around 
ER-binding has been well-characterized, it is expected that reducing off-target ER-binding would 
be highly feasible.  
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 Using raloxifene as a starting point, we next purchased analogs of raloxifene, as well as 
tamoxifen (the first-generation selective ER modulator, SERM), and other ER ligands (Figure 
2.10) to perform an analog-by-catalog effort. In general, analogs of raloxifene were found to be 
more potent inhibitors of all four GUS enzymes in comparison to the other ER ligands tested 
(Table 2.5). Moreover, the commercial analog bazedoxifene showed minor potency 
improvements over raloxifene, suggesting that there is an opportunity to make even more potent 
compounds through rational medicinal chemistry. Thus, from the LOPAC screen and subsequent 
analyses, we identified raloxifene as an initial inhibitor compound capable of disrupting the 
catalytic activity of the gut microbial GUS enzymes that process regorafenib-glucuronide. 
Synthesis of Novel GUS Inhibitor Analogs 
 We next sought to create analogs of raloxifene that varied at four key positions to 
examine the SAR of this scaffold for inhibiting the four gut microbial GUS enzymes that process 
regorafenib-glucuronide (Figure 2.11A). Raloxifene was chosen due to its commercial 
availability and straightforward, modular synthesis. While we examined the two hydroxyl 
moieties and the ketone present in raloxifene, the piperidine group and its associated flexible 
linker were varied most extensively (Figure 2.11A). Given the low μM potency of bazedoxifene 
towards Rg3 and Rh2GUS, we were particularly interested in incorporating some of the 
structural features of bazedoxifene into the raloxifene scaffold (Figure 2.10). We synthesized a 
total of 20 raloxifene analogs that sample changes at each of these four positions (Figure 2.12, 
Appendix A), and we examined the ability of each of these analogs to inhibit the processing of 
regorafenib-glucuronide by the four gut microbial enzymes of interest, Rg3GUS, Rh2GUS, 
H11G11 and FpL2-6 (Table 2.6). Taken together, the data collected revealed that five novel 
analogs exhibited 2- to 6-fold improved potencies toward the four enzymes of interest compared 
to the starting molecule, raloxifene (Figure 2.11B, Table 2.4). First, we observed that reduction 
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of the carbonyl group of raloxifene as in UNC7084, increasing the overall flexibility of the 
molecule, led to a modest increase in potency for all four enzymes. Second, replacing the 
phenoxyethylpiperidine moiety with a phenylpiperazine as in both UNC7087 and UNC7159 led 
to improvements in efficacy. Interestingly, UNC7268 which contains both of these modifications 
demonstrated overall comparable potencies to both UNC7084 and UNC7159 and therefore an 
additive increase in potency was not observed. UNC7267, in which the piperidine is replaced 
with a larger azepane ring and the carbonyl group is reduced to more closely resemble 
bazedoxifene, is also more potent than raloxifene for the four enzymes tested but exhibits 
potencies comparable to the other improved analogs. Additionally, methylation of either a single 
or both hydroxyl groups did not result in consistent changes in potency across the four enzymes. 
The fact that the hydroxyl groups can be modified while still maintaining GUS inhibition is 
promising, as the 6’ hydroxyl group of raloxifene is necessary for ER binding (37). This suggests 
that methylation of this group can therefore decouple GUS inhibition from ER activity, if 
necessary.   
 We have previously shown for Loop 1 GUS enzymes that piperazine/piperidine rings are 
effective at potently inhibiting these particular gut microbial GUS enzymes (26); we were 
therefore intrigued to observe that a piperazine moiety enhanced inhibitor efficacy with the four 
enzymes screened. Thus, perhaps such ring structures with secondary amines may prove to be 
effective against a range of gut microbial GUS enzymes. Each chemotype appears specific, 
however, to a small clade of enzymes: UNC7084, UNC7087, UNC7159, the three most potent 
analogs, show limited inhibition of the mammalian GUS enzyme, or other gut microbial GUS 
proteins (Figure 2.13), indicating that they are selective for the regorafenib-glucuronide 
processing proteins of interest in this study. Further, we show that they do not affect bacterial 
43 
cell viability in either R. gnavus or E. coli (Figure 2.14). Taken together, these data reveal that 
small adjustments to the chemical structure of the screening hit raloxifene produced promising 
results with respect to targeted inhibition of gut microbial GUS enzymes capable of reactivating 
regorafenib from regorafenib-glucuronide. 
Inhibition of Regorafenib-Glucuronide Reactivation in Mouse Ex Vivo Intestinal Samples 
 Finally, we sought to examine the reactivation of regorafenib-glucuronide by gut 
microbial GUS enzymes present in mammalian intestinal contents.  We term these assays “in 
fimo” from the proper Latin word for excrement (41). We recently reported that the mouse 
GUSome contains 444 unique GUS enzymes, roughly 50% more than were found in the HMP 
(42). The mouse GUSome contains sequences containing ≥ 80% identity to Rg3GUS, Rh2GUS, 
and FpL2-6, three of the four enzymes identified from the Human Microbiome Project capable 
of reactivating regorafenib-glucuronide in vitro. We therefore reasoned that mice would be an 
appropriate model of regorafenib-reactivation in fimo. Using material derived from the GI tract, 
we extracted the full set of active enzymes in each sample and examined them for substrate-
processing activity. Typically, these assays take time points over the course of 1-3 hours after 
addition of 1 mM substrate to monitor parent compound appearance and/or glucuronide 
disappearance. However, using both the fluorescence assay and HPLC methods we observed no 
conversion of regorafenib-glucuronide to regorafenib over 4 hours in fecal samples. We tried 10 
different mice that varied in strain (C57BL/6 and BALB/c), sex (M/F), and age (8-16 weeks). 
Similarly, these experiments were conducted with human feces from two donors, and again we 
see no regorafenib-glucuronide reactivation in feces alone.  
 Given the lack of activity observed in feces, we then dissected luminal samples from 
euthanized specific pathogen free (SPF) C57BL/6J mice into three portions: cecum, small 
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intestine, and large intestine. We homogenized these intact samples to create lysates that would 
include microbial and host factors. We then repeated the assays using lysates from the 
homogenized samples, with time points up to 48 hours. Although we see activity in every portion 
of the GI with these homogenates, we see relatively little conversion of regorafenib-glucuronide 
to regorafenib after 48 hours in the small and large intestine (Figure 2.15A). This may be due to 
a combination of factors, including the abundance of total GUS proteins within the sample 
matrix and the fact that the quantity of these specific enzymes capable of hydrolyzing 
regorafenib-glucuronide is low. In contrast to the small and large intestinal samples, within the 
same 48-hour time frame, almost all regorafenib-glucuronide is converted to regorafenib in the 
cecal extracts of the SPF mice tested (Figure 2.15A). These results are akin to those published 
previously with the N-glucuronide of the nearly isostructural cancer drug sorafenib, which was 
shown to be subject to reactivation by mouse cecal contents (14).  We then replicated the 
regorafenib-glucuronide experiment using the ceca of germ-free (GF) mice to confirm that this 
reaction was not driven by host factors. We excised the cecum of 5 GF mice and dissected them 
into two parts: one contained the cecum and all of its contents (Figure 2.15B) and the second 
contained just the cecal contents (Figure 2.15C). After 48 hours of incubation with regorafenib-
glucuronide, we find that neither the cecum nor its contents were able to catalyze the reactivation 
of regorafenib from regorafenib-glucuronide. Thus, in the mouse cecum, the conversion of 
regorafenib to regorafenib-glucuronide is exclusively catalyzed by gut microbial enzymes.  
 Focusing on the cecal homogenates from SPF mice that showed the largest percent 
conversion of regorafenib-glucuronide, we next sought to examine the ability of our novel 
analogs to inhibit this conversion. We tested three inhibitors, UNC7084, UNC7087, and 
UNC7159 and one negative control compound, UNC7088, that showed no inhibition in vitro. As 
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expected, UNC7088 showed no inhibition in the cecal mixtures up to 100 µM (Figure 2.15D). 
However, at 20 µM inhibitor concentration, UNC7084, UNC7087, and UNC7159 significantly 
inhibited the conversion of regorafenib-glucuronide to regorafenib in two of the three samples 
tested (Figure 2.5D, Figure 2.16). UNC7084 failed to inhibit conversion by the cecal contents of 
one mouse, suggesting the possibility that additional regorafenib-glucuronide processing GUS 
enzymes exist that have yet to be discovered.  In summary, however, we show that microbial 
GUS enzymes present in the GI tracts of mice, particularly in the cecum, are capable of 
converting regorafenib-glucuronide into regorafenib, and are subject to inhibition by the small 
molecules presented here.  
 Taken together, we have identified unique group of gut microbial GUS enzymes that 
process the unusual drug glucuronide of regorafenib, and have inhibited this reactivation both in 
vitro and ex vivo using novel analogs designed from a preliminary screening hit. However, there 
are several limitations to the current study.  First, the connection between regorafenib-induced 
gut toxicity and the intestinal microbiota has not been established, and this will be a crucial focus 
of future work.  If germ-free or antibiotic-treated mice still demonstrate regorafenib-induced gut 
damage, reversing such toxicity with inhibitors of gut microbial GUS enzymes would be unlikely 
to succeed.  Second, in our experience, sub-µM inhibitors are necessary to observe protection 
against drug-induced gut toxicity in mice. Because we do not yet have this level of potency in the 
initial compounds presented here, we have not yet tested their efficacy against regorafenib-
induced intestinal damage in vivo. Again, this will be performed as more potent compounds are 
developed.  Third, the potential for raloxifene and the analogs described to alter the 
glucuronidation of regorafenib by mammalian UGT enzymes needs to be assessed. However, the 
data presented here demonstrate that unusual drug-glucuronide conjugates like regorafenib-
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glucuronide are processed by a unique small group of gut microbial GUS enzymes, which are in 
turn subject to targeted inhibition by compounds related to the SERM raloxifene. These results 
set the stage for the examination of the key questions outlined above toward the potential 
improvement of regorafenib and related kinase inhibitors like sorafenib in the clinical treatment 
of human malignancies. 
Conclusion 
 This study pinpointed a subset of distinct gut microbial GUS enzymes capable of 
reactivating regorafenib from regorafenib-glucuronide. We identified structural features of these 
enzymes that are essential to this reactivation, and we developed inhibitors that block this 
process both in vitro and in intestinal preparations from mice. Further, we show by comparing 
specific pathogen free and germ-free mice that reactivation is exclusively catalyzed by gut 
microbial enzymes. Thus, we have successfully initiated the development of the tools necessary 
to address regorafenib-induced gut toxicity.  In addition, we provide a roadmap for the 
identification of gut microbial enzymes responsible for the toxic side effects of other tyrosine 
kinase inhibitors and the discovery of microbiome-targeted reagents to block these side effects.  
Experimental Procedures 
Gene Synthesis, Expression, and Purification of GUSs  
 Genes for Fp2GUS, Rh2GUS, Rg3GUS, and H11G11 and the 27 other GUS enzymes 
tested here were synthesized by BioBasic and incorporated into a pLIC-His vector via ligation 
independent cloning, and resultant plasmids were transformed into BL21-G E. coli cells. 
Glycerol stocks were made from overnight cultures and snap frozen and stored at − 80 °C. 
Verification of successful transformation and sample integrity were determined by DNA 
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sequencing.  As outlined below, expression and purification were identical for each of the 31 
enzymes, and all showed >95% final purity by SDS-PAGE analysis. 
 Cultures of 100 mL LB with ampicillin were inoculated with glycerol stock and 
incubated overnight at 37 °C with shaking at 225 rpm. For protein expression, 50 mL of the 
overnight, approximately 40 μL Antifoam 204, and 750 μL of 2000x ampicillin were added to 
1.5 L LB in a 2.5 L Erlenmeyer flask and incubated at 37 °C at 225 rpm. At an OD of 
approximately 0.6, the temperature was reduced to 18 °C and induced with IPTG (100 µM) and 
incubated overnight with shaking at 225 rpm. Cultures were spun down in a Sorvall Instruments 
RC-3B centrifuge at 4500g for 25 min in 1 L round, flat bottom plastic bottles. Cultures were 
resuspended in LB and transferred to a 50-mL falcon tube and spun down in a ThermoScientific 
Sorvall ST 40R centrifuge for 15 min at 5000g. Supernatant was discarded and proteins were 
stored at − 80 °C until purification. 
 Cell pellets were lysed in 30 mL Nickel A buffer [20 mM KH2PO4, 500 mM NaCl, 
50 mM imidazole (pH 7.4)] with DNase, lysozyme, and a Roche EDTA-free protease inhibitor 
tablet. The resultant cell slurry was sonicated on a Fischer Scientific Sonic dismembrator model 
500 twice with 1 s pulses for 1.5 min. The resultant lysate was subsequently spun down on a 
Beckman Coulter J2-HC centrifuge for 1 h at 17,000 rpm. The supernatant was subject to 
filtration with a 0.22-μm filter prior to purification. 
 Protein was first purified with an Aktaxpress FPLC (Amersham Bioscience) via a Ni 
NTA column. Protein was eluted in one step using Nickel B buffer [20 mM KH2PO4, 500 mM 
NaCl, 500 mM imidazole (pH 7.4)]. The eluent was then subject to size exclusion 
chromatography on a HiLoadTM 16/60 Superdex 200 gel filtration column. Size exclusion 
buffer was utilized for elution [20 mM Hepes, 50 mM NaCl (pH 7.4)]. Fractions were collected 
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and an SDS-PAGE gel was performed to assess purity and stability of the enzyme. Protein 
concentration was determined on an ND-1000 spectrophotometer and then snap frozen in liquid 
nitrogen and stored at − 80 °C. 
Site-directed Mutagenesis of GUSs  
 All mutants were created via site-directed mutagenesis. Mutagenesis primers were 
synthesized by Integrated DNA technologies. Mutant plasmids were sequenced by Eton 
Bioscience to confirm successful mutagenesis.  
Determination of GUS Reactivity  
 To assess the activities of 31 WT GUS enzymes we measured their ability to hydrolyze 
the fluorescent reporter substrate 4-MUG and regorafenib-glucuronide. Reactions were 
performed in black Costar 96-well plates with a flat, clear bottom, and reaction volumes were as 
follows: 10 μL buffer [25 mM Hepes, 25 mM NaCl, (pH 6.5)], 10 μL GUS (15 nM final), and 
30 μL 4-MUG/regorafenib-glucuronide at 500 μM. Reactions were initiated by addition of 
substrate. For initial determination of protein viability, enzyme and substrate were incubated for 
15 minutes, after which a relative fluorescence unit was recorded. All enzymes exhibited activity 
above background [(-) GUS] and were thus considered catalytically active. 
In vitro Kinetic Assay for Catalytic Efficiency Determination of GUSs  
 To assess the activities of WT and mutant GUSs, we measured their ability to hydrolyze 
the fluorescent reporter substrate 4-MUG and regorafenib-glucuronide. Regorafenib-N-β-D-
glucuronide sodium salt and 4-Methylumbelliferyl-β-D-glucuronide were purchased as solids 
(Toronto Research Chemicals) and resuspended in DMSO to a concentration of 10 mM. 
Reactions were performed in black Costar 96-well plates with a flat, clear bottom, and reaction 
volumes were as follows: 10 μL buffer [25 mM Hepes, 25 mM NaCl, (pH 6.5)], 10 μL GUS (15 
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nM final), and 30 μL 4-MUG/regorafenib-glucuronide at 500 μM. Reactions were initiated by 
addition of substrate. All reactions were continuously monitored with excitation at 350 nm and 
emission at 450 nm in a BMG Labtech PHERAstar plate reader for 4-MUG assay. Reactions 
were continuously monitored with excitation at 300 nm and emission at 380 nm in a TECAN 
infinite M1000PRO plate reader for regorafenib-glucuronide assay. Initial velocities at substrate 
concentrations between 50-120 μM from the resultant data were fit by linear regression with a 
custom MATLAB program to obtain catalytic efficiency data. 
LOPAC High Throughput Screening 
 Assays were performed in Greiner 384 well plates and reaction volumes were as follows: 
25 µL Rg3GUS diluted in buffer [25 mM Hepes, 25 mM NaCl (pH 6.5) and 1mM CHAPS], and 
40 µM final 4-MUG. Plates were pre-stamped with 1mM compound for a final assay volume of 
50 uL (for 20 uM final compound and 2% DMSO). Test compounds were in the middle 320 
wells with columns 1, 2, 23, 24 reserved for high and low controls and a control dose response 
curve. Percent inhibition for test compounds was determined using data from control columns.  
Enzyme was pre-incubated with compound, then reactions were initiated by addition of 
substrate. After 8 minutes, reactions were quenched with 50 uL Sodium Carbonate. Following 
quenching, plates were read with excitation at 350 nm and emission at 450 nm in an Enspire 
plater reader (Perkin Elmer). Controls included IC50 with a known pan-GUS inhibitor, 
saccharolactone, and -GUS/-Compound controls (substituted with DMSO). 4-MUG assay was 
validated with Z’ scores of >0.8 for Rg3GUS. Buffer optimization, day-to-day reproducibility, 
DMSO tolerance, volume miniaturization, and use of liquid handling lab automation all were 
conducted to pharmaceutical industry standards (data not shown). 
In vitro Inhibition Assay 
50 
 All analog-by-catalog compounds were purchased through Cayman Chemical as solid 
and dissolved in DMSO for 10 mM stock concentrations. In vitro inhibition of bacterial GUS 
enzymes was assessed as previously described (22,23). Reactions consisted of 10 μL of GUS (15 
nM final), 5 μL of inhibitor (various concentrations), 30 μL of 4-MUG (900 μM final), and 5 μL 
of assay buffer [25 mM NaCl, 25 mM HEPES, (pH 6.5)]. Reactions were initiated by addition of 
4-MUG and then incubated for 1 hour, after which the end point absorbance was determined. 
Percent inhibition values were subsequently plotted against the log of inhibitor concentration and 
fit with a four-parameter logistic function in SigmaPlot 13.0 to determine the IC50. Due to the 
slow binding nature of the piperazine and piperidine compounds, the IC50 was determined as the 
inhibitor concentration that yielded at 50% reduction in the maximum absorbance of the 
uninhibited reaction where percent inhibition was calculated as: Where Aexp is the end point 
absorbance at a particular inhibitor concentration, Amax is the absorbance of the uninhibited 
reaction and Abg is the background absorbance in the assay. Percent inhibition values were 
subsequently plotted against the log of the inhibitor concentration and fit with a four-parameter 
logistic function in SigmaPlot 13.0 to determine the IC50. 
% inhibition =[1 − (
𝐴𝑒𝑥𝑝−𝐴𝑏𝑔
𝐴𝑚𝑎𝑥−𝐴𝑏𝑔
)] × 100 
In vitro inhibition of bacterial GUS enzymes by non-piperazine/piperidine-containing inhibitors 
were determined using the reaction conditions described above, but the IC50 was determined as 
the inhibitor concentration that yielded 50% reduction in the maximum initial velocity of the 
uninhibited reaction. 
Regorafenib-Glucuronide Processing Assay in Intestinal Homogenates 
 All animal studies were approved by the University of North Carolina Institutional 
Animal Care and Use Committee (IACUC), in accordance with the Care and Use of Laboratory 
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Animals guidelines set by the National Institutes of Health. 12-14-week old C57BL/6J mice were 
individually housed in  a specific pathogen-free (SPF) vivarium in sterile ventilator cages 
containing corn bedding. Germ-free C57/BL6J mice were bred in flexible film isolators 
ventilated via HEPA-filtered air. All animals were maintained at 22 ± 1°C with a 12-h light/dark 
cycle, and ad libitum access to chow and water.  Animals were deeply anesthetized with CO2 
followed by manual cervical dislocation. First, the entire gastrointestinal tract from duodenum to 
anus was excised and rinsed with sterile PBS. The small intestine was separated at the ileocecal 
joint, apportioned into segments, and placed into sterile microfuge tubes. The cecum was 
separated from the colon, and both were collected into separate tubes. 1 ml of NP40 buffer 
containing 1x Complete Protease Inhibitor cocktail (Roche) was used per 20 mg of tissue, and all 
samples were kept on ice.  
 After the tissue was dissected it was transferred to a mechanical shear homogenizer and 
500 µL NP-40 buffer + protease inhibitor was added for every 10 mg of tissue. Homogenization 
protocol adapted from Simpson (43).  Tissues were homogenized thoroughly using a mechanical 
shear homogenizer, three times for 20-30 sec each, pausing for 10-15 sec between each 
homogenization, and then kept on ice for 30 minutes, vortexing occasionally to allow further 
extraction of proteins. Then the samples were sonicated for 5 five minutes at 180 watts (in 
rounds of 10 seconds sonication/10 seconds rest for each cycle) to break the tissue up further and 
to shear DNA. Samples were kept on ice during sonication. Samples were centrifuged at 
13,000xg for 10 minutes to remove cell debris and particulate matter, then snap frozen in liquid 
nitrogen to be stored at -80°C.  
 To perform the assay, frozen homogenized tissue and fecal samples were rehydrated in 
15× assay buffer (weight/volume; 20 mM HEPES, 50 mM NaCl, [pH 5.5 for samples from the 
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cecum and pH 6.5 from small and large intestinal samples], 1 × Complete® Protease inhibitor 
cocktail (Roche)). Homogenate was sonicated for 4 min, and then clarified by centrifugation for 
10 minutes at 13,000×g. All experimental manipulation until this point occurred at 4 °C. In vitro 
assays were conducted at 37°C in a 50 μL total volume. 25 μL of intestinal slurry supernatant 
was used to initiate the hydrolysis reaction of 5 mM regorafenib-glucuronide resuspended in the 
same buffer. The inhibition assays consisted of 5 µL inhibitor, 25 µL supernatant, and 20 µL 
substrate. Parallel reactions containing only regorafenib-glucuronide or only buffer/intestinal 
slurry were used as negative controls. Each sample was assayed using three technical replicates. 
Reactions were incubated at 37°C over 48 hours and quenched with 50 μL of 25% trichloroacetic 
acid (TCA) at 4, 8, 12, 24 and 48 hours. After centrifugation at 13,000xg for 10 min, the 
resultant supernatant was subjected to HPLC analysis. The concentration of regorafenib-
glucuronide remaining after each timepoint was quantified on a Agilent 1260 Infinity II liquid 
chromatograph system. Samples were separated on an Agilent InfinityLab Poroshell 120 C18 
column (4.6 x 100 mm, 2.7 μm particle size) at 38°C. The flow rate was 0.9 mL/min, and the 
injection volume was 10 μL. LC conditions were set at 98% water with 0.1% formic acid (A) for 
2 mins, then ramped linearly over 10 mins to 98% acetonitrile with 0.1% formic acid (B) and 
held until 14 mins. At 15 mins the gradient was switched back to 100% A and allowed to re-
equilibrate until 17 mins. Regorafenib-G was monitored at 280 nm. The concentration of 
regorafenib was determined from a standard curve (0-500 μM regorafenib in assay buffer). 
Bacterial Survival Assays 
 Two bacterial strains with distinct growth requirements were used to test whether 
raloxifene analogs affect bacterial cell growth. Ruminococcus gnavus (ATCC 29149) was 
cultured anaerobically in Reduced Clostridial Medium (RCM; Gibco). Log phase bacteria were 
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diluted to OD600 of 0.1, placed in fresh RCM media containing 10 uM of raloxifene analogs, 
and cultured for 24 hours. The OD600 was measured to quantify growth rate. Cell viability was 
assessed by plating limiting dilutions on RCM agar, and quantifying bacterial colonies. E. coli 
(ATCC 700926) was cultured aerobically in LB medium. Log phase bacteria were diluted to 
OD600 of 0.3, placed in fresh LB media containing 10 uM of raloxifene analogs, and cultured 
for 16 hours. The OD600 was measured to quantify growth rate. Cell viability was assessed by 
plating limiting dilutions on LB agar and quantifying bacterial colonies. 
SSN Construction 
 The sequence similarity network diagram of GUS enzyme sequences was generated using 
the enzyme function initiative-enzyme similarity tool (EFI-EST) online tool (26). The sequences 
obtained from the GUS rubric were used in combination with the EFI-EST "FASTA" tool to 
create a sequence with 279 nodes. Each node represents sequences bearing ≥90% sequence 
identity to each other. A BLAST E-value of 1 x 10-220 was employed. 
CD Analysis of GUS Mutants  
 The protein stabilities of the WT and mutant GUS enzymes described above were 
determined using the Circular Dichroism method (44). Enzyme (2.5 µM) in CD buffer containing 
10 mM potassium phosphate (pH 7.4) and 100 mM potassium fluoride was loaded into a 1-mm 
pathlength cuvette. Using a Chirascan-plus instrument (Applied Photophysis Limited), spectra 
from 185 to 260 nM were recorded at 20 ± 1.0 °C. Measurements were corrected for background 
signal using a CD buffer sample. The melting profile of the sample (2.5 µM) was monitored at 
228 nm from 20 °C to 94 °C. 
General Chemistry Procedures 
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 Reactions were carried out using conventional glassware. All reagents and solvents were 
used as received unless otherwise stated. Reagents were of 95% purity or greater, and solvents 
were reagent grade unless otherwise stated. Any anhydrous solvents used were purchased as 
“anhydrous” grade and used without further drying. “Room” or ambient temperature varied 
between 20-25˚C. Analytical thin layer chromatography (TLC) was carried out using glass plates 
pre-coated with silica gel (Merck) impregnated with fluorescent indicator (254 nm). TLC plates 
were visualized by illumination with a 254 nm UV lamp. Analytical LCMS data for all 
compounds were acquired using an Agilent 1260 Infinity II system with the UV detector set to 
254 nm. Samples were injected (<10 µL) onto an Agilent ZORBAX Eclipse Plus C18, 600 Bar, 
4.6 x 50 mm, 1.8 μM column at 25.0˚C. Mobile phases A (H2O + 0.1% acetic acid), B (MeOH + 
0.1% acetic acid), and C (99% MeCN + 1% H2O + 0.1% acetic acid) were used with a linear 
gradient from 10% to 100% B or C in 5.0 min, followed by a flush at 100% B or C for another 2 
minutes with a flow rate of 1.0 mL/min. Mass spectra (MS) data were acquired in positive ion 
mode using an Agilent InfinityLab LC/MSD single quadrupole mass spectrometer with an 
electrospray ionization (ESI) source. Normal phase column chromatography was performed with 
a Teledyne Isco CombiFlash®Rf 200 using RediSep®Rf SILICA columns with the UV detector 
set to 254 nm and 280 nm. Reverse phase column chromatography was performed with a 
Teledyne Isco CombiFlash®Rf 200 using C18 RediSep®Rf Gold columns with the UV detector 
set to 220 nm and 254 nm. Analytical LCMS (at 254 nm) was used to establish the purity of 
targeted compounds. Unless otherwise noted, all compounds that were evaluated in biochemical 
and biophysical assays had >95% purity as determined by LCMS. 
Nuclear Magnetic Resonance Spectroscopy (NMR) 
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 1H, 13C, and 19F NMR spectra were obtained on a Varian 400MR at 400 MHz, 100 MHz, 
and 376 MHz respectively. Chemical shifts are reported in ppm and coupling constants are 
reported in Hz with CDCl3 referenced at 7.26 (
1H) and 77.1 ppm (13C), DMSO-d6 referenced at 
2.50 (1H) and 39.5 ppm (13C), acetone-d6 referenced at 2.05 (
1H) and 29.8 ppm (13C), and 
MeOD-d4 referenced at 3.31 (
1H) and 49.0 ppm (13C). 
High Resolution Mass Spectrometry 
 Samples were analyzed with a Q Exactive HF-X (ThermoFisher, Bremen, Germany) 
mass spectrometer. Samples were introduced via a heated electrospray source (HESI) at a flow 
rate of 10 µL/min. One hundred time domain transients were averaged in the mass spectrum. 
HESI source conditions were set as: nebulizer temperature 100 deg C, sheath gas (nitrogen) 15 
arb, auxillary gas (nitrogen) 5 arb, sweep gas (nitrogen) 0 arb, capillary temperature 250 degrees 
C, RF voltage 100 V, spray voltage 3.5 KV. The mass range was set to 150-2000 m/z. All 
measurements were recorded at a resolution setting of 120,000. Solutions were analyzed at 0.1 
mg/mL or less based on responsiveness to the ESI mechanism. Xcalibur (ThermoFisher, 
Breman, Germany) was used to analyze the data. Molecular formula assignments were 
determined with Molecular Formula Calculator (v 1.2.3). All observed species were singly 
charged, as verified by unit m/z separation between mass spectral peaks corresponding to the 12C 








TABLE 2. 1: GUS activity of 31 GUS enzymes examined with 4-MUG 
aSuperscripted numbers refer to literature citations in our listed references. bAccession IDs are 
from NCBI. Data are presented in µM as the average of 3 biological replicates ± SEM.  RFU, 








TABLE 2. 2: Rates of Regorafenib-Glucuronide Processing by FpL2-6, H11G11, Rg3 and 
Rh2 GUS Enzymes 
 




TABLE 2. 3: Catalytic Efficiency of 4-MUG by FpL2-6, H11G11, Rg3 and Rh2 GUS 
Enzymes 
 
Data are presented in µM as the average of 3 biological replicates ± SEM. Kcat/KM is catalytic 





TABLE 2. 4: IC50 (µM) of Raloxifene and the Most Effective Analogs 
 
 




























Figure 2. 1: Identification of Regorafenib-glucuronide Processing GUS Enzymes.  
A. Structure of N-linked regorafenib-glucuronide with the glucuronide moiety highlighted in 
green. B. Sequence Similarity Network (SSN) highlighting reactive GUS enzymes. SSN contains 
279 GUS enzymes identified through the Human Microbiome Project (circles). Triangles are 
GUS enzymes tested. Yellow triangles are GUS enzymes that can reactivate regorafenib-
glucuronide. SSN is color-coded by loop categorization defined previously*.  C. kcat
apparent rates of 








Figure 2. 3: Structural Basis for Regorafenib-glucuronide Processing.  
A. Structure of Rg3GUS (PDB: 6MVG) with regorafenib-glucuronide docked at active site 
(spheres) B. Inset of Rg3GUS active site and modeled regorafenib-glucuronide. Residues of 
interest for mutagenesis are highlighted. Catalytic glutamates are highlighted in magenta. C. 
Rates of Rg3GUS mutants in descending order from no effect to complete inactivation 
 
 
Figure 2. 4: Structural Basis for 4-MUG Processing.  
A. Rates of Rg3GUS mutants incubated with 4-MUG, created to probe activity with regorafenib-
glucuronide. B. 4-MUG modeled in GUS active site, highlighting point mutants. Catalytic 
glutamates are highlighted in magenta. 
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Figure 2. 5: Previously Unresolved Domain of Rg3GUS. 
A. Structure of Rg3GUS (PDB: 6MVG) with regorafenib-glucuronide docked at active site 
(spheres) in green. The yellow portion has not been resolved in the crystal structure and is 
modeled from extant GUS structure BuGUS2 (5UJ6). B. Progress curves of WT and STP641 

























Figure 2. 7: Significance of Active Site Methionine. 
A. Overlay of Rg3GUS (PDB: 6MVG) and FpL2-6 (PDB: 6MVF) the fastest and slowest GUS 
enzymes respectively. B. Inset of Rg3GUS and FpL2-6 GUS active sites and modeled 
regorafenib-glucuronide. Where Rg3GUS contains a methionine, FpL2-6 contains a glycine. 
Catalytic glutamates are highlighted in magenta. C. Rates of FpL2-6 mutant G380M. Mutation to 









Figure 2. 8: Steric Occlusion by GUS Orthologs. 
Regorafenib-glucuronide is modeled in each of the active site architectures (L1, L2, NL, mL1, 
mL2, mL1,2) overlaid with Rg3GUS (grey). Each ortholog contains active site features 





Figure 2. 9: Results of LOPAC HTS. 
Correlation coefficient plot of duplicate runs of Library of Pharmacologically Active 
Compounds (LOPAC) screen. From left to right is increasing levels of inhibition where hits were 
considered those that inhibited 100% in duplicate trials. Most hits were dismissed as non-




Figure 2. 10: Structures of ER Ligands. 
12 ER ligands were purchased to determine their inhibition towards GUS enzymes. 
 
 
Figure 2. 11: Inhibitor Scaffolds. 
A. Highlighted positions indicate modifications of raloxifene for SAR analysis. B. Three analogs 







Figure 2. 12: Synthesized Raloxifene Analogs. 
 
 
Figure 2. 13: Targeted Inhibition of Regorafenib-Glucuronide processing GUS Enzymes. 
The raloxifene analogs were tested against non-regorafenib-glucuronide reactivating enzymes 





Figure 2. 14: Bacterial Cell Viability. 
A. Optical density of R. gnavus anaerobically cultured for 24 hours with 10 μM of indicated 
compounds. Where UNC7084 significantly increases OD compared to vehicle (one-way 
ANOVA Dunnett’s test for multiple comparisons) via an undefined mechanism, other raloxifene 
analogs do not impact R. gnavus growth. B. Raloxifene analogs do not alter R. gnavus viability 
when plated on RCM agar. C. Optical density of E. coli aerobically cultured for 16 hours with 10 
μM of indicated compounds. Raloxifene analogs do not impact E. coli growth. D. Raloxifene 
analogs do not alter E. coli viability when plated on LB agar. 
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Figure 2. 15: Cleavage and Inhibition of Regorafenib Processing in Mouse Intestines. 
A. Intestinal homogenate incubation with regorafenib-glucuronide in C57BL/6J mice after 48-
hour incubation at 37°C. B. In-tact cecum incubation with regorafenib-glucuronide in germ-free 
C57BL/6J mice shows no reactivation of regorafenib-glucuronide after 48-hour incubation at 
37°C. X-axis delineates mouse (M) 1-5. C. Cecal content incubation with regorafenib-
glucuronide in germ-free C57BL/6J mice shows no reactivation of regorafenib-glucuronide after 
48-hour incubation at 37°C. X-axis delineates mouse (M) 1-5. D. 48-hour incubation of cecal 











Figure 2. 16: HPLC Results of Mouse Intestinal Incubation. 
A. Representative chromatogram of cecum + regorafenib-glucuronide incubated for 48 hours. B. 
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CHAPTER 3: GUT MICROBIAL β-GLUCURONIDASES REACTIVATE ESTROGENS 
AS COMPONENTS OF THE ESTROBOLOME3 
 
Introduction 
 The gastrointestinal (GI) microbiome harbors incredible metabolic potential and is 
intimately connected to human physiology. Possessing 150 times more genes than are found in 
the human genome, the gut microbiome encodes a vast number of enzymes that function in a 
variety of metabolic pathways, including the biosynthesis of essential vitamins and the 
breakdown of complex, non-digestible polysaccharides (1-4). The GI microbiota play potentially 
significant but enigmatic contributions to human health via the estrobolome, the aggregate of the 
enteric bacterial genes whose products are capable of metabolizing estrogens (5). It has been 
suggested that a woman's estrobolome plays a key role in a number of hormonal disorders 
including breast, endometrial, and ovarian cancers (5-8). Hypothesized to be especially important 
to metabolism within the estrobolome are bacterial species possessing β-glucuronidases (GUS) 
enzymes.  
 During phase II metabolism, UDP-glucuronosyltransferase enzymes (UGTs) append a 
glucuronic acid moiety to a variety of endo- and xenobiotics, typically inactivating them marking 
them for excretion. GUS proteins within the GI tract can intercept this process, cleaving the 
glucuronic acid, allowing the reactivated compound to be recirculated throughout the body, 
thereby reversing phase II glucuronidation. In the case of SN-38, the active metabolite of the 
anticancer drug irinotecan, this process of glucuronidation and de-glucuronidation through the 
action of GUS has been shown to cause severe GI toxicity. By inhibiting the GUS enzymes 
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responsible for this reactivation, the diarrhea associated with administration of SN-38 can be 
alleviated (9-12). The same has been established for lower GI damage caused by non-steroidal 
anti-inflammatory compounds (13-17). 
 Similar to SN-38 and NSAIDs, estrogenic compounds are glucuronidated in the liver 
during phase II metabolism. Upon entry into the GI tract, they are exposed to GUS enzymes that 
could, in theory, cleave the sugar moiety, reactivating the parent compound and allowing the 
unconjugated estrogen to be reabsorbed in the blood stream and undergo iterative rounds of 
enterohepatic recirculation (18,19). This is potentially significant in oncology as there is now 
general agreement that the concentrations of unbound estrogens are much higher in plasma and 
tissues of women with hormone driven cancers (20-23). Therefore, an estrobolome enriched in β-
glucuronidase enzymes that promote estrogen metabolite deconjugation reactions may result in 
greater reabsorption of free estrogens and a greater risk of hormone receptor positive, (HR +) 
cancers (Figure 3.1).  
 Although it has been postulated that the GUS enzymes within the estrobolome play an 
integral role in estrogen reactivation and recirculation, this role has yet to be proven. Here we 
take a panel of 35 human gut microbial GUS enzymes and the glucuronides of two estrogens, 
estradiol (E2, dominant during reproductive years) and estrone (E1, dominant after menopause), 
and assess the ability of these enzymes to process these substrates. With this in vitro panel we 
show that 17 of the 35 GUS enzymes tested are capable of reactivating estrogen conjugates. 
Guided by novel crystal structures of two human gut microbial GUS enzymes and 12 additional 
structures already in-hand, we pinpoint structural features critical to estrogen-glucuronide 
processing. Further, we examine the inhibition of key gut microbial GUS enzymes in vitro, ex 
vivo and in vivo, and test the estrobolome hypothesis with respect to breast tumor growth in an 
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HR + mouse model. Taken together, our results validate gut microbial GUS enzymes as active 
members of the estrobolome but highlight the likely complex relationship between the 
estrobolome and tumorigenesis in vivo. 
Results 
Identification of Estrogen Glucuronide Processing Gut Microbial GUS Enzymes 
 Gut microbial GUS enzymes have been shown to share a common fold but exhibit unique 
active site architectures and differential activities with distinct substrates (24,25). To gain greater 
insight into the specific sequence-structure-function relationships among GUS proteins, we 
generated a sequence similarity network (SSN) using sequences of β-glucuronidase enzymes 
found within the Human Microbiome Project (HMP). The resultant SSN clusters the 279 unique 
protein sequences based on sequence identity and homology (26).  
 Of the 279 unique GUS enzymes identified in the HMP, we have cloned, expressed, and 
purified 35 of these for in vitro study (Figure 3.2A [triangles], Table 3.1). Enzymes were 
chosen so that the prevalence of each loop category was comparable to what has been previously 
reported in the HMP (27). However, an exception to this is the Loop 1 enzymes, which are over-
represented in our panel of 35 proteins as these have been previously shown to efficiently 
reactivate small molecule drug substrates, a key focus of our work (27). Of the 35 enzymes 
examined, crystal structures have been reported for 18 (Table 3.1), and these structural data 
correlate with the family groupings present in the SSN. 
 To identify GUS enzymes capable of processing estrogen glucuronides, we employed an 
assay that couples the formation of glucuronic acid to its utilization by uronate dehydrogenase 
and subsequent reduction of NAD+ to NADH+H+, which we use an endpoint cleavage 
measurement (Figure S1, Methods). Of the 35 enzymes tested, 17 were capable of cleaving the 
glucuronide moiety of estrone (E1-3G) and 15 were capable of cleaving the glucuronide of 
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estradiol (E2-17G). We find that the GUS enzymes capable of cleaving estrogen cluster into 
three distinct categories: Loop 1 enzymes (red), mini-Loop 1 enzymes (green), and FMN-
binding GUS enzymes (yellow). The GUS enzymes that processed glucuronides of estrogen are 
highlighted on the SSN (Figure 3.2A [colored triangles]).  
 These classes have been described in detail previously (27-30); briefly, the Loop 1 and 
mini-Loop 1 enzymes contain active sites-proximal loops that provide favorable interactions for 
binding smaller substrate-glucuronides.  The Loop 1 and mini-Loop 1 enzymes are most 
frequently associated with the cleavage of small molecule glucuronides, including drug-
glucuronide substrates. The FMN-binding GUS enzymes possess a flavin-mononucleotide 
cofactor at an allosteric site that aids in structural stability. To date the exact role of FMN is 
unclear, but we have found that these enzymes are uniquely capable of small molecule 
glucuronide cleavage.  
 We determined catalytic efficiency (M-1 s-1) values with E1-3G for the 17 enzymes 
identified. These rates range from 6.40 × 105 to 1.08 × 102 s-1 M-1 (Figure 3.2B). The catalytic 
efficiencies were also determined for the 15 enzymes capable of processing estradiol-17-
glucuronide. These rates range from 1.83 × 104 to 1.26 × 102 s-1 M-1 (Figure 3.2C). Several of 
these enzymes have been examined previously with the standard GUS assay substrate 4- 
nitrophenyl β-D-glucuronide (pNPG), where the catalytic efficiencies range from 9.2 × 105-3.6 
× 101 comparable to what we observe with the estrogen-glucuronides (28). This result suggests 
that some gut microbial GUS enzymes may have evolved to be able to process estrogen-
glucuronide substrates efficiently to gain the six-carbon source of energy.  
 With the estrogen-glucuronide substrates, we find that the rates of the Loop 1 enzymes 
are, in general, the fastest processors of both estrone- and estradiol-glucuronide, with the FMN-
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binding GUSs the second fastest, and the mini-Loop 1 GUS enzymes as the slowest estrogen 
processors.  In summary, we provide the first detailed in vitro data on the ability of human gut 
microbial GUS enzymes to process the glucuronides of estrone and estradiol, and thus that 
bacterial GUS proteins are active components of the estrobolome. 
Structural Rationale for Estrogen Glucuronide Processing Gut Microbial GUS Enzymes 
 With concerted modeling and site-directed mutagenesis efforts, we have highlighted the 
residues involved in catalysis, providing rationale for rate differences of the three categories. 
First, we modeled E1-3G and E2-17G into the active site of a tetrameric Loop 1 GUS from C. 
perfringens (4JKM) (9). Because we know precisely where and how the glucuronide moiety 
binds (11, 12, 25, 27, 28), and these substrate molecules have a limited number of rotatable 
bonds, we know with reasonable certainty where these estrogens are within the active site. From 
these models we have identified aromatic residues within the Loop 1 architecture that provide 
potential pi-stacking interactions that would facilitate substrate binding to optimize cleavage 
(Figure 3.4A).  
 One of these residues (F363) comes from the Loop 1 itself, providing an edge-to-face 
interaction. The second residue, F368, is donated from the Loop 1 of an adjacent monomer, 
providing a face-to-face interaction. These residues, coupled with the completely conserved 
Y472 create an aromatic cage, perhaps explaining why the Loop 1 enzymes exhibit the highest 
catalytic efficiencies that we measured in vitro (Figure 3.4A). To test this hypothesis, mutants 
proteins of F363A, F368A and Y472A were created. The Y472A mutation is detrimental to 
structural stability and as a result is inactive. However, the mutants of F363A and F368A are 
both stable yet significantly reduce the catalytic efficiency of the molecule. Furthermore, the 
double mutation, F363A + F368A, eliminates activity of the enzyme entirely (Figure 3.4B). 
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These experiments help to confirm our modeling and establish the critical role the aromatic cage 
in a gut microbial GUS Loop 1 region to the turnover of estrogen-glucuronides.  
 Second, we used the same model of estrogens overlaid with the structure from the 
tetrameric B. fragilis β-glucuronidase (3CMG) to identify structural features within the mini-
Loop 1 architecture that aid in turnover. Like the Loop 1 GUS enzymes, the mini-Loop 1 possess 
the conserved tyrosine present in all GUS structures (e.g. Y472 in C. perfringens Loop 1 GUS) 
and an aromatic residue in the mini-Loop 1, Y389 (Figure 3.4C). The tetramer of this GUS is 
different from the previously resolved Loop 1 GUS enzymes, however, in that the active site 
interfaces do not overlap. Indeed, the loop of an adjacent monomer does not extend into the 
active site like it does in the Loop 1 architecture; thus, it only has the one aromatic residue rather 
than two, making the aromatic cage notably smaller, perhaps explaining the slower rates of the 
mini-Loop 1 enzymes compared to the Loop 1 enzymes (Figure 3.4C). To test this, we created a 
Y389A mutation in B. fragilis GUS and found that it reduces the rate of estrone-glucuronide 
cleavage by an order of magnitude, from a rate of 7.75 ×103 to 3.20 × 102 s-1 M-1 (Figure 3.4D). 
Thus, structural modeling and mutagenesis provide a rationale for why the mini-Loop 1 enzymes 
are less efficient than the Loop 1 enzymes in processing estrone-3-glucuronide.   
 Third, we modeled the estrogens within the active site of a dimer from R. gnavus3 GUS 
(6MVG), an FMN-binding GUS (30). We have previously shown that although these enzymes 
have an open, planar active site with few aromatic residues, they contain roughly 150 residues 
that have yet to be resolved in any of the crystal structures we have determined to date (30). 
However, a model of this domain has been created based on a Loop 2 GUS from B. uniformis 
(5UJ6) (27), and this model places the C-terminal domain roughly 15Å from the active sites of 
these enzymes. This potentially flexible C-terminal domain could influence catalytic activity of 
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the FMN enzymes (Figure 3.4E). Indeed, when this domain is eliminated (mutant: STP641), 
enzyme activity of R. gnavus3 GUS is virtually eliminated (Figure 3.4F). Thus, the C-terminal 
domains of the FMN-binding human gut microbial GUS enzymes play critical roles in substrate 
turnover that allows these FMN-binding GUS proteins to behave akin to Loop 1 GUS enzymes. 
 Finally, the ratio of the cleavage rate of estrone-3-glucuronide over estradiol-17-
glucuronide was calculated for each of the enzymes tested (Table 3.2). Interestingly, the Loop 1 
GUS and mini-Loop 1 GUS orthologs show preference for E1-3G over E2-17G. Furthermore, 
while two of the three mini-Loop 1 GUS proteins tested show some activity with E2-17G, the B. 
fragilis enzyme does not process E2-17G at all. Two distinctions between these substrates may 
be involved in these differences. First, E1-3G contains an aromatic ring immediately adjacent to 
the ether-linked glucuronic acid moiety. The planar feature of this aromatic ring may enhance 
activity because it can form favorable interactions with the GUS active sites in Loop 1 and some 
mini-Loop 1 enzymes.  In contrast, the more flexible cyclopentane ring in E2-17G cannot form 
potential pi-pi stacking interactions at the enzyme active site, and thus serves as a less optimal 
substrate. 
 Second, the methyl group on E2-17G appears to interfere with optimal positioning of the 
catalytic glutamates, which would certainly reduce catalytic activity with GUS enzymes (Figure 
3.5). In contrast, this methyl group in E1-3G is directed away from the active site glucuronic 
acids, likely allowing these catalytic residues more ready access to the ether linkage to be 
cleaved in E1-3G compared to E2-17G. Thus, differences in aromatic ring and methyl group 
positioning between these two estrogen glucuronides likely explain why the 3-glucuronide of E1 
is a more efficient substrate for the Loop 1 and mini-Loop 1 GUS enzymes compared to E2-17G. 
In contrast, the FMN-binding GUS enzymes which exhibit no preference for the 3- versus 17- 
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positions have more open active sites and may not encounter the same steric hindrance as the 
Loop 1 and mini-Loop 1 GUS enzymes. Taken together, we provide structure-guided insights 
into the observed differences in estrogen-glucuronide substrate turnover between the three 
categories of GUS enzymes found to process these compounds.  
Novel GUS Structures Reveal Unique Active Site Architectural Motifs 
 We were particularly intrigued with the observation that although the mini-Loop 1 
enzyme from F. prausnitzii  and the Loop One enzyme from uncultured Clostridium sp. process 
these estrogenic compounds, they were hundreds of times slower than every other mini-Loop 1 
and Loop 1 enzyme examined (Figure 3.2A [squares] Figure 3.2B, Figure 3.2C). We reasoned 
that there may be unique features to the F. prausnitzii and uncultured Clostridium sp. GUS 
proteins that make them slow with these estrogen-glucuronide substrates.  
 Using a multiple sequence alignment of all 279 GUS enzymes identified from the HMP, 
we found that 14 contained a loop insert of roughly 25 residues, like in E. eligens GUS (6BJW) 
(29). These residues were near the active site, adjacent to the Loop 1/mini-Loop 1 site, and could 
potentially contribute to binding (Figure 3.6). F. prausnitzii and Clostridium sp. GUS were both 
members of this group of 14 enzymes with the hypothesized novel loop. Therefore, we 
determined the x-ray crystal structures of these two novel tetramers to 2.7 Å and 2.2 Å 
resolution, respectively, (Table 3.3) and compared them to the classic architectures observed in 
several previous structures determined by our laboratory.  
 In the case of the F. prausnitzii GUS (PDB: 6U7I, Figure 3.7A), inspection of the active 
site reveals that this novel loop, adjacent to the mini-Loop 1 site, sterically occludes estrogen 
binding by this F. prausnitzii GUS. In fact, F153 and F154 (Figure 3.7A inset [purple]) on this 
loop extend into the active site and may prevent optimal recognition of these estrogenic 
compounds in this enzyme. Additionally, we observe a unique positioning of a critical aromatic 
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residue situated on this min-Loop 1 region expected to coordinate estrogen binding (e.g BfGUS: 
Y389). We find that this aromatic residue (Y378) is directed away from the active site in this 
novel structure, 10 Å further from the active site than previously resolved mini-Loop 1 GUS 
structures (Figure 3.7A inset). Thus, for F. prausnitzii GUS, steric occlusion by a loop not 
present in other mini-Loop 1 enzymes likely explains its poor functioning with the two estrogen-
glucuronides of interest in this report. 
 Second, the 2.2 Å resolution structure of the GUS from the uncultured Clostridium sp. 
(PDB: 6U7J, Figure 3.7B) initially revealed no obvious differences in quaternary or tertiary 
structure from the other Loop 1 enzymes, as the predicted novel loop contained ordered β-
strands, similar to E. coli GUS (PDB: 3LPF) (11). From E. coli GUS we know that deletion of 
this region does not impact substrate turnover with pNPG or diclofenac-glucuronide (28). 
However, inspection of the active site reveals a unique positioning of a critical aromatic residue 
situated on the Loop 1 region expected to coordinate estrogen binding in other Loop 1 and mini-
Loop 1 GUS enzymes (e.g., for Loop 1 enzymes EeGUS: F374, and CpGUS: F363; for the mini-
Loop 1 enzymes BfGUS: Y389).   
 While these aromatic residues are positioned to contact the steroid scaffold of bound 
estrogen-glucuronides in the standard Loop 1 and mini-Loop 1 GUS structures determined to 
date, the equivalent residues, F370, in the uncultured Clostridium sp. GUS is directed away from 
the active site and toward the solvent surface (Figure 3.7B inset). Furthermore, F370 in the 
uncultured Clostridium sp. GUS is stabilized in this position away from the active site by 
contacts with F379, H419 and W149 in this GUS structure, and thus is not likely to be capable of 
shifting in position into the active site to facilitate the binding of estrogen glucuronides. Taken 
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together, these novel human gut microbial GUS crystal structures provide molecular 
explanations for their relatively poor activity with the estrogen glucuronides examined. 
In vitro Inhibition of Gut Microbial GUS Enzymes that Process Estrogen Glucuronides 
 We have developed a series of chemotypes that are selective for and potently and non-
lethally inhibit human gut microbial GUS enzymes (9-12, 29). To date, these compounds are 
selectively for the Loop 1 group of microbial GUS enzymes (28, 29). Of the compounds 
examined, one inhibitor—UNC10201652— is particularly potent, as it contains a piperazine ring 
that intercepts the catalytic cycle of Loop 1 microbial GUS enzymes and is capable of forming a 
long-lived inhibitor-glucuronide moiety that remains bound at the enzyme’s active site (30). 
Thus, we chose to examine UNC10201652 (Figure 3.8) for its ability to inhibit estrogen-
glucuronide processing by a range of Loop 1 and non-Loop 1 gut microbial GUS enzymes.  
 As expected, UNC10201652 potently inhibits E1-3G and E2-17G processing by several 
“standard” Loop 1 gut microbial GUS enzymes, particularly those that showed efficient activities 
with these substrates in vitro, such as E. eligens, and C. perfringens (Figure 3.9A). 
UNC10201652 does not inhibit the activities of the Loop 1 GUS enzymes from F. prausnitzii or 
L. rhamnosus, however, which corroborates previous observations regarding these enzymes (28). 
Furthermore, it does not affect the activities of the unique gut microbial GUS enzymes from F. 
prausnitzii or the uncultured Clostridium sp. examined above. Variability in UNC1020165 
potency may be a result of differences in the amino acid sequences at the Loop 1 region as 
previously hypothesized (28). In addition, UNC1020165 may be ineffective against F. 
prausnitzii (mini-Loop 1) because of the novel loop identified here. 
 We also tested UNC10201652’s effect on the processing of estrogen-glucuronide 
substrates by non-Loop 1 human gut microbial GUS enzymes in vitro. As expected, because 
UNC10201652 has been shown to be specific for Loop 1 GUS enzymes with standard small-
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molecule GUS substrates and glucuronidated drugs (28, 29), this compound had no effect on the 
non-Loop 1 enzymes capable of processing estrogen-glucuronides in our in vitro studies (Figure 
3.9A). Thus, UNC10201652 is a potent and effective inhibitor of estrogen-glucuronide 
processing by a targeted subset of the gut microbial Loop 1 GUS enzymes examined.  
 Finally, we tested the ability of UNC10201652 to inhibit estrogen-glucuronide 
conversion by living E. coli cells. We have previously constructed a variant of E. coli K-12 
MG1655 cells in which the gus gene was truncated to remove the amino acids between the two 
conserved catalytic glutamates (GUSΔ413-504). As expected, in this knockout strain, we see no 
GUS activity in cultured cells (Figure 3.9B). We find with WT E. coli K-12 MG1655 cells, that 
UNC10201652 show EC50 values of 155 ± 7 nM and 148 ± 8 nM toward E1-3G and E2-17G 
processing, respectively (Figure 5B), similar to what has been observed previously with this 
inhibitor and other substrates (29). Thus, taken together, we have demonstrated that our most 
potent gut microbial GUS inhibitor to date is effective in vitro and in cells against several key 
estrogen-glucuronide processing Loop 1 GUS enzymes, but does not inhibit all the β-
glucuronidases that would appear to participate in the complete estrobolome. 
In fimo Evaluation of Estrobolome Modulation 
 Next we sought to examine the reactivation of estrogen-glucuronides by gut microbial 
GUS enzymes present in mammalian intestinal contents. We use the Latin term in fimo to 
describe studies on fecal samples obtained ex vivo. In this in fimo study, we obtained fecal 
sample preparations from 11 BALB/c mice (6 female, 5 male) and tested their ability to 
deconjugate E1-3G and E2-17G in fimo. Fecal samples were homogenized, sonicated, and then 
subjected to centrifugation, after which the resulting supernatant was used to quantify GUS 
activity. 
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 After incubation of the estrogen conjugate and the in fimo specimen for an hour, we find 
that every fecal sample is capable of processing these estrogen-glucuronides to varying degrees 
to produce the parent compounds, estrone and estradiol, indicated that GUS enzymes are indeed 
active members of the estrobolome (Figures 3.10A, B). Further, we tested the ability of 
UNC10201652 to inhibit estrogen-glucuronide conversion by these in fimo preparations. We find 
that upon addition of 10 µM UNC10201652, we can inhibit in fimo the formation of estrone and 
estradiol from E1-3G and E2-17G respectively. All samples tested showed a trend toward 
reduction in these reaction rates. The variability in response to UNC10201652 likely arises from 
the differential levels of Loop 1 GUS enzymes present in each sample. Taken together, these 
data support the conclusion that gut microbial GUS enzymes are active components of the 
estrobolome, and that such enzymes may be amenable to control using targeted small molecule 
inhibitors.  
In vivo Model of the Estrobolome Hypothesis 
 We have previously shown for both irinotecan and NSAIDs that targeted Loop 1 GUS 
inhibitors effectively alleviate GI toxicity associated with these drugs (11, 13, 14). This is despite 
the fact that we have also shown that other GUS orthologs including the mini-Loop 1 and FMN 
GUS enzymes, also reactivate these glucuronides (28). As such, we hypothesized that our 
inhibitor could similarly be used to prevent tumor growth in an HR + breast cancer model. 
 MMTV-PyMT is a transgenic mouse model in which the expression of the oncogene is 
driven by the mouse mammary tumor virus promoter, resulting in widespread transformation of 
the mammary epithelium and development of multifocal mammary adenocarcinomas and 
metastatic legions in the lung and lymph nodes (31-33). Additionally, in this model, mice exhibit 
a gradual loss of steroid hormone receptors (estrogen and progesterone) similar to human breast 
cancer. Because the MMTV-PyMT mouse model is characterized by short latency, high 
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penetrance, and a high incidence of lung metastasis, it was chosen to test the role of β-
glucuronidase enzymes within the GI as they contribute to total estrogen burden and breast 
cancer risk.  
 PyMT females were gavaged beginning at 4 weeks old with UNC10201652 (or saline for 
control group) for 9 weeks every day except weekends (20 µg/mouse/day). On the final day, 
animals were sacrificed, and histology analysis of breast tissue, liver, and kidneys was 
performed. We hypothesized that the group given UNC10201652 would have fewer and smaller 
tumors by the end of the treatment period, as the Loop 1 GUS enzymes were shown to be fastest 
in vitro at reactivating estrogens from their glucuronides. In fact, we see no difference in legion 
size or quantity in mammary pads between the control and treated mice (Figure 3.10B, Figure 
3.11, Table 3.4, Table 3.5). This result may be because only one inhibitor chemotype was 
examined, at a single dose, with one dosing regimen; at this point, however, we only have potent 
gut microbial GUS inhibitors that target Loop 1 GUS enzymes. Therefore, such a compound may 
be insufficient to block the reactivation of estrogens in the gut that potentially participate in 
tumor growth in this model. 
Discussion 
 The estrobolome, first defined in 2011 as the aggregate of all enteric bacteria capable of 
metabolizing estrogen, is predicted to impact endogenous estrogen metabolism by modulating 
the enterohepatic circulation of estrogens, thus affecting plasma estrogen levels (5). This initial 
review, and subsequent contributions to the literature, suggest that gut microbial β-glucuronidase 
enzymes are especially important in total estrogen circulation (5-8). Further, it has been 
hypothesized that an estrobolome rich in deconjugating GUS enzymes would be a contributing 
factor in breast cancer.  
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 Here, we probe the potential roles of gut microbial GUS proteins in the estrobolome by 
testing a panel of 35 human gut microbial GUS enzymes with two endogenous small molecule 
estrogens: estradiol-17-glucuronide and estrone-3-glucuronide. Guided by the structures of 14 
GUS enzymes, including novel structures reported here, we have identified characteristics of 
GUS enzymes that contribute to deconjugation. In general, specific members of three subtypes of 
GUS enzymes are able to process these glucuronides: Loop 1 GUS, mini-Loop 1 GUS, and 
FMN-binding GUS. In addition to defining key residues involved in estrogen-glucuronide 
processing, we demonstrated that we can inhibit estrogen reactivation by Loop 1 GUS enzymes 
using a targeted microbial GUS inhibitor, UNC10201652. In spite of these promising 
preliminary data, UNC10201652 alone was not able to impact tumor development in the PyMT 
mouse model of breast cancer. 
 We have previously demonstrated that GUS orthologs other than the Loop 1 enzymes are 
capable of processing irinotecan and NSAIDs, yet our targeted Loop 1 inhibitors effectively 
alleviate gut toxicity associated with these drugs (11, 13, 14, 28). As such, we hypothesized that 
the same paradigm could apply to inhibiting hormone reactivation in the GI and possibly impact 
tumor growth in the PyMT mouse model of HR + breast cancer. However, we see no difference 
in mammary lesion size between mice treated with vehicle or UNC10201652.  
 Lack of impact on breast tumor lesions may be because only a single inhibitor 
chemotype, at a single dose, with one dosing regimen was examined. This inhibition may not be 
sufficient to disrupt estrogen regeneration in the GI tract that has been hypothesized to be 
reabsorbed and trafficked to the developing tumors in breast tissues. Future studies could focus 
on variabilities in dosing and regimen to answer this question more completely. However, 
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ultimately, the inability to combat breast tumor formation in the PyMT model is most likely the 
consequence of the complexity of breast tumor formation.   
 There is increasing evidence from epidemiological, animal, and in vitro studies that 
endogenous estrogens are involved in breast carcinogenesis (34-36). As such, steroid hormone 
biosynthetic pathways have been under investigation for decades and there is abundant 
information on their metabolism in humans. Cytochrome P450s, UGTs, sulfotransferases, and 
catechol-O-methyltransferases are just a few of the major enzymatic families that metabolize 
estrone, for example (37-41). Some of the major metabolites of estrone are highlighted in Figure 
3.12. It is possible that estrone and estradiol are first glucuronidated in the liver and, after being 
transported to the gut, are immediately acted on by GUS enzymes. These GUS enzymes then 
reactivate the parent estrogen and allow them to be further metabolized into methoxy-estrogens, 
semiquinones, and quinones, etc. Such considerations might explain why targeting GUS has no 
impact on tumorigenesis in the PyMT model. However, it must be noted that sulfonation and 
hydroxylation play much larger roles in human metabolism than glucuronidation does. The 
action of sulfatase enzymes is perhaps more likely the preferred deconjugation step of estrogenic 
metabolites in the gut. Future studies will be required to evaluate the role of sulfatases in gut 
estrogen metabolism. 
 Further, the metabolites outlined in Figure 3.12 do not include the incredible, diverse, 
and surprising amount of novel chemistry that occurs in the gastrointestinal tract. For example, 
the sterol scaffold-related bile acids are a good example of our growing understanding of the 
biotransformations that occur during mammalian-microbial symbiosis. Bile acids can be 
conjugated, deconjugated, hydrolyzed, epimerized, oxidized, methylated, etc., to play roles in 
absorption and digestion (42-45). Therefore, like bile acids, it may be that endogenous estrogens 
90 
are transformed and repurposed for use in other areas of the body, like distal mucosal or receptor 
sites. We therefore propose that the estrobolome acts as an estrogen reservoir in the gut and is 
capable of creating estrogenic metabolites for local and non-local functions, rather than only 
simple reactivation. Future studies with other model systems and deeper bioanalytical 
investigations will be required to unravel how gut estrogen metabolism may affect hormone-
dependent tumor growth in vivo. Taken together, these observations support the conclusion that 
the estrobolome’s effects on breast cancer development is likely complex and multivariant. 
Conclusion 
 Guided by initial data with 35 gut microbial GUS enzymes, and then by the subsequent 
detailed analysis of 14 GUS proteins including the resolution of relevant novel crystal structures, 
we have pinpointed molecular characteristics that contribute to estrogen deconjugation. These 
are key initial data to validate the fact that gut microbial GUS enzymes are functional members 
of the estrobolome. Furthermore, we postulate that the gut may serve as a reservoir for estrogenic 
metabolites capable of acting locally and perhaps distantly in systemic homeostasis and the 
development of disease.  
Experimental Procedures 
Gene Synthesis, Expression, and Purification of GUSs 
 All genes were synthesized by BioBasic and incorporated into a pLIC-His vector via 
ligation independent cloning, and resultant plasmids were transformed into BL21-G E. coli cells. 
Glycerol stocks were made from overnights and snap frozen and stored at − 80 °C. Verification 
of successful transformation and sample integrity were determined by DNA sequencing. 
 Cultures of 100 mL LB with ampicillin were inoculated with glycerol stock and 
incubated overnight at 37 °C with shaking at 225 rpm. For protein expression, 50 mL of the 
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overnight, approximately 40 μL Antifoam 204, and 750 μL of 2000x ampicillin were added to 
1.5 L LB in a 2.5-L Erlenmeyer flask and incubated at 37 °C at 225 rpm. At an OD of 
approximately 0.6, the temperature was reduced to 18 °C and induced with IPTG (100 mM) and 
incubated overnight with shaking at 225 rpm. Cultures were spun down in a Sorvall Instruments 
RC-3B centrifuge at 4500g for 25 min in 1 L round, flat bottom plastic bottles. Cultures were 
resuspended in LB and transferred to a 50-mL falcon tube and spun down in a ThermoScientific 
Sorvall ST 40R centrifuge for 15 min at 5000g. Supernatant was discarded and proteins were 
stored at − 80 °C until purification. 
 Cell pellets were lysed in 30 mL Nickel A buffer [20 mM KH2PO4, 500 mM NaCl, 
50 mM imidazole (pH 7.4)] with DNase, lysozyme, and a Roche EDTA-free protease inhibitor 
tablet. The resultant cell slurry was sonicated on a Fischer Scientific Sonic dismembrator model 
500 twice with 1 s pulses for 1.5 min. The resultant lysate was subsequently spun down on a 
Beckman Coulter J2-HC centrifuge for 1 h at 17,000 rpm. The supernatant was subject to 
filtration with a 0.22-μm filter prior to purification. 
 Protein was first purified with an Aktaxpress FPLC (Amersham Bioscience) via a Ni 
NTA column. Protein was eluted in one step using Nickel B buffer [20 mM KH2PO4, 500 mM 
NaCl, 500 mM imidazole (pH 7.4)]. The eluent was then subject to size exclusion 
chromatography on a HiLoadTM 16/60 Superdex 200 gel filtration column. Size exclusion 
buffer was utilized for elution [20 mM Hepes, 50 mM NaCl (pH 7.4)]. Fractions were collected 
and an SDS-PAGE gel was performed to assess purity and stability of the enzyme. Protein 
concentration was determined on an ND-1000 spectrophotometer and then snap frozen in liquid 
nitrogen and stored at − 80 °C. 
Site-directed Mutagenesis of GUSs 
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 All mutants were created via site-directed mutagenesis. Mutagenesis primers were 
synthesized by Integrated DNA technologies. Mutant plasmids were sequenced by Eton 
Bioscience to confirm successful mutagenesis.  
SSN Construction 
 The sequence similarity network diagram of GUS enzyme sequences was generated using 
the enzyme function initiative-enzyme similarity tool (EFI-EST) online tool (26). The sequences 
obtained from the GUS rubric were used in combination with the EFI-EST "FASTA" tool to 
create a sequence with 279 nodes. Each node represents sequences bearing ≥90% sequence 
identity to each other. A BLAST E-value of 1 x 10-220 was employed. 
In vitro Coupled Assay Estrogen Processing Assay 
 Estrone-3-β,D-glucuronide (E1-3-G) and Estradiol-17-β,D-glucuronide (E2-17-G) were 
purchased as solids (Toronto Research Chemicals, North York, ON) and resuspended in DMSO 
to a concentration of 10 mM. In vitro assays were conducted in 50 μL total volume. Reactions 
consisted of 5 μL uronate dehydrogenase (1 µM final), 5 µL enzyme (30 nM final), 10 µL NAD+ 
(2 mM Final), and 30 μL E1-3-G or E2-17-G (500 μM final) all diluted in assay buffer (50 mM 
HEPES, 50 mM NaCl, various pH). The pH of each reaction was chosen based on the optimal 
pH determined for each GUS with pNPG. Reactions were incubated at 37°C for 30 minutes, after 
which reactions were quenched with equivalent volume sodium carbonate. Final absorbance was 
monitored at 340 nm in a BMG lab tech PHERAstar plate reader. Enzyme was considered to 
process substrate if the final absorbance monitored was at least twice that of the minus enzyme 
control.  
Manual Docking of Estrogens in PyMOL 
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 Estrone and estradiol were accessed from the PDB in previously solved crystal structures. 
These were then imported into PyMOL and manually aligned to the GlcA-bound BuGUS-1 
structure (PDB 6DW6) with the 3-button editing tool. After manual alignment of the sugar 
monosaccharides, structures of the L1, mL1, and FMN binding GUS enzymes were aligned to 
the monomer of BuGUS-1. Visual inspection and final figures after alignment were generated in 
PyMOL. 
In vitro HPLC Estrogen Processing Assay  
 Estrone-3-β,D-glucuronide (E1-3-G) and Estradiol-17-β,D-glucuronide (E2-17-G) were 
purchased as solids (Toronto Research Chemicals, North York, ON) and resuspended in DMSO 
to a concentration of 10 mM. In vitro assays were conducted at 37°C in a 50 μL total volume. 
Reactions consisted of 10 μL assay buffer (50 mM HEPES, 50 mM NaCl, various pH), 10 μL 
enzyme (various concentrations), and 30 μL E1-3-G or E2-17-G (various concentrations) diluted 
in assay buffer. The pH of each reaction was chosen based on the optimal pH determined for 
each GUS with pNPG. Reactions were quenched at six time intervals with 50 μL of 25% 
trichloroacetic acid (TCA). After centrifugation at 13,000xg for 10 min, the resultant supernatant 
was subjected to HPLC analysis. The concentration of E1-3-G or E2-17-G remaining at each 
time point was quantified on a Agilent 1260 Infinity II liquid chromatograph system. Samples 
were separated on an Agilent InfinityLab Poroshell 120 C18 column (4.6 x 100 mm, 2.7 μm 
particle size) at 38°C. The flow rate was 0.9 mL/min, and the injection volume was 10 μL. LC 
conditions were set at 98% water with 0.1% formic acid (A) for 2 mins, then ramped linearly 
over 10 mins to 98% acetonitrile with 0.1% formic acid (B) and held until 14 mins. At 15 mins 
the gradient was switched back to 100% A and allowed to re-equilibrate until 17 mins. E1 and 
E2 were monitored at 280 nm. The concentration of E1 and E2 were determined from a standard 
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curve (0-500 μM E1-3-G/E2-17-G in assay buffer). Resultant progress curves were fit by a 
custom linear regression analysis program in MATLAB. Initial velocities were then plotted 
against substrate concentration and fit with linear regression in Microsoft Excel to determine 
catalytic efficiency (kcat/Km). Control reactions were performed in which enzyme was 
substituted with buffer. Background hydrolysis was not observed at each pH tested. Reactions 
were performed in triplicate for each enzyme. 
Crystallization and Structure Determination  
 Crystals of F. prausnitzii and uncultured Clostridium sp. were produced via the sitting-
drop method. F. prausnitzii crystals were formed by incubation of 10 mg/mL GUS in 0.1 M Bis-
Tris: HCl, pH 8.5 and 1.8 M Magnesium Sulfate at 20°C. uncultured Clostridium sp. GUS 
crystals were formed by incubation of 12 mg/mL GUS in 0.2 M Calcium Chloride, 0.1 M Tris: 
HCl, pH 8.5 and 20 % (w/v) PEG 4000 at 20°C. Diffraction data for all crystals were collected at 
APS beamline 23-ID-D and ID-B, and data were collected at 100 K. Structures were solved via 
molecular replacement with PDB 5Z1B and 4JKM respectively in the software Phenix. 
Refinement was also performed in Phenix, with initial rounds of simulated annealing. Final 
coordinates and structure factors have been submitted to the RCSB and assigned accession codes 
6U7I and 6U7J respectively. 
In vitro Inhibition Assay  
 Reactions consisted of 10 μL of GUS (15 nM final), 5 μL of inhibitor (1 µM final for 
inhibitor UNC102016520 and 10 µM final for all other inhibitors), 30 μL of Estrone-3-
Glucuronide or Estradiol-17-Glucuronide (900 μM final), and 10 μL of assay buffer (25 mM 
NaCl, 25 mM HEPES, pH 7.4 final). Reactions were initiated by addition of pNPG and then 
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incubated for 1 hour, after which the end point absorbance was determined. Final percent 
inhibition was determined via HPLC as described above. 
In Cell Inhibition Assay 
 WT E. coli K-12 MG1655 was grown overnight in 10 mL of LB, and a 100 μL portion 
was subcultured the following morning in 5 mL of fresh LB. Cells were grown to an OD of 
approximately 0.6 and used for the cell-based assay. Reactions were carried out in costar 96-well 
black clear bottom plates. Reaction volumes consisted of 90 μL of cells premixed with 700 μM 
estrone-3-glucoronide or estradiol-17-glucuronide and various concentrations of 10 μL of 
inhibitor. This reaction was incubated for 24 h at 37 °C with a low evaporation lid. Incubations 
were quenched by addition of 50 μL of 0.2 M sodium carbonate. Absorbance values were 
measured at 410 nm in a BMG lab tech PHERAstar plate reader. Percent inhibition and EC50 
values were determined as described previously (29). 
In fimo Estrogen Deconjugation and Inhibition 
 All animal studies were approved by the University of North Carolina Institutional 
Animal Care and Use Committee (IACUC), in accordance with the Care and Use of Laboratory 
Animals guidelines set by the National Institutes of Health. BALB/c mice were individually 
housed in specific pathogen-free conditions with sterile ventilator cages containing corn bedding, 
with ad libitum access to chow and water. Fecal pellets were collected from each mouse shortly 
by gentle abdominal palpation and snap frozen in sterile microfuge tubes. To perform the assay, 
frozen fecal samples were rehydrated in 15× assay buffer (weight/volume; 20 mM HEPES, 
50 mM NaCl, pH 6.5, 1 × Complete® Protease inhibitor cocktail (Roche). Bacterial cells were 
lysed using a Tissuelyzer II (Qiagen) for 2 min at 30 Hertz. 
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 Homogenate was sonicated for 4 min, and then clarified by centrifugation for five 
minutes at 13,000×g. All experimental manipulation until this point occurred at 4 °C. 0.1 mg/mL 
of protein from the fecal slurry supernatant was used to initiate the hydrolysis reaction of 1 mM 
estrone-3-glucuronide or estradiol-17-glucuronide resuspended in the same buffer. Parallel 
reactions containing 10 µM inhibitor were used to determine percent inhibition; additionally, 
only estrogen or only buffer/fecal slurry were used as negative controls. An aliquot of each 
sample was heat inactivated at 95 °C and used in the assay for further background establishment. 
Each sample was assayed using two technical replicates with the HPLC protocol above. The total 
amount of estrogen produced was calculated from a standard curve, and then normalized to the 
total fecal protein content calculated using a standard Bradford assay. 
UNC102016520 GUS Inhibitor Administration in PyMT Mouse Model 
 All animal studies were completed in accordance with the Care and Use of Laboratory 
Animals guidelines set by the National Institutes of Health. PyMT males, a gift from Jeffery 
Pollard lab, and FVB females were put in one cage for genotyping pups. Males are kept for 
continuous breeding with FVB females. PyMT females were used for UNC10201562 assays. 
Two groups of 11 mice each were individually housed in specific pathogen-free individually 
housed vivarium maintained with 12h:12h light/dark cycle, in specific pathogen-free conditions 
with sterile ventilator cages containing corn bedding, with ad libitum access to chow and water. 
Beginning at 4-weeks old, female PyMT mice were gavaged with UNC10201562 for a final 
concentration of 100 µL/20µg/mouse (Final DMSO 0.67%) every day except weekends for 9 
weeks. On the last day, animals were deeply anesthetized with CO2 followed by manual cervical 
dislocation to collect samples for histology analysis of breast tissue, liver, kidney et al.  
 
97 
TABLE 3. 1: GUS Accession Numbers and Initial Activity 
 
aAccession IDs are from NCBI.  Data are presented in µM as the average of 3 biological 
















































TABLE 3. 4: Size of Legions in Vehicle Treated PyMT Mice. 
 





TABLE 3. 5: Size of Legions in UNC10201652 Treated PyMT Mice
 






Figure 3. 1: β-glucuronidase Enzymes Reactivate Estrogens.  
Gut microbial β-glucuronidase enzymes within the GI deconjugate estrone-3- and estradiol-17- 
glucuronides to the aglycones estrone and estradiol, respectively. This reactivation allows 
unbound estrogens to be recirculated through the bloodstream, possibly contributing to a variety 









Figure 3. 2: Identification of Estrogen Deconjugating β-glucuronidase Enzymes. 
A. Sequence Similarity Network of 279 unique GUS enzymes from the Human Microbiome 
Project. Each circle represents a unique protein sequence. Of the 279, 35 enzymes were tested for 
their ability to reactivate estrone-3-glucuronide and estradiol-17-glucuronide (triangles). Colored 
triangles are those enzymes that can reactivate estrogens while grey triangles cannot. Colored 
squares are the two novel GUS proteins identified here that can reactivate estrogen glucuronides. 
B. Catalytic efficiencies of 17 GUS enzymes that reactivate estrone-3-glucuronide. * Denotes 
statistical difference with p-value 0.0001. ** Denotes statistical difference with p-value 0.00001. 
C. Catalytic efficiencies of 15 GUS enzymes that reactivate estradiol-17-glucuronide. * Denotes 







Figure 3. 3: GUS/UDH Coupled Assay. 
Assay scheme showing the coupled formation of glucuronic acid to uronate dehydrogenase and 















Figure 3. 4: Structural Rationale for Estrogen Glucuronide Processing Gut Microbial GUS 
Enzymes. 
In purple and pink are estrone-3-glucuronide and estradiol-17-glucuronide respectively. Catalytic 
glutamates are highlighted in marine and N-K glucuronide recognition motif is highlighted in 
magenta. A. Active site of Loop 1 GUS from C. perfringens. In cyan are the residues that 
contribute to aromatic cage that allow the Loop 1 enzymes to be the fastest processors of 
estrogen glucuronides. B. Mutagenesis of aromatic residues of Loop 1 C. perfringens that 
contribute to binding. * Denotes statistical difference with p-value 0.0001. ** Denotes statistical 
difference with p-value 0.00001. C. Active site of mini-Loop 1 GUS from B. fragilis. In cyan are 
the residues that contribute to aromatic cage that allow the mini-Loop 1 enzymes to process 
estrogen glucuronides D. Mutagenesis of aromatic residues of mini-Loop 1 B. fragilis that 
contribute to binding. * Denotes statistical difference with p-value 0.0001. ** Denotes statistical 
difference with p-value 0.00001. E. Monomer and active site of FMN-binding GUS from R. 
gnavus. The C-term domain (pink) is modeled from a previously resolved structure (5UJ6) F. 
Mutagenesis of residues that may contribute to binding of estrogen glucuronides. As there are no 
obvious residues at the active site that contribute to binding, mutants were made to probe steric 
occlusion of S344 and the role of the C-term domain. * Denotes statistical difference with p-




Figure 3. 5: Structural Rational for Slower Rates of Estradiol-17-Glucuronide Processing. 
Estrone-3-glucuronide contains the aromatic ring nearest the glucuronic acid moiety; the planar 
features of the aromatic ring compared to the more flexible cyclopentane ring may promote 
optimal substrate turnover. Additionally, the methyl group on estradiol-3-glucuronide may 
prevent optimal recognition by the catalytic glutamates as it is positioned between the steroid 
scaffold and the glucuronic acid. In contrast, this methyl group is directed away from the 










Figure 3. 6: Novel Active Site Loop Identification. 
A. Multiple sequence alignment of 14 proteins from the 279 identified from the Human 
Microbiome Project that are predicted to contain a novel loop adjacent to the Loop 1 region. 
Novel structures are in bold. E. coli and BuGUS2 which do not contain the loop region have 
been added for reference. B. Sequence similarity network spatially relating the 14 “novel-loop” 
sequences identified from the HMP. Enlarged points are predicted to contain the loop. E. eligens 
GUS (6BJW) is highlighted as a triangle for reference. Squares are enzymes tested in this panel. 
Grey points do not contain the loop, red points are Loop 1 enzymes, and green points are mini-
Loop 1 enzymes. C. Position of novel loop site in E. eligens GUS where the Loop 1 site is in red 




Figure 3. 7: Novel GUS Structures Reveal Unique Active Site Architectural Motifs that 
Contribute to Estrogen Glucuronide Reactivation Rates. 
In purple and pink are estrone-3-glucuronide and estradiol-17-glucuronide respectively. Catalytic 
glutamates are highlighted in marine and N-K glucuronide recognition motif is highlighted in 
magenta. A. Structure of mini-Loop 1 enzyme from F. prausnitzii. In green is the conserved 
tyrosine on the mini-Loop 1 region; this residue is 10 Å further from the active site than 
previously resolved mini-Loop 1 GUS structures. Active site also reveals novel loop (purple) that 
extends into the active site, possibly contributing to its slow rate with these estrogenic substrates. 
B.  Structure of Loop 1 enzyme from an uncultured Clostridium sp. revealing the conserved 











Figure 3. 9: Inhibition by UNC10201652. 
A. In vitro inhibition of all 17 estrogen-reactivating enzymes identified in this study. 
UNC10201652 is only effective towards the Loop 1 GUS architecture. B. In cell activity and 
inhibition by UNC10201652. E. coli was incubated with estrone-3-glucuronide and estradiol-17-
glucuronide and with/without inhibitor. In the absence of UNC10201652 E. coli shows 100% 
activity. In the presence of inhibitor activity is reduced by 80%. 
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Figure 3. 10: Ex vivo and in vivo Application of UNC10201652. 
A. Fecal samples from 11 mice were incubated with estrone-3-glucuronide in the presence and 
absence of UNC10201652. Fecal samples incubated with inhibitor show decreased activity. * 
Denotes statistical difference with p-value 0.001. B. Fecal samples from 11 mice were incubated 
with estradiol-17-glucuronide in the presence and absence of UNC10201652. Fecal samples 
incubated with inhibitor show decreased activity. * Denotes statistical difference with p-value 
0.001. C. Legion size of PyMT treated mouse model of breast cancer. Mice treated with 





Figure 3. 11: Legion Size of Vehicle and UNC10201652 Treated PyMT Mice at 4 Biopsied 
Areas. 











Figure 3. 12: Estrone metabolism. 
Although many metabolites are possible, this study focuses on the deconjugation of estrone-3-
glucuronide to estrone. In addition to being glucuronidated, estrone can be sulfonated, 
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CHAPTER 4: STRUCTURAL INSIGHTS INTO ENDOBIOTIC REACTIVATION BY 
HUMAN GUT MICROBIOME-ENCODED SULFATASES4 
 
Introduction 
 Sulfatases are unique within the alkaline phosphatase (AP) superfamily of hydrolytic 
metalloenzymes (1, 2) because their active sites contain a formylglycine (fGly) residue generated 
via the co-translational modification of a catalytic serine or cysteine side chain (3–6). Human 
sulfatases have been well characterized and paired with their cognate substrates, including 
hormones and polysaccharides (7–12). Analysis of the action of human steroid sulfatase on 
estrone has led to the development of inhibitors to disrupt its role in breast and ovarian cancers 
(13, 14). Human sulfatases also degrade oligosaccharides and have been associated with 
autosomal recessive lysosomal storage diseases (8, 10–12). By contrast, the gut microbial 
sulfatases are considerably less well examined. While they were originally thought to simply 
scavenge environmental sulfur (15, 16), research from the past decade reveals that gut bacterial 
sulfatases are involved in modulating mammalian-microbial symbiosis and host-pathogen 
interactions (17, 18).  
Phase II metabolism of xenobiotic and endobiotic processing adds solubilizing sulfates or 
glucuronides to endogenous and exogenous compounds to inactivate them and mark them for 
excretion, often via the gastrointestinal (GI) tract (19). While UDP-glucuronosyltransferases 
(UGTs) appear to function predominantly on drugs and xenobiotics during Phase II metabolism, 
the sulfotransferases (SULTs) instead act preferentially on endobiotic compounds (19). The 
reactivation of such Phase II conjugates in the gut leads to the enterohepatic recirculation of 
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xenobiotics and endobiotics, as well as the GI toxicities of a range of therapeutics (20, 21). Such 
reactivation is catalyzed by gut microbial enzymes encoded by the human intestinal microbiome. 
For example, gut microbial -glucuronidase (GUS) enzymes remove the glucuronic acid sugar 
appended to xenobiotics like irinotecan and NSAIDs and have been effectively blocked using 
targeted small molecule inhibitors (Figure 4.1A) (22, 23).  
Like GUS enzymes, gut microbial sulfatases are also poised to reactivate sulfated small 
molecule conjugates sent to the GI tract for excretion (24–26). Reactivation and subsequence 
enterohepatic recirculation may play key roles in human health and disease states. For example, 
key multifunctional molecules like estrogen and dehydroepiandrosterone (DHEA) are heavily 
sulfated in humans (27–31) and gut reactivation of these hormones by microbial sulfatases may 
generate recirculating estrogens that contribute to the progression of hormone related diseases 
like breast and ovarian cancers (32). Sulfatases encoded by the gut microbiome are also of 
interest for the roles they may play in the reactivation of neurotransmitters, and other 
endogenous compounds that reach the GI tract as sulfate conjugates (Figure 4.1B). 
Next-generation sequencing data present in open-access databanks like the Human 
Microbiome Project (HMP) and Integrated Gene Catalogue (IGC) have facilitated the study of 
complex biological systems, like the gastrointestinal tract, at the level of individual proteins. The 
HMP Stool Sample Catalog, the genes sequenced from 139 donor fecal samples, contains more 
than 4.8 million translated protein sequences in its Clustered Gene Indices (HMGC) database 
(33). The IGC contains deep-sequencing data from 1,267 fecal samples collected from 1,070 
people around the world (34). We employed a protein structure-guided approach to identify the 
microbial sulfatases present in the HMP and IGC databases. Furthermore, we elucidated human 
gut microbial sulfatase structures and examined extant sulfatase structures from intestinal and 
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environmental bacteria (1HDH, P. aeruginosa, PAS; 2QZU; B. fragilis; 3ED4, E. coli; 6J66, 
Vibrio sp. FC509; 5G2V, B. thetaiotaomicron;, 5G2T, B. thetaiotaomicron; 4UPI, Silicibacter 
pomeroyi; 4UPL: Silicibacter pomeroyi; 6BIA, Pseudoalteromonas sp. PS47; 6HHM, Formosa 
agariphila; 6HR5: Formosa agariphila; 4UG4, Rhizobium meliloti) (35–41) to define the 
variable motifs that drive quaternary structure and substrate specificity. Together, these results 
provide an atlas of human gut microbial sulfatases as well as key insights into the structural and 
functional diversity of enzymes with the potential to impact human health and disease. 
Results  
Sulfatase Identification from the HMP  
 A two-step rubric was employed based on the microbial sulfatase from Pseudomonas 
aeruginosa, (PAS, 1HDH), the first crystal structure of a bacterial arylsulfatase (35), to find gut 
microbial genes that encode sulfatase enzymes. First, the HMGC database was screened to select 
proteins that shared ≥25% sequence identity and core fold in a pairwise alignment to PAS 
(Figure 4.2A) (1HDH) (35). Next, the sequences identified from the first step were screened for 
essential active site residues C/SxP(A)xR, where the C/S is modified to fGly during enzyme 
maturation. This second active site structure-guided step identified 728 unique, non-redundant 
sulfatase proteins from the 4.8 million in the HMGC database.  
Next, to provide a more comprehensive census of human gut microbial sulfatases, and to 
examine the portability of these structure-guided methods, we examined the Integrated Gene 
Catalogue (IGC) database. The IGC is a metagenomic catalogue containing deep-sequencing 
data from 1,267 fecal samples collected from 1,070 people around the world, containing more 
than 9.9 million unique protein sequences (34). The IGC contains the HMP and as a result is a 
more comprehensive database. 1,766 distinct gut microbial sulfatases were identified from the 
IGC. Of the 1,766 sequences, 1,038 were unique to the IGC database. These results provide an 
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initial atlas of human gut microbial sulfatases, extend our understanding of the catalytic potential 
of the microbiota, and further highlight the utility of employing structure-guided rubrics to 
annotate microbiome sequencing data (42, 43). 
Analysis of Gut Microbial Sulfatase Localization and Function   
A sequence Similarity Network (SSN) was created from the 728 unique sulfatases 
identified in the HMP. Such analyses have the potential to differentiate a family of sequences 
into functionally-relevant groups, even if the full scope of the family’s function is not yet 
completely understood (Figure 4.2B) (44). This SSN reveals two key features: first, more than 
half of the sulfatase sequences identified are uncharacterized proteins – database entries without 
associated functions. This observation highlights the level of discovery that remains in the 
human gut microbial proteome. Second, of those with designated functions, the majority are 
annotated as being involved in carbohydrate metabolism (Figure 4.2B). Numerous gut 
carbohydrates are heavily sulfated, including heparin, dermatan, and chondroitin (8–12). In fact, 
the majority (62%) of the human gut microbial sulfatases examined here have a predicted N-
terminal signal peptide sequence that mark enzymes for potential trafficking to the periplasmic 
space (45). The genes for these putatively secreted enzymes were also found to be in in 
polysaccharide utilization loci (PULs) indicating their likely role in degrading polysaccharides 
for microbial energy harvesting. Indeed, previous data on sulfatase enzymes from the gut 
microbial symbiont Bacteroides thetaiotamicron and others has established that sulfatases are 
involved in extracellular polysaccharide processing (37, 38, 46, 47). Thus, secreted, periplasmic 
gut microbial sulfatases appear to participate in polysaccharide metabolism.  
Here, we focus exclusively on the roles microbial sulfatases play in processing sulfated 
small molecule endobiotic substrates. Thus, we chose five sulfatase sequences, synthesized their 
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genes sans secretion signals, and expressed and purified the resultant proteins for detailed 
analysis. These sequences were chosen to cover the taxonomic phyla and clades present in the 
SSN (Figure 1B). Data on these enzymes, Alistipes obesi (AoSulf), Bacteriodes fragilis (BfSulf), 
Culturomica massiliensis (CmSulf), E. coli (EcSulf [3ED4]), and Hungatella hathewayi 
(HhSulf), is presented below.  
Human Gut Microbial Sulfatase Active Site Motifs  
 Several pathways can install the essential fGly into the sulfatase active site. In aerobic 
conditions, the formylglycine generating enzyme (FGE) recognizes the catalytic pentapepide 
motif CxPxR and converts the catalytic cysteine to fGly (5–7, 17). In anaerobic conditions, an 
anerobic sulfatase maturating enzyme (anSME) recognizes either a CxPxR or SxPxR motif to 
produce the fGly from either a Cys or Ser side chain (4, 47–50) (Figure 4.2C). Finally, there is 
also at least one other uncharacterized mechanism that can occur in E. coli (51).  
Given that the gut is an anaerobic environment, it would be expected that anSME 
enzymes, which process either Cys- or Ser-type sulfatases, would be primarily employed. As 
such, one would predict that the ratio of Cys- to Ser-sulfatases in the 728 enzymes found in the 
HMP Stool Sample catalog would be roughly 1:1. This is in contrast to the catalytic motifs 
observed in >4,000 microbial sulfatase sequences in the UniProt database; in this broader set of 
sequences, 80% contain the cysteine consensus motif, CxPxR (52). Surprisingly, 80% of the 
sulfatases identified from the HMP are Ser-type sulfatases (Figure 4.2C, inset).  
The reason for serine active site predominance in gut microbial sulfatases is revealed in 
the taxonomy of the HMP sequences identified. 80% of the sulfatases found within HMP Stool 
Sample database belong to the Bacteroidetes phylum, which only encode Ser-type sulfatases 
(Figure 4.3). The remainder of the sulfatases in the census assembled here arise from Firmicutes, 
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Fusobacteria, Proteobacteria, Spirochaetes, and Verrucomicrobia phyla (Figure S2A). Firmicutes 
only encode Cys-type sulfatases, while some phyla, like the Verrucomicrobia, can encode both 
Ser- and Cys-type enzymes (Figure 4.3). Thus, 80% of gut microbial sulfatases are 
Bacteroidetes Ser-type enzymes, with Cys-type sulfatases arising from the other predominant gut 
microbial phyla. 
Structural Analysis of Arylsulfatases 
We determined the crystal structures of two human gut microbial sulfatases identified 
here, from B. fragilis CAG:558 (BfSulf) and H. hathewayi (HhSulf). Their structures were 
refined to 2.5 Å and 2.6 Å resolution, respectively (RCSB accession codes 6USS and 6UST, 
respectively; Table 4.1). E. coli sulfatase (EcSulf, 3ED4, deposited in 2008) is also found in the 
catalog of 728 human gut microbial sulfatases identified from the HMP Stool Sample database. 
The monomers of all three enzymes, BfSulf, EcSulf, and HhSulf, contain open active sites that 
appear amenable to processing small molecule substrates sulfate (Figure 4.4A). In contrast, 
while PAS shares 22-31% sequence identify with BfSulf, EcSulf, and HhSulf (Figure 4.5), the 
PAS active site is completely occluded by peripheral loops (Figure 4.4A).    
 When compared to human arylsulfatase A (7), BfSulf, EcSulf, and HhSulf exhibit 
RMSDs of 4.1, 3.6, and 4.1 Ȧ, over 308, 408, and 200 equivalent Cα positions, respectively 
(Figure S3). All four enzymes share common core secondary structural elements but exhibit 
distinct active site-proximal loops (Figure 4.4B). Despite these differences, eight residues within 
the active site are conserved both in sequence and structure between the gut microbial and 
human enzymes (Figure 4.4C). Using this new structural knowledge, we refined the initial 
sulfatase rubric to take these residues into consideration. Using these more stringent parameters, 
only 131 unique gut microbial sulfatases were identified from the HMP database—only 18% of 
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the original census . The sulfatases not retained most commonly lacked H211 and K375; when 
these two residues were not included in the rubric, we retained 590 of the original sequences. 
Surprisingly, using these new parameters to probe the IGC databases yielded 1,395 sequences —
almost 80% of the original census. Furthermore, within the IGC database, 90% of these 
sequences contain six additional conserved residues (Y106, P200, D291, D317, P386, D409).  
Future structural analyses will be needed to fully unravel the unique differences between these 
databases.  
 Comparing the structures presented here with the twelve extant microbial sulfatase 
structures (six from taxa capable of colonizing humans and six from environmental taxa) reveals 
that the fourteen sequences exhibit 17-38% sequence identity and RMSD values of 2.3-6.9 Ȧ 
over 192-448 equivalent Cα positions (Figure 4.5). Again, all structures share core secondary 
structural features (8 helices and 12 β-strands; Appendix B, Figure 4.6), as shown using a 
modification of the numbering scheme in Lukatela et al. (7). Notably, the least conserved 
features between all enzymes are the active-site adjacent loops (Figure 4.6, grey). Taken 
together, these observations support the conclusion that microbial sulfatases have a core sulfatase 
fold with a range of distinct structural motifs adjacent to their catalytic sites. 
Structural Motifs Unique to Microbial Sulfatases  
 Sulfatases possess five active site adjacent loops – Loop 1: orange, Loop 2: red, Loop 3: 
blue, Loop 4: green, Loop 5: purple (Figure 4.7). Of these five, two vary the most in size and 
composition between microbial enzymes: Loop 2 and Loop 3 (Figure 4.7, Appendix B).  The 
38-residue Loop 2 of BfSulf (G194-F230) contains little secondary structure and may be flexible 
to facilitate substrate binding (Figure 4.8A). This stretch is 15 residues shorter in HhSulf (S143-
P164). The 21-residue Loop 3 in HhSulf (R213-K243), by contrast, contains two β-strands near 
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the active site and may act as a solvent-barrier to improve hydrophobic substrate binding. This 
region is not present in BfSulf (Figure 4.8A, Appendix B).  
 Furthermore, examination of Loops 2 and 3 in the twelve bacterial sulfatase enzymes 
previously deposited in the PDB (35–41) reveals remarkable sequence and structural diversity 
(Figure 4.8, Appendix B). PAS (1HDH) (35) and the Silicibacter pomeroyi proteins (4UPI, 
4UPL) (41) are known to process small molecule sulfates and even phosphates and have 
relatively long Loop 2 and 3 regions (Figure 4.8B). The Silicibacter pomeroyi sulfatases 
resemble phosphate monoester hydrolases, which are known to be promiscuous and process a 
range of sulfate and phosphate mono- and di-esters (45) (Figure 4.8B). The sulfatases presented 
in Figure 4.8C and Figure 4.8D have shorter Loop 2 and 3 regions, and have been previously 
characterized as polysaccharide and oligosaccharide processing sulfatases, respectively (37–40). 
In contrast, the sulfatase of B. thetaiotaomicron 4656 (5G2V) is only capable of cleaving the 
sulfates of the monosaccharide glucosamine (40), and exhibits Loop 2 and 3 motifs that frame a 
smaller active site (Figure 4.8E).  
Structure-guided considerations of Loop 2 and 3 regions may assist in predicting the 
types of substrates utilized by uncharacterized sulfatases. Indeed, the sulfatases of B. fragilis 
(2QZU), E. coli (3ED4), and S. melliloti (4UG4) have not been assigned cognate substrates 
(Figure 4.8F); however, their Loop 2 and Loop 3 regions are similar to enzymes of known 
structure with known substrates. For example, the Loop 2 and 3 regions of B. fragilis (2QZU) 
and E. coli (3ED4) are similar to that of P. sp. FC615 (6J66) and F. agariphila (6HR5), which 
are known to process oligosaccharide sulfates. Loops 2 and 3 of S. melliloti (4UG4) create a 
relatively small active site, suggesting that this enzyme processes small molecule sulfates. In 
summary, although the core arylsulfatase fold is highly conserved (Figure 4.8G, Figure 4.6), 
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marked structural variations in Loop 2 and 3 facilitate the generation of a family of functionally 
diverse gut microbial sulfatases.  
Microbial Sulfatase Quaternary Structural Diversity 
 In additional to their effects on active site geometry, Loops 2 and 3 also impact the 
quaternary structure of gut microbial sulfatases.  Examination of the fourteen microbial 
sulfatases in the PDB, including the two reported here, reveals that six are monomers (1HDH, 
6HHM, 5G2T, 5G2V, 2QZU and 6HR5) and 6BIA is the sole trimer. The seven remaining 
enzymes are dimers (3ED4, 4UG4, 4UPI, 4UPL, 6J66, BfSulf, HhSulf). Remarkably, all seven of 
these sulfatases form distinct dimer complexes (Figure 4.9). For four of these seven enzymes, C-
terminal α-helical contacts contribute to differences in oligomerization state (Figure 4.9A, 
magenta). This helix, which helps to form the variable interfaces between monomers, exhibits 
low sequence identity between sulfatases (Appendix B). Loops 2 and 3 (red and blue, 
respectively), as well as other peripheral loops (green), also influence how the C-terminal helix 
defines unique sulfatase dimer contacts (Figure 4.9A). Like the C-terminal helix, Loops 2 and 3 
exhibit low sequence identity (Appendix B). Hashimoto and Panchenko revealed the importance 
of loop insertions to protein quaternary structure in 2010 (53). Indeed, loop insertions alone, like 
Loops 2, 3, govern the unique dimers observed for BfSulf, (Figure 4.9B), EcSulf (3ED4) 
(Figure 4.9C) and P. sp. FC615 (6J66) (Figure 4.9D). Thus, unique structural inserts, like 
Loops 2 and 3, produce an array of distinct sulfatase quaternary structures.  
 Given their importance in defining unique active site geometries and oligomerization 
states, the Loop 2 and 3 regions were examined across all 728 sulfatases catalogued here. Loop 2 
motifs were identified in 49% of the enzyme orthologues and ranged from 25-49 residues in 
length, while Loop 3 motifs were present in 44% of sequences and spanned 25-118 amino acid 
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lengths. As a subset of those outlined above, 18% of the human gut microbial sulfatases maintain 
both Loops 2 and 3. The Loop 2 and 3 regions were also examined across the 1,395 sulfatases 
found in the larger IGC database. Loop 2 motifs were found in 77% of the enzymes and ranged 
from 25-81 residues in length, while Loop 3 regions were present in 45% of sequences and 
spanned from 25 to 116 amino acids in length.  
Finally, we sought to determine if the presence of Loops 2 and/or 3 were enough to 
define unique clades of gut microbial sulfatases within the SSN. However, despite employing a 
range of alignment scores, Loop 2 and 3 regions do not cluster into distinct clades within the 
sulfatase SSNs (Figure 4.10). Thus, while these loop regions are prevalent, they are a distinctly 
variable feature of microbial sulfatases encoded by the human gut microbiome.  
Endobiotic Processing by Gut Microbial Sulfatases  
We next sought to ascertain the functional capacity of gut microbial sulfatases toward 
endobiotic-sulfate substrates. Five sulfatases from the 728 unique enzymes identified in the HMP 
were expressed heterologously in E. coli and purified to homogeneity for in vitro study: Alistipes 
obesi (AoSulf), Bacteriodes fragilis (BfSulf), Culturomica massiliensis (CmSulf), E. coli 
(EcSulf), and Hungatella hathewayi (HhSulf). Each enzyme was co-expressed with FGE (see 
Figure 4.2C), which specifically recognizes the CxPxR motif for fGly installation. Native 
serines were replaced with cysteines in AoSulf, BfSulf, CmSulf, and EcSulf by site-directed 
mutagenesis. As a measure of installation efficiency, iterative refinements of the BfSulf crystal 
structure reported here defined fGly occupancy at 20% (Figure 4.11), a level comparable to 
existing literature (36). Interestingly, we were unable to obtain crystals of the HhSulf enzyme 
when co-expressed in E. coli with FGE. The structure of HhSulf reported here is of protein 
expressed without FGE and contains a native active site cysteine. When co-expressed with FGE, 
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all five enzymes exhibit sulfatase activity, indicating fGly installation. By contrast, when co-
expressed without FGE, only trace sulfatase activity is observed; it is possible this trace activity 
results from the fGly installation pathway that has yet to be characterized in E. coli (51).  
 The pH optima were defined for each enzyme using the para-nitrophenyl sulfate (pNPS) 
reporter substrate and ranged from 4.5 to 6.5, values relevant to the human gut (Table 4.2). 
Catalytic efficiencies measured with pNPS ranged from 4.2 × 102 to 7.8 ×104 s-1 M-1 (Table 
4.2), values comparable with previous reports for this substrate (41). We then examined the 
processing of sulfates of the endobiotics dopamine, serotonin, melatonin, estrone, DHEA, and 
thyroxine (Figure 4.12A). While little reactivation of the sulfates of dopamine, melatonin, and 
serotonin was observed after 4 and 8 hours, all five sulfatases reactivated the steroid hormones 
estrone and DHEA and the thyroid hormone, thyroxine (Figure 4.12B, Figure 4.13) (54). 
Comparing levels of reactivation at 4 and 8 hours reveals evidence for differential actions, with 
BfSulf processing the hormones most efficiently and AoSulf processing the hormones least 
efficiently (Figure 4.12B, Figure 4.13). Thus, microbial sulfatases exhibit differential activities 
with distinct endobiotic-sulfate substrates.  
We next examined the ability of human steroid sulfatases inhibitors to impact the activity 
of gut microbial sulfatases. 667 Coumate (STX64) exhibits low nM IC50 and Ki values toward 
human steroid sulfatases and was the first steroid sulfatase inhibitor to be tested in 
postmenopausal women with breast cancer (13). Danazol, an anabolic steroid used to treat 
endometriosis (55), exhibits modest human steroid sulfatase inhibition. 667 Coumate and 
danazol were tested for their ability to inhibit estrone reactivation from estrone-sulfate by BfSulf 
and HhSulf, the two fastest enzymes with this substrate. While danazol at 100 µM failed to 
inhibit either enzyme, 667 Coumate at 100 µM inhibited BfSulf but not HhSulf (Figures 4.14A, 
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4.14B).  Molecular docking reveals that human estrone sulfatase maintains numerous contacts 
with these inhibitors, while BfSulf and HhSulf offer considerably fewer such contacts (Figures 
4.14C-H). In spite of this, BfSulf contains more aromatic residues in its active site than HhSulf, 
which may explain 667 Coumate’s ability to inhibit only the BfSulf enzyme ortholog.  667 
Coumate may serve as a starting place for the development of more potent inhibitors that are 
selective for gut microbial sulfatases. 
Finally, to examine the roles of Loops 2 and 3 in sulfatase activity, the corresponding 
active site-proximal loops of BfSulf and HhSulf were created, generating BfSulfΔL2 and 
HhSulfΔL3 (see Figure 4.8). While these variants retained their structural integrity (Figure 
4.15) and dimeric quaternary structure as assessed by size-exclusion chromatography, both 
exhibited significantly decreased activity compared to native enzymes with the sulfates of 
thyroxine, DHEA, and estrone (Figure 4.12C, D). Specifically, reactivation of these substrates 
by HhSulfΔL3 was reduced 30-45% (Figure 4.12C), while BfSulfΔL2 activity was reduced 75-
90% (Figure 4.12D). Taken together, these data indicate that Loops 2 and 3 play important roles 
in the processing of endobiotic substrates by gut microbial sulfatases.  
Discussion  
Potentially harmful compounds are often eliminated through their conjugation to the 
sugar glucuronic acid or to a sulfate group, both of which mark xeno- and endobiotics for 
excretion. These mechanisms are typically employed by “first-pass” tissues like liver and the 
intestinal epithelium, which express the human UGTs and SULTs that perform these Phase II 
conjugation reactions, as well as Phase II efflux pumps that send conjugates out of the cells for 
excretion, often via the GI tract (19). A collective microbial “yang” to this human metabolic 
“yin” are the gut bacterial β-glucuronidases and sulfatases that remove the conjugating moieties, 
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and thus reactivate the previously inactivated parent compounds. Conceptually, these microbial 
enzymes are akin to the phosphatases that act on phosphorylated small molecule and proteins and 
are crucial to metabolism, cell signaling and systemic physiology (1). As such, glucuronidases 
and sulfatases reverse Phase II drug metabolism, effectively resurrecting biologically active 
compounds from the path of elimination. While the gut microbial β-glucuronidases are becoming 
well examined, linked to clinically relevant adverse drug events, and even controlled using 
targeted inhibitors (22, 23), the sulfatases encoded by the gut microbiome have not been 
comprehensively examined. 
 We find that there are 1,766 unique gut microbial sulfatases that share structural and 
functional features with bacterial and human sulfatases of known structure. They all share a 
common core fold, as expected, but exhibit remarkable variability in active site-adjacent loops 
and in quaternary structure, both of which impact the processing of endobiotic sulfates 
substrates. Indeed, the present study reveals that the distinct gut microbial sulfatase oligomeric 
states observed to date are heavily influenced by the Loop 2 and 3 motifs. As such, small 
changes in sulfatase sequence can lead to large changes in protein structure, which then dictate 
both catalytic activity and substrate preference. In summary, the human gut microbiome’s 
diverse array of sulfatase orthologs decorate their core scaffold with key variable loops to 
generate the functional diversity necessary to accommodate the myriad sulfated substrates 
present in the gut milieu.  
 Serum neurotransmitter levels are known to be influenced by gut microbial metabolism 
(56, 57).  While we did not observe high processing of neurotransmitter-sulfates here, it is likely 
that future studies will pinpoint gut microbial sulfatases that reactivate dopamine, serotonin, and 
melatonin. In contrast to the neurotransmitters, thyroxine, DHEA, and estrone were reactivated 
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from their cognate sulfates by all five sulfatases examined here. The impact of microbial 
sulfatases on systemic estrogen metabolism has clinical potential given the high levels of 
estrone-sulfate produced by humans, and the established roles of human sulfatases in the etiology 
and progression of hormone receptor positive cancers (28, 58, 59). Similarly, the levels of other 
hormones like thyroxine and DHEA can now be considered to be under the influence of gut 
microbial enzymes. Variabilities in disease onset, progression or recovery may be affected by 
inter-individual differences in the composition of gut microbiome-encoded sulfatases, a topic of 
future exploration toward more effective personalized medicine.  
The key limitation to the present study is the lack of an efficient method for the 
quantitative conversion of catalytic serine or cysteine residues to fGly in heterologously 
expressed proteins. This problem has been faced by several groups but has been recalcitrant to 
resolution (17, 36, 41). In addition, while activity with endogenous substrates has been 
demonstrated in vitro, we are several steps away from understanding the roles these enzymes 
may play in enterohepatic recirculation in vivo. Indeed, the lack of activity observed with 
neurotransmitter-sulfates is almost certainly due to the small panel of enzymes examined. In 
spite of these limitations, the data presented here provide a set of specific enzyme orthologs that 
can now be considered in the context of the full catalytic processing of endobiotic compounds by 
the human-microbial symbiont. 
Finally, the gut microbial sulfatase enzymes examined here exhibit active sites distinct 
from those found in human sulfatases. Based on these observations, mutagenesis data, and the 
smaller, less variable Loops 2 and 3 in human sulfatases (Figure 4.16), it is likely that gut 
microbial active site-adjacent loops will play important roles in the identification and 
development of targeted inhibitor compounds. Such compounds would be similar in concept to 
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those reported that inhibit gut microbial β-glucuronidases and reduce adverse events associated 
with therapeutic interventions and intestinal surgeries (22, 23, 60, 61). Gut microbial sulfatase 
inhibitors may have a future role in controlling estrogen reactivation, for example, in patients at 
risk for new or recurrent hormone-positive malignancies. The current work provides an initial 
atlas of gut microbial sulfatases, a key step toward understanding how the microbiome-encoded 
enzymes impact human disease.  
Experimental Procedures 
GI Sulfatase Identification 
 The HMP Stool Sample Catalog, the set of genes sequenced from 139 donor fecal 
samples collected by the HMP, contains more than 26.5 million translated protein sequences in 
its Gene Indices (HMGI) and 4.8 million in its Clustered Gene Indices (HMGC) databases (28). 
The clustered data consolidates proteins that share >95% sequence identity, and thus represents a 
library of unique proteins in the human GI microbiome.  To find genes that encode sulfatase 
enzymes, a two-step rubric was employed based on a microbial sulfatase protein with a known 
structure. First, the HMGI and HMGC databases were screened to identify proteins with E values 
< 0.0001 (significance threshold) and sequence identity ≥25% in a pairwise alignment to the 
sulfatase from Pseudomonas aeruginosa (1HDH) (8). Second, the sequences identified from the 
first step were then screened for conserved active site residues essential to hydrolyzing sulfate-
containing substrates (Figure 4.2A). The strictly conserved residues include the pentapeptide 
C/SxP(A)xR motif where the C/S is modified to fGly during enzyme maturation. This second, 
active site structure-guided step, identified 7,887 sulfatase enzymes unique non-redundant 
sulfatase proteins from the 4.8 million HMGC database. With this rubric, we obtained a total of 
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7,887 sulfatase enzymes from the 26 million sequences within the HMP. After omitting 
redundant sequences, we found a total of 729 unique sulfatase enzymes from within the HMP. 
Taxonomic Assignment of Sulfatase Sequences  
 The non-redundant protein sequences database was searched for sequences using NCBI 
BLASTp (50). For sequences which had a top (ranked by score) BLASTp sequence of ≥95% 
identity, taxonomy of the query sequence was defined as using most specific taxonomy available 
from that search. For all other sequences, the top 5 BLASTp results were analyzed for agreement 
in taxonomy at the most specific level possible, then assigned to that level if there was a 
consensus among all 5. If there was no consensus at any level, the protein was marked “unclear” 
with respect to taxonomy.  
Signal Peptide Identification 
 Following any correction of sequencing errors such as miscalled start sites found during 
analysis with BLASTp for taxonomic assignments, HMGC279 sequences were analyzed for 
signal peptide cleavage sites using the online SignalP 4.1 server (30, 51).  If a sequence was 
determined to have a potential signal peptide using this server, it was marked as such.  
Furthermore, sequences trimmed of the predicted signal sequence were manually interrogated for 
an N-terminal cysteine for possible lipidation for presentation on the outer membrane. 
Enzyme cloning. Genes codon-optimized for E. coli expression for the sulfatases from 
Hungatella hathewayi, (HhSulf [NCBI Protein Accession Code :WP_055654660.1]) Escherichia 
coli, (EcSulf [NCBI Protein accession number: WP_001361353.1]) Alistipes obesi, (AoSulf 
[NCBI Protein accession number: WP_019131223.1]) Culturomica massiliensis, (CmSulf 
[NCBI Protein accession number: WP_068691203.1]) and Bacteroides fragilis CAG:558, 
(BfSulf [NCBI Protein accession number: CCZ37892.1]) were purchased from BioBasic in the 
132 
pUC57 vector. Hhsulf was amplified and inserted into the pLIC-His vector using the primers in 
Table 4.3. All other genes were amplified and inserted into the pLIC-MBP vector (Table 4.3). 
The genes of EcSulf, AoSulf, CmSulf, and BfSulf, which contained the catalytic SxPxR motif at 
the active site, were changed to CxPxR using site directed mutagenesis (Table 4.3). This Ser-to-
Cys alteration gives E. coli a chance to install an fGly within each enzyme’s active site. Loop 
deletion variants (BfSulf ΔL1 and HhSulf ΔL2) were also purchased from BioBasic and 
synthesized into pLIC-MBP vectors.  
Enzyme Expression and Purification  
 Each sulfatase expression plasmid was co-transformed with pRSF-FGE, a generous gift 
from Mark Wold (via Addgene plasmid #102615), into BL21 DE3 Gold cells for enzyme 
expression. The FGE plasmid co-expresses the formylglycine generating enzyme necessary for 
installing fGly in E. coli at sites containing a CxPxR motif.  Cells were grown in the presence of 
kanamycin (FGE) and ampicillin in TB medium with vigorous shaking at 37 °C to an OD600nm 
of 1.0, at which point the temperature was reduced to 18 °C and L-arabinose (1% final) was 
added to induce FGE expression. At OD600=1.5, sulfatase expression was induced with 0.1 mM 
isopropyl-1-thio-D-galactopyranoside (IPTG) and incubation continued overnight. 
 Cells were collected by centrifugation at 4500xg for 20 min at 4 °C in a Sorvall (model 
RC-3B) swinging bucket centrifuge. Cell pellets were resuspended in Buffer A (20 mM 
Potassium Phosphate pH 7.4, 50 mM imidazole, 500 mM NaCl), DNase, lysozyme, and a Roche 
complete-EDTA free protease inhibitor tablet. Resuspended cells were sonicated and clarified 
via centrifugation at 17,000xg for 60 min in a Sorvall (model RC-5B). The subsequent lysate 
flowed over a Ni-NTA HP column (GE Healthcare) on an Aktaxpress FPLC system (Amersham 
Bioscience) and washed with Buffer A. Sulfatase protein was eluted with Buffer B (20 mM 
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Potassium Phosphate pH 7.4, 250 mM Imidazole, 500mM NaCl). Fractions containing the 
protein of interest were combined and passed over a HiLoadTM 16/60 SuperdexTM 200 gel 
filtration column. Protein was eluted in S200 Buffer (20 mM HEPES pH 7.4, 50 mM NaCl). 
Fractions were analyzed by SDS-PAGE and those with >95% purity were combined and 
concentrated for long-term storage at -80 °C. 
Crystallization and Structure Determination  
 Protein crystals derived from B. fragilis CAG:558 sulfatase were derived from protein co-
expression with FGE while the H. hathewayi sulfatase was not coexpressed with FGE for initial 
crystal hits. Both structures were derived from crystals grown at 20 °C via the sitting drop 
method in Hampton Research 3-well Midi Crystallization Plates (Swissci) by an Art Robbins 
Instruments Crystal Phoenix robot with the following drop conditions:  for B. fragilis CAG:558 
sulfatase, 100 nL of 9 mg/mL protein were added to 100 nL of 10% (w/v) PEG 8000, 100 mM 
potassium phosphate monobasic/ Sodium phosphate dibasic pH 6.2, and 200 mM sodium 
chloride; for H. hathewayi sulfatase, 100 nL of 10 mg/mL protein were added to 100 nL of 0.2 M 
potassium fluoride and 20% (w/v) PEG 3350. 
 Crystal specimen were cryo-protected in the crystallization conditions as described above 
with the addition of 20% glycerol, and diffraction data were collected at 100 K on APS Beamline 
23-ID-D. The data were processed with XDS and both structures were solved via molecular 
replacement in Phenix (52) using the structure of an endo-4S-ι-carrageenan sulfatase (PDB: 
6BIA) as a search model, which shares 25.6% and 27.2% sequence identity to BfSulf and 
HhSulf, respectively. The LLG and TFZ scores were 140.9 and 12.3, respectively, for BfSulf. 
The LLG and TFZ scores were 3432.9 and 152.5, respectively, for the HhSulf. The resulting 
starting model and maps from molecular replacement were then employed in the AutoBuild 
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function of Phenix. Structures were refined in Phenix and visually inspected and manually built 
using COOT (53). Final PDB coordinates for all structures have been deposited to the RCSB 
Protein Data Bank with corresponding PDB codes 6USS and 6UST for B. fragilis CAG:558 
sulfatase (BfSulf) and H. hathewayi sulfatase (HhSulf), respectively. 
Determination of Optimal pH 
 Para-nitrophenyl sulfate (PNPS) was purchased as a solid and dissolved in water at a 
concentration of 100 mM. Reactions were conducted in 96-well, black, clear-bottom assay plates 
(Costar, Tewksbury, MA) at 37° C. The pH assay was performed with 10 µL buffer at various 
pH values (4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5), 10 µL of 100 nM enzyme, and 30 µL of 5 mM substrate 
diluted in water. Each time point was measured by quenching the reaction with 100 µL 0.2 M 
sodium carbonate. Product formation for the pH and kinetic assays were measured via 
absorbance at 410 nm using a PHERAstar Plus microplate reader (BMG Labtech, Ortenberg, 
Germany). 
CD Analysis of Sulfatase Mutants 
 The protein stabilities of the WT and loop deletion enzymes described above were 
determined using the Circular Dichroism method (REF). Enzyme (2.5 µM) in CD buffer 
containing 10 mM potassium phosphate (pH 7.4) and 100 mM potassium fluoride was loaded 
into a 1-mm pathlength cuvette. Using a Chirascan-plus instrument (Applied Photophysis 
Limited), spectra from 185 to 260 nM were recorded at 20 ± 1.0 °C. Measurements were 
corrected for background signal using a CD buffer sample. The melting profile of the BfSulf 
sample (2.5 µM) was monitored at 228 nm from 20 °C to 94 °C. The melting profile of the 
HhSulf sample (2.5 µM) was monitored at 220 nm from 20 °C to 94 °C. 
SSN Construction 
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 The sequence similarity network diagram of sulfatase enzyme sequences was generated 
using the Enzyme Function Initiative-Enzyme Similarity Tool (EFI-EST) online tool (30). The 
sequences obtained from the sulfatase rubric were used in combination with the EFI-EST 
"FASTA" tool to create a sequence with 728 nodes. Each node represents sequences bearing 
≥90% sequence identity to each other. A BLAST E-value of 1 x 10-75 was employed. 
In vitro HPLC Sulfate-processing Assay 
 Dopamine-4-O-Sulfate (Toronto Research Chemicals, North York, ON), Serotonin-O-
Sulfate (Toronto Research Chemicals, North York, ON), Melatonin-Sulfate (Toronto Research 
Chemicals, North York, ON), Thyroxine-4’-O-Sulfate (Toronto Research Chemicals, North 
York, ON), Dehydroepiandrosterone Sulfate (Cayman Chemical, Ann Arbor, MI) and Estrone-3-
Sulfate (MilliporeSigma, St. Louis, MO) were purchased as solids and resuspended in DMSO to 
a concentration of 10 mM. In vitro assays were conducted at 37°C in a 50 μL total volume. 
Reactions consisted of 10 μL assay buffer (50 mM HEPES, 50 mM NaCl, various pH), 10 μL 
enzyme (50 nM), and 30 μL substrate (500 μM) diluted in assay buffer. The pH of each reaction 
was chosen based on the optimal pH determined for each sulfatase with pNPS. Reactions were 
quenched at various timepoints (up to 4 hours) with 50 μL of 25% trichloroacetic acid (TCA).  
 After centrifugation at 13,000xg for 10 min, the resultant supernatant was analyzed by 
HPLC. The concentration of converted product was quantified on an Agilent 1260 Infinity II 
liquid chromatograph system. Samples were separated on an Agilent InfinityLab Poroshell 120 
C18 column (4.6 x 100 mm, 2.7 μm particle size) at 38°C. The flow rate was 0.9 mL/min, and 
the injection volume was 10 μL. LC conditions were set at 98% water with 0.1% formic acid (A) 
for 2 mins, then ramped linearly over 10 mins to 98% acetonitrile with 0.1% formic acid (B) and 
held until 14 mins. At 15 mins the gradient was switched back to 100% A and allowed to re-
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equilibrate until 17 mins, monitored at 280 nm. The concentrations of each substrate were 
determined from a standard curve (0-500 μM substrate in assay buffer). Control reactions were 
performed in which enzyme was substituted with buffer. Background hydrolysis was not 
observed at each pH tested. Reactions were performed in triplicate for each enzyme. 
In vitro Inhibition Assay 
 Danazol and 667 Coumate were purchased through Millipore Sigma as solid and 
dissolved in DMSO for 10 mM stock concentrations. Reactions consisted of 10 μL of sulfatase 
(100 nM final), 5 μL of inhibitor (various concentrations), 30 μL of pNPS (5 mM final), and 5 
μL of assay buffer [25 mM NaCl, 25 mM HEPES, (pH 6.5)]. Reactions were initiated by 
addition of pNPS and then incubated in a BMG Pherastar plate reader for 1 hour. The IC50 was 
determined as the inhibitor concentration that yielded 50% reduction in the maximum initial 
velocity of the uninhibited reaction. Percent inhibition values were subsequently plotted against 
the log of inhibitor concentration and fit with a four-parameter logistic function in SigmaPlot 
13.0 to determine the IC50.  
Manual Docking of Ligands in PyMOL 
 Estrone, dopamine, serotonin, thyroxine, melatonin, and DHEA were accessed from the 
PDB in previously solved crystal structures. 667 Coumate and danazol were created using the 
ELBOW function in Phenix. These were then imported into PyMOL and manually aligned to k-
i-k-neocarrahexaose bound structure (RCSB: 6B0J) with the 3-button editing tool. After manual 
alignment of the sulfates, the structure of the BfSulf enzyme was aligned to the monomer of 
6B0J. Visual inspection and final figures after alignment were generated in PyMOL. 
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TABLE 4. 1: Crystallography Data Collection and Refinement Statistics 
 



























Figure 4. 1: Reactivation of Host Phase II Metabolites by Gut Microbial Enzymes. 
A.  Xenobiotics more commonly undergo Phase II drug metabolism mediated by UDP-
glucuronosyltransferases (UGTs) that append a glucuronic acid sugar (green) to compounds 
marked for excretion to the intestines, as shown here for the active metabolite SN-38 of the 
anticancer drug irinotecan. Gut microbial beta-glucuronidase enzymes (GUSs) remove the sugar 
as a carbon source and reactivate the drug in the gut lumen, leading to intestinal toxicity. B.  
Endobiotic compounds are more typically processed by the other primary form of Phase II drug 
metabolism - sulfotransferase enzymes (SULTs) that append a sulfate moiety to compounds prior 
to excretion to the intestines, as shown here for estrone. Gut microbial sulfatases remove the 
sulfate and reactivate in the gut the original endobiotic, which can then undergo enterohepatic 





Figure 4. 2: Sulfatase Identification from the Human Microbiome Project Stool Sample 
Database.  
A. A two-step structure-guided rubric was employed to identify gut microbial sulfatase enzymes. 
B. Sequence Similarity Network (SSN) of the 728 sulfatase enzymes identified from the Human 
Microbiome Project (HMP) Stool Sample database. Putative functions are annotated, and those 
without predicted functions are in grey. Enzymes purified for further in vitro study are in purple 
squares. C. Sulfatase enzymes utilize either an aerobic formylglycine generating enzyme (FGE) 
or an anaerobic sulfatase maturating enzyme (anSME) to convert catalytic Cys- or Ser- residues 
to fGly. The sequence prevalence diagram (upper right) reveals that 80% of the HMP sulfatases 





Figure 4. 3: Sulfatase Taxonomy in HMP Stool Sample Catalogue.  










Figure 4. 4: Structural Comparison of Human Gut Microbial Sulfatases.  
A. Surface representation of the monomers of two previously reported structures, PAS (1HDH) 
and EcSulf (3ED4), and the two structures reported here, BfSulf (6USS) and HhSulf (6UST). 
The active site region is indicated and the manually docked substrate, 6-hydroxy-melatonin 
sulfate, is in orange. B. Superimposition of the monomers of three microbial sulfatase enzymes 
from the HMP and human sulfatase A, with calcium in yellow. C. Active site superimposition of 
the sulfatases in panel C revealing conserved positions of active site residues, with calcium in 
yellow, the cysteine or serine residues converted to fGly indicated, and residues employed in our 




Figure 4. 5: Comparison of Microbial Sulfatases in the PDB.  
A. Sequence identities (%) between the 14 microbial sulfatases in the PDB. B. RMSD values 
over indicated number of Cα positions.  RMSDs range between 2.3 and 6.9 Ȧ. Number of Cα 






Figure 4. 6: Sulfatase Core Fold.  
In rainbow, core fold of A. BfSulf, B. HhSulf, C. PAS and D. human arylsulfatase A. Numbering 
scheme is a modification of that presented in Lukatela et al. (7) where helices are labeled αA-αI 








Figure 4. 7: Flexible Active Site Loops of Sulfatase Enzymes.  
Loop 1 (L1) in orange, Loop 2 (L2) in red, Loop 3 (L3) in blue, Loop 4 (L4) in green, Loop 5 





Figure 4. 8: Variable Active Site Loop Architectures of Microbial Sulfatases.  
Calcium is in green in panels A-F. A. Loop 2 and Loop 3 regions of novel sulfatases presented in 
this study. B. Loop 2 and Loop 3 regions of sulfatases known to process small molecule sulfates 
and phosphates. C. Loop 2 and Loop 3 regions of sulfatases known to process polysaccharides. 
D. Loop 2 and Loop 3 regions of sulfatases known to process oligosaccharides. E. Loop 2 and 
Loop 3 regions of a sulfatase known to process monosaccharides. F. Loop 2 and Loop 3 regions 
of sulfatases with no known biological substrate. G. Core fold of sulfatases shown in rainbow 




Figure 4. 9: Sulfatase Quaternary Structure Mediated by Secondary Structural Elements. 
Eight distinct microbial sulfatase dimers, with Loop 2 in red, Loop 3 in blue, C-term helices in 
magenta, other surface loops in green, and 2-fold axes of symmetry indicated. A. Sulfatase 
dimers mediated by contacts between C-term helices. B. Sulfatase dimer mediated by contacts 
between Loop 2 regions. C. Sulfatase dimer mediated by contacts between Loop 3 regions. D. 





Figure 4. 10: Sequence Similarity Networks of HMP Sulfatase Enzymes. 
 Enzymes are clustered using varying alignment scores and colored by presence of Loop 2 (red), 







Figure 4. 11: Electron Density at the Active Site of the 2.5 Å Resolution Structure of BfSulf. 
2Fo-Fc density in blue, positive Fo-Fc density in green, and negative Fo-Fc density in red. 
Densities contoured at 1.5 . A. With Cys-88 at 100% occupancy, positive difference density is 
evident. B. With an fGly-hydrate/gem-diol covalently linked to a sulfate ion at 100% occupancy, 
negative density is evident. C. Electron density is satisfied by an fGly-hydrate/gem-diol 






Figure 4. 12: Reactivation of Endogenous Sulfates.  
A. Neurotransmitter and hormone sulfates examined in this study. B. Percent aglycone formed 
after incubation of the sulfatase enzyme indicated with endogenous small molecule sulfates for 8 
hours. Neurotransmitters show little reactivation while hormones are reactivated to the parent 
compound completely. C. Percent aglycone formed after 8-hour incubation of wild-type and 
BfSulf Loop 2 knockout sulfatase with hormone sulfates. D. Percent aglycone formed after 8-










Figure 4. 14: Inhibition of Gut Microbial Sulfatases.  
A. Percent activity of BfSulf after addition of 100 µM inhibitor.; *** = P<0.001.  B. Percent 
activity of HhSulf after addition of 100 µM inhibitor. C. 667 Coumate docked in BfSulf active 
site; residues contacting the ligand are boxed, with additional aromatic residues in oval. D. 
Danazol docked in BfSulf active site; residues contacting the ligand are boxed, with additional 
aromatic residues in oval. E. 667 Coumate docked in HhSulf active site; residues contacting the 
ligand are boxed. F. Danazol docked in HhSulf active site; residues contacting the ligand are 
boxed. G. 667 Coumate docked in Human Estrone Sulfatase (1P49) active site; residues 
contacting the ligand are boxed. H. Danazol docked in Human Estrone Sulfatase (1P49) active 




Figure 4. 15: CD Scans.  










Figure 4. 16: Human Arylsulfatase Loop Regions.  
A. Loop 2 region of human arylsulfatase enzymes. B. Loop 3 region of human arylsulfatase 
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CHAPTER 5: THE GUT MICROBIOTA DRIVES CANCER ETIOLOGY THROUGH 
“PHASE IV METABOLISM” OF XENOBIOTICS AND ENDOBIOTICS5  
 
Introduction 
The gut microbiota is comprised of trillions of microorganisms that physically interact 
with host intestinal cells and functionally impact numerous host physiological systems. Here we 
focus on the interplay between gut microbiota and human xenobiotic and endobiotic metabolic 
processes. Host cytochrome P450s (CYPs) are primary drug converting enzymes, as they add 
functional groups to a wide range of xeno- and endobiotics as part of Phase I drug metabolism. 
Phase II enzymes append polar moieties to drugs/endobiotics to mark these compounds for 
excretion by drug metabolism’s Phase III efflux transporters into the urine or gastrointestinal 
(GI) tract.  
Beyond these three well characterized phases, the gut microbiome encodes a vast arsenal 
of metabolic enzymes that we believe should be formally defined as “Phase IV” of xeno- and 
endobiotic metabolism. Phase IV metabolism within the gut typically follows human Phase I-III 
processes, further alters the products of host metabolism, and directly and substantially impacts 
intestinal and systemic drug and endobiotic metabolism. Indeed, it has been known since the 
early days of drug discovery that the intestinal microbiota process drugs, including the first 
antibiotic sulfa compounds in the 1940s (1), as well as the heart medication digoxin (2) and the 
Parkinson’s drug levodopa (3) in the 1970s. Thus, the modification of intact and metabolized 
drugs and endobiotics by the GI microbes impacts the local and systemic actions of these 
compounds.  
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The gut microbiota performs reductions, decarboxylation, demethylation, deamination, 
and deacylation reactions, as well as hydrolysis and ring-opening reactions as part of Phase IV 
metabolism. This list will certainly grow as we discover and map the full catalytic capacity of the 
gut microbiome. It is already evident, though, that gut microbial enzymes can extends human 
drug metabolism, and understanding these reactions is key to treating and preventing disease. 
Given current and rapidly expanding data, Phase IV metabolism should grow into a richly 
appreciated and physiologically crucial process on par with Phase I-III metabolism in its 
importance to human health outcomes. 
Here we detail how the gut microbiota acts on host phase II metabolites of drugs and 
endobiotics important to cancer progression. In addition, we discuss potential mechanisms to 
disrupt cancer etiology related to the intestinal microbiome, including lifestyle choices and the 
novel paradigm of inhibiting gut microbial enzymes.  
Drugs and the Gut Microbiota 
Metagenomic and metabolomic studies have been crucial in firmly linking the 
gastrointestinal microbiome to cancer development. There is accumulating evidence that the gut 
microbiota is involved in formation and progression of cancers including esophageal, gastric and 
colorectal cancers. For example, several strong correlations have been established between the 
gut microbiota and CRC. Reddy et. al. treated germ-free and conventional rats with the 
carcinogen 1,2-dimethylhydrazine and found that 93% of conventional rats developed colonic 
tumors compared to only 21% of the germ-free animal (4). Gut Escherichia, Enterococcus, 
Bacteroides and Clostridium species have also been shown to promote colorectal carcinogenesis 
by increasing aberrant crypt foci (5). Mice transplanted with stool from patients with CRC 
showed enhanced intestinal cell proliferation and greater tumor formation (6). Since these 
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seminal contributions, many others have linked specific bacteria to CRC development and 
progression (7–11). Inspired by these data, here we focus on the specific gut microbial 
xenobiotic and endobiotic metabolism reactions that are known to, or can be reasonably expected 
to, directly influence cancer etiology. 
Following a cancer diagnosis, the gut microbiota also impacts the treatment of CRC with 
chemotherapeutics. For example, fluorouracil (5-FU) has remained a standard therapy for the 
treatment of advanced colorectal cancer for over 40 years, but it is known to cause severe 
toxicity in some patients. Two independent studies have suggested that enzymes within the gut 
microbiota responsible for the deamination of 5-fluorocytosine to 5-fluorouracil drive this 
toxicity and reduce drug efficacy (12,13).  
Drug toxicity and reduced efficacy are also driven by the gut microbiota for the CRC and 
pancreas cancer drug, irinotecan. The active metabolite of irinotecan, SN-38, is glucuronidated to 
inactive SN-38-G by host Phase II UDP-glucuronosyltransferase enzymes (UGTs) in the liver to 
facilitate intestinal excretion. In the gut, SN-38-G encounters microbial β-glucuronidase (GUS) 
enzymes that remove the glucuronic acid sugar, effectively reversing host Phase II metabolism 
and reactivating SN-38 in the GI lumen (Figure 5.1A). This reactivation causes severe, dose-
limiting gut toxicity in a significant fraction of patients. However, by inhibiting the GUS 
enzymes responsible for this reactivation, the associated toxicity can be significantly alleviated 
in animal models (14,15). Identifying patients with greater levels of relevant SN-38-reactivating 
GUS enzymes may serve as a diagnostic tool to improve patient outcomes, as discussed in more 
detail below.  
 Somewhere between 40 and 70% of drugs are subject to glucuronidation by UGTs (16).  
The exact number is not well defined because, unlike CYPs, the actions of UGTs on each drug 
161 
are not always specified. Gut microbial GUS enzymes are, in principle, capable of reactivating 
some fraction of all these metabolites, and thus can potentially impact the efficacy and toxicity of 
dozens of drugs. Indeed, we have shown that specific human gut microbial GUS enzymes are 
responsible for the toxicity of NSAIDs (17) as well as the CRC drug, regorafenib (18). Thus, gut 
microbiome-encoded GUS enzymes are major route of Phase IV drug metabolism and they drive 
poor therapeutic responses by causing intestinal toxicities.  
Preventing GUS-mediated drug reactivation may improve patient outcomes for many 
diseases. However, there are multiple phase II conjugation reactions beyond glucuronidation, 
including sulfation, methylation, and acetylation. It is critical to define how Phase II drug 
metabolites are processed by gut microbial sulfatases, methyltransferases, and deacetylases to 
fully unravel the impact of Phase IV drug metabolism on disease progression and therapeutic 
efficacy.  
Endobiotics and the Gut Microbiota 
The gut microbiota has also been hypothesized to influence the formation and 
progression of tumors distant from the GI tract. In particular, GUS enzymes have been 
implicated in a number of hormonal disorders including breast, endometrial, and ovarian cancers 
by reactivating inactivate estrogen-glucuronides to estrogen, similar to the reactivation of SN-38 
from SN-38-G (19). Our group has recently demonstrated that gut microbial GUS enzymes 
contribute to estrogen-glucuronide reactivation in vitro and ex vivo but have limited effect in in 
vivo mouse models (20). Thus, our findings suggest that the gut-estrogen metabolism is highly 
complex and likely involves a wide range of factors, including microbial sulfatases and catechol-
O-methyltransferases (COMTs).  
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 Like GUS enzymes, gut microbial sulfatases are capable of reactivating compounds 
inactivated by human Phase II metabolism. For example, estrone and dehydroepiandrosterone – 
key hormonal biomarkers of cancer progression – are sulfated in the liver and other metabolic 
tissues like the GI tract and sent to the gut for excretion. Given the prevalence of sulfate groups 
on dietary, endobiotic, and xenobiotic compounds, the gut lumen is expected to contain a diverse 
array of microbial sulfatases capable of removing sulfate moieties, thus reactivating hormones 
for potential reabsorption and systemic recirculation (Figure 5.1B). The impact of microbial 
sulfatases on estrogen metabolism may be significant and akin to the established roles human 
sulfatases play in the etiology of hormone receptor positive cancers (21).  
 Gut microbial catechol-O-methyltransferases (COMTs) are also poised to impact 
hormone bioavailability and disease etiology. After Phase I metabolism, it is reasonable to 
expect that hydroxylated estrogens will serve as substrates for gut microbial COMTs, which are 
abundant and, like host COMTs, methylate catecholamines and catechol-estrogens (22). We 
speculate that inter-individual differences in gut microbial COMTs may influence the circulating 
levels of drugs and endobiotics and, in the case of estrogens, would contribute to an individual’s 
total level of hormone. However, in contrast to gut microbial GUS and sulfatase enzymes that 
generate active estrogens implicated in disease progression, gut microbial COMTs would be 
protective by producing inactivated methylated hormone derivatives (Figure 5.1C). Thus, gut 
microbial Phase IV metabolism is capable of converting the products of human Phase I and II 
metabolism into chemicals that may fuel distal malignancies, like hormone-positive breast and 
ovarian cancers, or may facilitate the safe elimination of potentially harmful compounds. 
Carcinogens and the Gut Microbiota 
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Gut microbial Phase IV metabolism also drives carcinogenesis by producing carcinogenic 
chemicals in the lumen of the GI tract. PhIP (2-Amino-1-methyl-6-phenylimidazo[4,5-
b]pyridine) is a heterocyclic aromatic amine found in cooked meats. Dietary exposure to PhIP 
has been implicated in the etiology of cancer in humans (23). During Phase I metabolism PhIP is 
oxidized via cytochrome P4501A2 (CYP1A2) enzymes to a hydroxylated intermediate, N-OH-
PhIP (22). N-OH-PhIP, which is itself mutagenic, can be converted to a more biologically 
reactive form via Phase II metabolizing enzymes, primarily the acetyltransferases or 
sulfotransferases (22). The esterification generates electrophilic O-sulfonyl and O-acetyl esters, 
which bind DNA and cellular proteins (24).  
By contrast, human Phase II glucuronidation of N-OH-PhIP inactivates this compound. 
However, gut microbial Phase IV GUS enzymes may reactivate N-OH-PhIP and result in 
intestinal carcinogenesis (23). Thus, like SN-38-G and other therapeutics, gut microbial GUS 
enzymes reverse Phase II drug metabolic reactions to drive poor outcomes or transitions to 
disease.  
Numerous heterocyclic aromatic amines, including 2-aminonapthalene (Figure 5.1D), 
are also carcinogens. These compounds are known to be glucuronidated and, like PhIP-G, their 
gut reactivation produces mutagenic DNA adducts that promote carcinogenesis (25). When 
heterocyclic aromatic amines are acetylated by human N-acetyltransferases, the products are 
inactivated as mutagens and sent to the GI tract for elimination. Therefore, it is reasonable to 
expect that such acetylated compounds will encounter known microbial deacetylases (26) 
capable of reactivating mutagens toward increased gut epithelial tumorigenesis (Figure 1D).  
Although the interplay between host and agent is often very complex, we find that 
conjugation is regularly employed to inactivate and eliminate carcinogens via the GI tract. Thus, 
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such compounds may encounter gut microbial enzymes that metabolize and reactivate these 
carcinogens within the intestinal lumen and reverse the action of host enzymes. It is also likely 
that some compounds are first metabolized by the gut microbes and then absorbed via the 
vasculature for further processing by host metabolic enzymes. Thus, a more complete 
understanding the relationship between host and microbe is key to understanding carcinogenesis 
and its prevention.  
It is important to stress how little we know about gut microbiome and the functions it 
encodes. As a result, we have an incomplete understanding of the types of biotransformations 
that these carcinogens, as well as drugs and endobiotics undergo in the gut. We can certainly 
imagine that such compounds encounter microbial enzymes catalyzing hydrolysis, 
dehydrogenation, and elimination reactions, as well as a wealth of other transformations 
performed by the most talented chemists on earth — the microbes. It is also likely that some 
compounds are first metabolized by the gut and then absorbed via the vasculature for further 
processing by host metabolic enzymes. Thus, a detailed understanding of the enzymatic 
processes performed within the gut and their relationship to the host is fundamental to fuel new 
discoveries related to cancer etiology.  
Treating Cancer through the GI Microbiome 
Diet and other environmental factors impact health by modulating the composition and 
metabolic activity of the human gut microbiota. Smoking, stress, and obesity have all been 
associated with dysbiosis, while an active, non-sedentary lifestyle promotes a diverse and healthy 
gut microbiome (28). Additionally, western-style diets rich in fats and proteins have been shown 
to exert negative effects on the gut microbial composition and may contribute to chronic 
cardiovascular diseases, CRC and other conditions. However, while changes in diet, lifestyle, 
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and antibiotics may induce microbial shifts, their impact may not be sufficient alone improve 
health (29). 
Thus, in addition to dietary and lifestyle changes, pre- and probiotics have been explored 
to disrupt cancer etiology. Prebiotics are dietary substrates that selectively promote proliferation 
and/or activity of beneficial indigenous gut bacteria, while probiotics are live bacteria 
administered to achieve the same goals. Both have been shown to increase gut levels of select 
bacteria. The most commonly consumed probiotics are Lactobacillus and Bifidobacterium taxa.  
Pre- and probiotics may improve host health through several mechanisms including modulating 
the mucosal transfer of luminal organisms and metabolites, increasing mucosal antibody 
production, strengthening epithelia integrity, and direct antagonism of pathogenic 
microorganisms (29). Although outcomes vary, in general changes in human gut microbiota 
composition are relatively small and only persist for the period of intervention. Thus, definitive 
proof of the benefits of pre- and probiotics in combatting the complex etiology of cancer remains 
to be established.  
 The direct and selective modulation of gut microbial enzymes to address cancer etiology 
has shown promise in animal models and human ex vivo studies. As pioneered in Wallace et al., 
potent bacterial GUS inhibitors alleviated the GI toxicity caused by the gut reactivation of SN-38 
from SN-38-G (14). Inhibitors were highly specific for bacterial GUS enzymes and not 
mammalian orthologs; this is critical because mutations inactivating human GUS cause a lethal 
lysosomal storage disease. Selectivity was achieved based on active site features unique to 
bacterial GUSs to the human ortholog.  
Exploiting such differences between human and microbial enzymes may accelerate the 
development of other inhibitors that specifically target gut microbial enzymes. Further, 
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pinpointing specific microbial enzymes in human fecal samples may lead to precision 
biomarkers and individualized treatment regimens that realize the promise of personalized 
medicine for cancer and beyond. In addition, those at risk for CRC development or its return may 
employ GUS inhibitors to prevent the gut reactivation of carcinogens, perhaps lowering the 
chances of disease initiation or progression. 
Since gut microbial GUS enzymes were identified as the first drug target in the 
microbiome (30), the diversity and abundance of bacterial GUS proteins in the human and 
murine gut have been mapped (31,32). Such efforts have supported the hypothesis that 
interindividual variability in the types and numbers of gut microbial GUS enzymes is a direct 
cause of differential drug responses in human patients. By identifying and quantifying gut 
bacterial GUS enzymes from human feces with an activity-based probe-enabled proteomics 
pipeline, Jariwala et al. (33) pinpointed specific GUS enzymes responsible for SN-38 
reactivation and correlated GUS abundance to differential reactivation rates ex vivo. We have 
termed investigations on human fecal extracts as “in fimo,” from formal Latin (34). Combining 
in fimo proteomic and drug reactivation rate data defines the specific enzymes involved from 
perhaps the most complicated protein mixtures ever examined – those from human fecal isolates. 
Finally, studies like those conducted by Zimmermann et al. and Maier et al. provide 
crucial pathways to fully map gut microbial drug metabolic processes. Both used human gut 
microbiota and specific gut microbial strains to systematically identify microbial gene products 
that metabolize drugs and/or are influenced by the presence of drugs (35,36). Ultimately, 
optimized cancer treatment and prevention will never be a tangible reality until proteomic, 
metagenomic, and metabolomic, biochemical and structural biology studies completely define 
Phase IV drug metabolism conducted by the human gut microbiota. Only then can we fully 
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appreciate how these systems interface with human Phase I-III metabolism to drive the 
therapeutic outcomes and variabilities associated with cancer etiology. 
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Figure 5. 1: Host and Gut Microbiota Metabolic Interactions.  
A. The active metabolite of irinotecan, SN-38, is glucuronidated to inactive SN-38-G by host 
Phase II UDP-glucuronosyltransferase enzymes (UGTs) in the liver. In the gut, SN-38-G 
encounters microbial β-glucuronidase (GUS) enzymes that remove the glucuronic acid sugar, 
reactivating SN-38 in the GI lumen and causing GI toxicity. B. Estrone is sulfated in the liver via 
the action of sulfotransferases (SULTs) sent to the gut for excretion. The gut lumen contains 
microbial sulfatases capable of removing the inactivating sulfate moiety, reactivating hormones 
for reabsorption and systemic recirculation, contributing to hormone driven diseases. C. After 
Phase I metabolism, hydroxylated estrogens may serve as substrates for gut microbial COMTs, 
which, methylate catechol-estrogens, contributing to total estrogenic burden and thus may also 
contribute to hormone driven diseases. D. 2-naphthalene is acetylated by human N-
acetyltransferases (NATs); these acetylated compounds may encounter gut microbial small 
molecule deacetylases that reactivate the mutagen and facilitate gut epithelial tumorigenesis. 
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CHAPTER 6: CONCLUSIONS AND MAJOR FINDINGS 
Summary 
There is now ample evidence implicating the gut microbiota in defining both the efficacy 
and toxicity of therapeutic agents, highlighting the need to fully understand the ongoing chemical 
reactions that occur in the gastrointestinal tract. We sought to expand the model first proposed by 
Wallace et al. (1) in 2010, which showed that microbial enzymes were responsible for 
reactivation of SN-38 (Figure 5.1). Here we expand this model in three distinct ways: examining 
new drugs, examining endogenous compounds, and examining a new class of microbial 
enzymes.   
The first study examined the tyrosine kinase inhibitor used to treat colorectal cancer, 
regorafenib. Here we pinpointed a small subset of distinct gut microbial GUS enzymes capable 
of reactivating regorafenib from regorafenib-glucuronide. We identified structural features of 
these enzymes that are essential to this reactivation, and we developed inhibitors that block this 
process in vitro and ex vivo. Thus, like SN-38-G, we have successfully initiated the development 
of the tools necessary to address regorafenib-induced gut toxicity.  In addition, we provide a 
roadmap for the identification of gut microbial enzymes responsible for the toxic side effects of 
other tyrosine kinase inhibitors and the discovery of microbiome-targeted reagents to block these 
side effects. 
The second study examined the ability of β-glucuronidase enzymes from the human 
gastrointestinal tract to reactivate endogenous estrogenic compounds. Although it is clear from 
SN-38-G and regorafenib-glucuronide, that β-glucuronidase enzymes play roles in recirculation 
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of drugs and xenobiotics, their impact on endogenous hormones is initially less obvious. It has 
been suggested that a woman's estrobolome, the aggregate of the enteric bacterial genes whose 
products are capable of metabolizing estrogens, plays a key role in a number of hormonal 
disorders including breast, endometrial, and ovarian cancers (2-5). We thus hypothesized that gut 
microbial GUS enzymes are functional members of the estrobolome, and are capable of 
reactivating free estrogens. Guided by initial data with 35 gut microbial GUS enzymes, and then 
by the subsequent detailed analysis of 14 GUS proteins including the resolution of relevant novel 
crystal structures, we have pinpointed molecular characteristics that contribute to estrogen 
deconjugation. These are key initial data to validate gut microbial GUS enzymes as functional 
members of the estrobolome. Furthermore, we postulate that the gut may serve as a reservoir for 
estrogenic metabolites capable of acting locally and perhaps distantly in systemic homeostasis 
and the development of hormone driven diseases.  
We expand the model proposed by Wallace et al. (1) by examining a new class of gut 
microbial enzymes. Reports suggest that endogenous steroids like estrogen are heavily sulfated 
during phase II metabolism, and similar to β-glucuronidase enzymes, sulfatase enzymes reverse 
the action of Phase II metabolism. Thus, to assess the functional role of the microbiota in 
estrogen recirculation, we explored the structure and function of gut microbial sulfatase 
enzymes. In this study, we create a catalogue of 728 individual and unique sulfatase enzymes 
identified from the 4.8 million unique translated protein sequences in the Human Microbiome 
Project stool sample metagenome database. We have defined active site features of sulfatase 
enzymes that aid in substrate recognition and turnover of endogenous small molecules. This 
study provides a foundation for detailed structural analyses of the gut microbial sulfatase 
enzymes that may impact enterohepatic recirculation.  
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We show that gut microbial enzymes are responsible for the metabolism of a variety of 
drugs and small molecules, including regorafenib-glucuronide and estrogen glucuronide. We 
show, through detailed functional studies, that there are unique structural differences between 
individual enzymes that contribute to their ability to reverse the action of Phase II metabolism. 
The work here highlights the multifaceted roles of gut microbial enzymes in enterohepatic 
recirculation of small molecules. Further, we demonstrate the validity and necessity of defining 
the specific enzymatic reactions present within the GI microbiota.  
Finally, we propose that there are a variety of ways upon which this paradigm can be 
expanded further. Here we outline how the gut microbiota uniquely contributes to cancer 
etiology by processing products of human drug and endobiotic metabolism. We formally propose 
that the reactions performed by the gut microbiota should be classified as “Phase IV xenobiotic 
and endobiotic metabolism”. Finally, we discuss new data on the control of cancer by the 
inhibition of gut microbial Phase IV enzymes responsible for tumor initiation and progression. 
We show that gut microbial enzymes are responsible for the metabolism of a variety of drugs and 
small molecules, including regorafenib-glucuronide and estrogen glucuronide. We show, through 
detailed functional studies, that there are unique structural differences between individual 
enzymes that contribute to their ability to reverse the action of Phase II metabolism. The work 
here highlights the multifaceted roles of gut microbial enzymes in enterohepatic recirculation of 
small molecules. Further, we demonstrate the validity and necessity of defining the specific 
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APPENDIX A: REGORAFENIB ANALOG SYNTHETIC ROUTES 
 
Compounds Derived from Commercial Raloxifene Hydrochloride (TCI) 
UNC7081 and UNC7082 (Raloxifene methylation) 
 CAUTION! TMS-diazomethane is volatile and extremely toxic! Use only in a fume hood, 
avoid any skin exposure, reglove often, and quench all equipment with dilute acid. 
 To a 25 mL flask was added Raloxifene hydrochloride (0.26 g, 1 Eq, 0.50 
mmol), acetonitrile (4.5 mL), and methanol (0.5 mL), which were stirred to a slurry. Next was 
added DIPEA (0.19 g, 0.26 mL, 3 Eq, 1.5 mmol), resulting in a mostly-homogeneous, bright 
yellow solution. A septum and nitrogen flow were added, and TMS-diazomethane (2M in 
hexanes, 0.25 mL, 1 Eq, 0.50 mmol) was added dropwise. The needle and syringe were rinsed 
thoroughly with acetic acid diluted in methanol. The reaction was left to stir overnight, resulting 
in some precipitation at the bottom of flask. The next day, the reaction was quenched with a few 
drops of acetic acid and the volatiles were removed by rotary evaporation. The residue was 
purified by reverse-phase chromatography (10-100% methanol in water + 0.1% TFA) to yield 
mostly unreacted raloxifene plus small quantities of the two monomethylated products, 




yl)ethoxy)phenyl)methanone 2,2,2-trifluoroacetate (4.98 mg, 1.7%) 
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1H NMR (400 MHz, Methanol-d4) δ 7.76 (d, J = 8.9 Hz, 2H), 7.42 (dd, J = 8.8, 0.5 Hz, 1H), 7.32 
– 7.26 (m, 3H), 6.93 (d, J = 8.9 Hz, 2H), 6.88 (dd, J = 8.8, 2.3 Hz, 1H), 6.78 (d, J = 8.8 Hz, 2H), 
4.40 – 4.32 (m, 2H), 3.73 (s, 3H), 3.62 – 3.55 (m, 2H), 3.55 – 3.51 (m, 2H), 3.04 (t, J = 12.0 Hz, 
2H), 2.00 – 1.89 (m, 2H), 1.87 – 1.71 (m, 3H), 1.60 – 1.46 (m, 1H). 
LCMS (ESI, +ve mode) expected m/z for C29H30NO4S [M+H]




yl)ethoxy)phenyl)methanone 2,2,2-trifluoroacetate (6.21 mg, 2.1%) 
1H NMR (400 MHz, Methanol-d4) δ 7.74 (d, J = 8.9 Hz, 2H), 7.51 (d, J = 8.9 Hz, 1H), 7.47 (d, J 
= 2.3 Hz, 1H), 7.19 (d, J = 8.7 Hz, 2H), 6.99 (dd, J = 8.9, 2.4 Hz, 1H), 6.92 (d, J = 8.9 Hz, 2H), 
6.62 (d, J = 8.6 Hz, 2H), 4.40 – 4.32 (m, 2H), 3.88 (s, 3H), 3.62 – 3.55 (m, 2H), 3.55 – 3.50 (m, 
2H), 3.04 (d, J = 12.3 Hz, 2H), 2.00 – 1.88 (m, 2H), 1.87 – 1.70 (m, 3H), 1.60 – 1.44 (m, 1H). 
LCMS (ESI, +ve mode) expected m/z for C29H30NO4S [M+H]
+ 488.19, found 488.15 




 To a flask containing commercial raloxifene hydrochloride (250 mg, 1 Eq, 490 µmol) 
was added anhydrous THF (10 mL) under nitrogen atmosphere. The flask was stirred rapidly and 
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cooled to 0 °C in an ice bath, and LiAlH4 (200 mg, 10.8 Eq, 5.27 mmol) was added cautiously 
(effervescence). The reaction mixture turned deep green and was allowed to come to room 
temperature overnight. The next day, residual LiAlH4 was quenched by addition of ethyl acetate 
to the grey-green slurry. The mixture was diluted with half-saturated Rochelle salt and stirred at 
room temperature for an hour. The layers were separated, and the aqueous layer extracted twice 
more with ethyl acetate. The combined organic layers were washed once with half-saturated 
Rochelle salt, once with water, and once with brine, then dried over sodium sulfate and 
concentrated to a yellow solid (234 mg, quantitative). Attempted salt formation with TFA, p-
toluenesulfonic acid, or HCl in ether, ethyl acetate, or 1,4-dioxane led only to decomposition, so 
the remaining residue was used without further purification. 
 To a flask containing crude 3-(hydroxy(4-(2-(piperidin-1-yl)ethoxy)phenyl)methyl)-2-(4-
hydroxyphenyl)benzo[b]thiophen-6-ol (50 mg, 1 Eq, 0.11 mmol) was added DCM (2 mL) 
and triethylsilane (15 mg, 20 µL, 1.2 Eq, 0.13 mmol) and cooled in an ice-water bath under 
nitrogen atmosphere. To the stirring solution was added TFA (1.0 mL) dropwise – formation of 
the benzylic cation was characterized by a blue colour, which rapidly disappeared upon silane 
reduction. Upon reaction completion as indicated by LCMS, the solvents were removed in vacuo 
and the residue purified by reverse-phase chromatography (10-100% methanol in water + 0.1% 
TFA), concentrated, and lyophilized to yield 2-(4-hydroxyphenyl)-3-(4-(2-(piperidin-1-
yl)ethoxy)benzyl)benzo[b]thiophen-6-ol 2,2,2-trifluoroacetate (55 mg, 91% over two steps) as a 
white solid.  
 1H NMR (400 MHz, Methanol-d4) δ 7.28 (dd, J = 8.7, 2.1 Hz, 3H), 7.18 (d, J = 2.2 Hz, 
1H), 7.06 (d, J = 8.6 Hz, 2H), 6.87 (d, J = 8.7 Hz, 2H), 6.79 (d, J = 8.3 Hz, 2H), 6.75 (dd, J = 
8.7, 2.3 Hz, 1H), 4.28 (dd, J = 5.6, 4.3 Hz, 2H), 4.12 (s, 2H), 3.62 – 3.54 (m, 2H), 3.53 – 3.46 
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(m, 2H), 3.02 (td, J = 12.3, 3.2 Hz, 2H), 1.98 – 1.88 (m, 2H), 1.86 – 1.71 (m, 3H), 1.59 – 1.44 
(m, 1H). 
LCMS (ESI, +ve mode) expected m/z for C28H30NO3S [M+H]
+ 460.19, found 460.15 
HRMS (ESI, +ve mode) expected m/z for C28H30NO3S [M+H]




 To a glass vial was added 2-(4-hydroxyphenyl)-3-(4-(2-(piperidin-1-
yl)ethoxy)benzyl)benzo[b]thiophen-6-ol 2,2,2-trifluoroacetate (UNC7084, 5.0 mg, 1 Eq, 8.7 
µmol) and methanol (0.1 mL). The methanol was stirred, and Oxone™ (16 mg, 3 Eq, 26 
µmol) dissolved in water (0.1 mL) was added. The reaction was stirred at room temperature until 
LCMS indicated complete conversion, whereupon the reaction was quenched by the addition of a 
few drops of aqueous sodium bisulfite. The crude reaction mixture was purified by reverse phase 
chromatography (10-100% acetonitrile in water + 0.1% TFA), concentrated, and lyophilized to 
yield 6-hydroxy-2-(4-hydroxyphenyl)-3-(4-(2-(piperidin-1-yl)ethoxy)benzyl)benzo[b]thiophene 
1,1-dioxide 2,2,2-trifluoroacetate (4.79 mg, 91%) as a yellow solid.  
 1H NMR (400 MHz, Methanol-d4) δ 7.41 (d, J = 8.7 Hz, 2H), 7.17 (d, J = 5.1 Hz, 1H), 
7.15 (d, J = 5.4 Hz, 2H), 7.10 (d, J = 2.3 Hz, 1H), 6.93 (d, J = 8.7 Hz, 2H), 6.88 – 6.83 (m, 3H), 
4.33 – 4.25 (m, 2H), 3.96 (s, 2H), 3.63 – 3.54 (m, 2H), 3.54 – 3.47 (m, 2H), 3.02 (td, J = 12.3, 
3.1 Hz, 2H), 1.99 – 1.67 (m, 5H), 1.59 – 1.44 (m, 1H). 
 LCMS (ESI, +ve mode) expected m/z for C28H30NO5S [M+H]
+ 492.18, found 492.20 
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General Synthetic Procedures for Raloxifene Analogs Prepared from 6-methoxy-2-(4-
methoxyphenyl)benzo[b]thiophene 
 With the exception of UNC7088 (made by demethylation of 6-methoxy-2-(4-
methoxyphenyl)benzo[b]thiophene) and UNC7152 (made by demethylation of UNC7086), the 
remaining compounds were synthesized according to the following scheme: 
 
 
a) 4-fluorobenzoyl chloride, AlCl3 b) pyridine hydrochloride, 180˚C c) NaH, DMF d) neat 
or DMSO, 100˚C e) i. LiAlH4, THF ii. Et3SiH, 2:1 DCM/TFA 
 
General Procedure A: Friedel-Crafts Acylation 
To a flask was added 6-methoxy-2-(4-methoxyphenyl)benzo[b]thiophene and anhydrous DCM. 
The reaction was cooled to 0˚C, and 4-fluorobenzoyl chloride (1.1 Eq) was added dropwise, 
followed by granular anhydrous AlCl3 (1.2 Eq). The reaction was stirred at room temperature 
overnight, then quenched with 2M HCl. The aqueous layer was extracted thrice with DCM, and 
the combined organic layers were further washed with a 50/50 mixture of 2M HCl and brine, 
then brine alone, dried over sodium sulfate, concentrated and purified by normal phase 
chromatography over silica gel. 
General Procedure B: Aryl Ether Demethylation 
 The aryl ether starting material was added to a glass vial with 0.2-1.0 g of pyridine 
hydrochloride and heated to 180˚C for 2 hours. Dilution with water or sodium bicarbonate 
followed by extraction with ethyl acetate and chromatography yielded the free phenol. 
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General Procedure C: Nucleophilic aromatic substitution with alcohols 
 The appropriate alcohol (5 Eq) was dissolved in anhydrous DMF and cooled to 0˚C, 
followed by addition of excess 60% sodium hydride (8-12 Eq). The solution was brought to 
room temperature over 30 minutes, and the fluoroketone substrate (1 Eq) was then added. The 
reaction was then stirred for 5 hours at room temperature (R1 = CH3) or 50˚C (R1 = H). The 
reaction was quenched with water, optionally extracted with ethyl acetate, and subjected to 
reverse-phase chromatography (methanol in water + 0.1% TFA).  
General Procedure D: Nucleophilic aromatic substitution with amines 
 The fluoroketone substrate and excess amine were added to a glass vial. If the amine was 
a solid, DMSO was added as solvent, otherwise the reaction was conducted neat. The vial was 
heated to 100-120˚C for 5 hours, cooled, diluted with water and purified by reverse-phase 
chromatography (methanol in water + 0.1% TFA). 
General Procedure E: Ketone reduction with LiAlH4 and ionic reduction with TFA/Et3SiH 
 To a glass vial were added the ketone substrate and THF. The vial was cooled to 0˚C and 
excess LiAlH4 (10-40 eq) was added. The reaction was stirred at room temperature until 
complete consumption of starting material as determined by LC/MS, then quenched by the 
addition of saturated sodium bicarbonate. The mixture was partitioned between ethyl acetate and 
0.5 M potassium sodium tartrate, washed again with tartrate solution, dried by passage through a 
phase separator and concentrated to a yellowish residue that was used without further 
purification.  
 
 To a glass vial was added the crude alcohol, DCM, and triethylsilane (1.3 eq). The vial 
was cooled to 0˚C, and TFA was added dropwise to a final ratio of 2:1 DCM/TFA. The reaction 
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was stirred until complete conversion as determined visually (the intermediate cation before 
reduction is a vivid blue color) and by LCMS. The solvents were removed by rotavap and the 
residue purified by reverse-phase chromatography (methanol in water + 0.1% TFA). 
UNC7088 
 
 To a glass vial was added 6-methoxy-2-(4-methoxyphenyl)benzo[b]thiophene (27 mg, 1 
Eq, 0.10 mmol) and pyridine hydrochloride (0.12 g, 10 Eq, 1.0 mmol). The vial was then heated 
to 180˚C for 2 hours. The first 30 minutes were accompanied by vigorous bubbling and steam 
evolution starting at ~140˚C. The reaction was cooled, diluted with water, and extracted thrice 
with ethyl acetate. The combined organic layers were washed twice with 0.5 M citric acid, once 
with water, and once with brine, then dried over sodium sulfate, filtered, and concentrated to an 
off-white solid. Normal phase chromatography over silica gel (0-50% ethyl acetate in hexanes) 
yielded 2-(4-hydroxyphenyl)benzo[b]thiophen-6-ol (15.5 mg, 64%) as an off-white solid .  
1H NMR (400 MHz, Acetone-d6) δ 7.59 (d, J = 8.5 Hz, 1H), 7.54 (d, J = 8.7 Hz, 2H), 7.42 (d, J = 
0.7 Hz, 1H), 7.28 (dt, J = 2.3, 0.7 Hz, 1H), 6.90 (d, J = 8.8 Hz, 3H). 
LCMS (ESI, +ve mode) expected m/z for C14H10NaO2S [M+Na]
+ 265.03, found 265.30 
HRMS (ESI, -ve mode) expected m/z for C14H9O2S [M-H]
- 241.03287, found 241.03273 
 
 
Key Intermediate I 
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 To a flask was added 6-methoxy-2-(4-methoxyphenyl)benzo[b]thiophene (0.54 g, 1 Eq, 
2.0 mmol), DCM (20 mL), and 4-fluorobenzoyl chloride (0.35 g, 0.26 mL, 1.1 Eq, 2.2 
mmol) under nitrogen atmosphere. The flask was cooled in an ice-water bath, and aluminum 
chloride (0.32 g, 1.2 Eq, 2.4 mmol) was added portionwise, with the solution turning a deep 
blood red. The reaction was allowed to come to room temperature with stirring overnight. The 
next day, the reaction was quenched with the addition of 2M HCl and extracted three times with 
DCM. The combined organic layers were washed once with a 50/50 mixture of 2M HCl and 
brine, once with water, and once with brine, then dried over sodium sulfate, filtered, and 
concentrated to an orange oil. Normal phase chromatography over silica gel (0-30% ethyl acetate 
in hexanes) provided (4-fluorophenyl)(6-methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-
yl)methanone (591 mg, 75%) as a clear yellow gum. 
1H NMR (400 MHz, Chloroform-d) δ 7.79 (dd, J = 8.9, 5.4 Hz, 2H), 7.63 (d, J = 8.9 Hz, 1H), 
7.33 (d, J = 2.4 Hz, 1H), 7.30 (d, J = 8.8 Hz, 2H), 7.00 (dd, J = 8.9, 2.4 Hz, 1H), 6.93 (t, J = 8.6 
Hz, 2H), 6.74 (d, J = 8.8 Hz, 2H), 3.89 (s, 3H), 3.74 (s, 3H). 
19F NMR (376 MHz, Chloroform-d) δ -104.80. 
13C NMR (100 MHz, Chloroform-d) δ 192.75, 165.64 (d, JCF = 255.4 Hz), 159.93, 157.78, 
144.23, 140.11, 133.92 (d, JCF = 2.9 Hz), 133.71, 132.51 (d, JCF = 9.5 Hz), 130.47, 129.87, 




 To a round bottom flask was added 2-(piperidin-1-yl)ethan-1-ol (33 mg, 5 Eq, 0.25 
mmol) and anhydrous DMF (0.5 mL). The flask was cooled in an ice-water bath, and sodium 
hydride (60% dispersion in mineral oil, 20 mg, 10 Eq, 0.51 mmol) was slowly added. The 
reaction was allowed to come to room temperature with stirring over 30 minutes. Next, (4-
fluorophenyl)(6-methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl)methanone (20 mg, 1 Eq, 
51 µmol) was dissolved in DMF (0.5 mL) and added dropwise to the flask. The reaction was 
allowed to proceed at room temperature for 4 hours, and then quenched by the addition of water. 
The aqueous layer was extracted 3 times with ethyl acetate, and the combined organic layers 
were washed twice with water, once with saturated sodium bicarbonate, and once with brine, and 
then dried by passage through a phase separator and concentrated to a yellow residue. 
Purification by reverse-phase chromatography (10-100% methanol in water + 0.1% TFA) 
provided (6-methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl)(4-(2-(piperidin-1-
yl)ethoxy)phenyl)methanone 2,2,2-trifluoroacetate (22.40 mg, 71%) as a yellow solid following 
lyophilization. 
1H NMR (400 MHz, Methanol-d4) δ 7.74 (d, J = 8.9 Hz, 2H), 7.47 (d, J = 6.8 Hz, 1H), 7.46 (s, 
1H), 7.29 (d, J = 8.8 Hz, 2H), 6.97 (dd, J = 8.8, 2.5 Hz, 1H), 6.91 (d, J = 8.9 Hz, 2H), 6.77 (d, J 
= 8.8 Hz, 2H), 4.39 – 4.29 (m, 2H), 3.87 (s, 3H), 3.72 (s, 3H), 3.61 – 3.54 (m, 2H), 3.54 – 3.50 
(m, 2H), 3.02 (td, J = 12.3, 3.1 Hz, 2H), 1.98 – 1.72 (m, 5H), 1.58 – 1.43 (m, 1H). 
LCMS (ESI, +ve mode) expected m/z for C30H32NO4S [M+H]




 To a glass vial with septum was added 3-(piperidin-1-yl)propan-1-ol (18 mg, 19 µL, 2 
Eq, 0.13 mmol) and anhydrous DMF (0.5 mL). Then sodium hydride (5.6 mg, 2.2 Eq, 0.14 
mmol) was added portionwise, and allowed to stir for 30 minutes. To the vial was then added (4-
fluorophenyl)(6-methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl)methanone (25 mg, 1 Eq, 
64 µmol). The reaction turns deep blood-red and was allowed to stir at room temperature 
overnight. The reaction was then quenched with saturated sodium bicarbonate and extracted 
thrice with ethyl acetate. The combined organic layers were washed three times with saturated 
sodium bicarbonate and once with brine, then dried over sodium sulfate, filtered, and 
concentrated to a yellow residue. The residue was purified by reverse-phase chromatography 
(10-100% methanol in water + 0.1% TFA), and the collected fractions were concentrated and 
lyophilized to yield (6-methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl)(4-(3-(piperidin-1-
yl)propoxy)phenyl)methanone 2,2,2-trifluoroacetate (16.5 mg, 41%) as an off yellow solid. 
1H NMR (400 MHz, Methanol-d4) δ 7.71 (d, J = 8.9 Hz, 2H), 7.45 (d, J = 1.1 Hz, 1H), 7.44 (d, J 
= 5.1 Hz, 1H), 7.28 (d, J = 8.8 Hz, 2H), 6.96 (dd, J = 9.0, 2.4 Hz, 1H), 6.82 (d, J = 8.9 Hz, 2H), 
6.76 (d, J = 8.8 Hz, 2H), 4.06 (t, J = 5.8 Hz, 2H), 3.86 (s, 3H), 3.71 (s, 3H), 3.58 – 3.50 (m, 2H), 
3.27 – 3.18 (m, 2H), 2.90 (td, J = 12.4, 2.9 Hz, 2H), 2.23 – 2.12 (m, 2H), 1.98 – 1.88 (m, 2H), 
1.87 – 1.66 (m, 3H), 1.50 (ddt, J = 16.2, 12.4, 6.4 Hz, 1H). 
LCMS (ESI, +ve mode) expected m/z for C31H34NO4S [M+H]





 To a glass vial was added (4-fluorophenyl)(6-methoxy-2-(4-
methoxyphenyl)benzo[b]thiophen-3-yl)methanone (25 mg, 1 Eq, 64 µmol) and 1-
methylpiperazine (64 mg, 71 µL, 10 Eq, 0.64 mmol). The vial was heated to 100 °C for 5 hours, 
then cooled, diluted with water, and purified by reverse-phase chromatography (10-100% 
methanol in water + 0.1% TFA). The collected fractions were concentrated and lyophilized to 
provide (6-methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl)(4-(4-methylpiperazin-1-
yl)phenyl)methanone 2,2,2-trifluoroacetate (15.2 mg, 41%) as a yellow solid.  
1H NMR (400 MHz, Methanol-d4) δ 7.66 (d, J = 9.0 Hz, 2H), 7.43 (d, J = 2.3 Hz, 1H), 7.40 (d, J 
= 8.9 Hz, 1H), 7.29 (d, J = 8.8 Hz, 2H), 6.94 (dd, J = 8.9, 2.4 Hz, 1H), 6.84 (d, J = 9.0 Hz, 2H), 
6.75 (d, J = 8.8 Hz, 2H), 4.07 – 3.92 (m, 2H), 3.85 (s, 3H), 3.70 (s, 3H), 3.60 – 3.46 (m, 2H), 
3.20 – 3.06 (m, 4H), 2.91 (s, 3H). 
LCMS (ESI, +ve mode) expected m/z for C28H29N2O3S [M+H]
+ 473.19, found 473.20 
UNC7087 
  
 To a glass vial was added (4-fluorophenyl)(6-methoxy-2-(4-
methoxyphenyl)benzo[b]thiophen-3-yl)methanone (25 mg, 1 Eq, 64 µmol), piperazine (55 mg, 
10 Eq, 0.64 mmol) , and DMSO (0.2 mL). The vial was capped and heated to 100 °C for 5 hours, 
then cooled, diluted with water, and purified by reverse-phase chromatography (10-100% 
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methanol in water + 0.1% TFA). The collected fractions were concentrated and lyophilized to 
yield (6-methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl)(4-(piperazin-1-
yl)phenyl)methanone 2,2,2-trifluoroacetate (15.4 mg, 42%) as a yellow solid. 
1H NMR (400 MHz, Methanol-d4) δ 7.66 (d, J = 9.0 Hz, 2H), 7.43 (d, J = 2.3 Hz, 1H), 7.40 (dd, 
J = 8.9, 0.5 Hz, 1H), 7.29 (d, J = 8.8 Hz, 2H), 6.94 (dd, J = 8.9, 2.4 Hz, 1H), 6.84 (d, J = 9.1 Hz, 
2H), 6.75 (d, J = 8.8 Hz, 2H), 3.85 (s, 3H), 3.70 (s, 3H), 3.55 – 3.49 (m, 4H), 3.30 – 3.25 (m, 
4H). 
LCMS (ESI, +ve mode) expected m/z for C27H27N2O3S [M+H]
+ 459.17, found 459.20 
HRMS (ESI, +ve mode) expected m/z for C27H27N2O3S [M+H]
+ 459.17369, found 459.17285 
UNC7152 
  
 To a glass vial was added (6-methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl)(4-(4-
methylpiperazin-1-yl)phenyl)methanone (8.0 mg, 1 Eq, 17 µmol) and pyridine hydrochloride 
(200 mg, 100 Eq, 1.73 mmol). The vial was then heated to 180˚C for 2 hours. The reaction was 
cooled, diluted with sodium bicarbonate, and extracted thrice with ethyl acetate. The combined 
organic layers were washed once more with sodium bicarbonate, twice with water, and once with 
brine, then dried over sodium sulfate, filtered, and concentrated to an off-white solid. Reverse 
phase chromatography (10-100% methanol in water + 0.1% TFA) followed by concentration and 
lyophilization yielded (6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)(4-(4-
methylpiperazin-1-yl)phenyl)methanone 2,2,2-trifluoroacetate (3.75 mg, 40%) as a yellow solid. 
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1H NMR (400 MHz, Methanol-d4) δ 7.69 (d, J = 9.0 Hz, 2H), 7.37 (d, J = 8.8 Hz, 1H), 7.25 (d, J 
= 2.2 Hz, 1H), 7.20 (d, J = 8.7 Hz, 2H), 6.89 (d, J = 9.1 Hz, 2H), 6.85 (dd, J = 8.8, 2.3 Hz, 1H), 
6.62 (d, J = 8.6 Hz, 2H), 4.17 – 3.90 (m, 2H), 3.62 – 3.36 (m, 3H), 3.26 – 3.07 (m, 3H), 2.93 (s, 
3H). 
LCMS (ESI, +ve mode) expected m/z for C26H25N2O3S [M+H]
+ 445.16, found 445.20 
Key Intermediate II 
  
 To a vial was added (4-fluorophenyl)(6-methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-
3-yl)methanone (100 mg, 1 Eq, 255 µmol) and pyridine hydrochloride (589 mg, 20 Eq, 5.10 
mmol). The vial was loosely covered and heated to 180 °C for a 2 hour period. After cooling, the 
residue was diluted with water and 2M HCl, and extracted 3 times with ethyl acetate. The 
combined organic layers were washed 3 times with 0.5 M citric acid, once with water, and once 
with brine, then dried by passage through a phase separator and concentrated to an orange 
residue. Normal phase chromatography over silica gel (0-50% ethyl acetate in hexanes) 
provided (4-fluorophenyl)(6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)methanone 
(69.4 mg, 74.7%) as an orange oil that solidified on standing.  
1H NMR (400 MHz, Acetone-d6) δ 7.79 (dd, J = 8.9, 5.5 Hz, 2H), 7.55 (dd, J = 8.8, 0.5 Hz, 1H), 
7.41 (dd, J = 2.3, 0.5 Hz, 1H), 7.22 (d, J = 8.6 Hz, 2H), 7.07 (t, J = 8.8 Hz, 2H), 6.99 (dd, J = 
8.8, 2.3 Hz, 1H), 6.73 (d, J = 8.7 Hz, 2H). 
19F NMR (376 MHz, Acetone-d6) δ -107.08. 
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13C NMR (100 MHz, Acetone-d6) δ 192.98, 166.27 (d, JCF = 252.7 Hz), 158.83, 156.41, 144.28, 
140.86, 135.21 (d, JCF = 2.7 Hz), 133.79, 133.25 (d, JCF = 9.5 Hz), 131.28, 130.51, 125.52, 
124.76, 116.34, 116.24, 115.99 (d, JCF = 4.6 Hz), 107.80. 
UNC7153 
  
 To a glass vial with septum was added 2-morpholinoethan-1-ol (16 mg, 5 Eq, 0.12 
mmol) and anhydrous DMF (0.5 mL). The vial was cooled in an ice-water bath and sodium 
hydride (7.9 mg, 8 Eq, 0.20 mmol) was added portionwise, then allowed to stir for 30 minutes 
while warming to room temperature. To the vial was then added (4-fluorophenyl)(6-hydroxy-2-
(4-hydroxyphenyl)benzo[b]thiophen-3-yl)methanone (9.0 mg, 1 Eq, 25 µmol) (the reaction turns 
deep blood-red) and the reaction was heated to 50 °C for 5 hours. The reaction was then cooled, 
quenched with water, acidified with TFA, and purified by reverse-phase chromatography (10-
100% methanol in water + 0.1% TFA). The collected fractions were concentrated and 
lyophilized to yield (6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)(4-(2-
morpholinoethoxy)phenyl)methanone 2,2,2-trifluoroacetate (7.00 mg, 48%) as an off yellow 
solid. 
1H NMR (400 MHz, Methanol-d4) δ 7.74 (d, J = 8.8 Hz, 2H), 7.43 (d, J = 8.8 Hz, 1H), 7.26 (d, J 
= 2.2 Hz, 1H), 7.17 (d, J = 8.6 Hz, 2H), 6.92 (d, J = 8.9 Hz, 2H), 6.87 (dd, J = 8.8, 2.3 Hz, 1H), 
6.60 (d, J = 8.6 Hz, 2H), 4.42 – 4.35 (m, 2H), 4.13 – 3.91 (m, 2H), 3.90 – 3.68 (m, 2H), 3.64 – 
3.58 (m, 2H), 3.58 – 3.46 (m, 2H), 3.30 – 3.19 (m, 2H). 
LCMS (ESI, +ve mode) expected m/z for C27H26NO5S [M+H]




 To a glass vial with septum was added 2-(azepan-1-yl)ethan-1-ol (18 mg, 5 Eq, 0.12 
mmol) and anhydrous DMF (0.5 mL). The vial was cooled in an ice-water bath and sodium 
hydride (7.9 mg, 8 Eq, 0.20 mmol) was added portionwise, then allowed to stir for 30 minutes 
while warming to room temperature. To the vial was then added (4-fluorophenyl)(6-hydroxy-2-
(4-hydroxyphenyl)benzo[b]thiophen-3-yl)methanone (9.0 mg, 1 Eq, 25 µmol) (the reaction turns 
deep blood-red) and the reaction was heated to 50 °C for 5 hours. The reaction was then cooled, 
quenched with water, acidified with TFA, and purified by reverse-phase chromatography (10-
100% methanol in water + 0.1% TFA). The collected fractions were concentrated and 
lyophilized to yield (4-(2-(azepan-1-yl)ethoxy)phenyl)(6-hydroxy-2-(4-
hydroxyphenyl)benzo[b]thiophen-3-yl)methanone 2,2,2-trifluoroacetate (14.65 mg, 99%) as a 
yellow solid. 
1H NMR (400 MHz, Methanol-d4) δ 7.73 (d, J = 8.9 Hz, 2H), 7.43 (d, J = 8.8 Hz, 1H), 7.26 (d, J 
= 2.2 Hz, 1H), 7.17 (d, J = 8.6 Hz, 2H), 6.91 (d, J = 8.9 Hz, 2H), 6.87 (dd, J = 8.8, 2.3 Hz, 1H), 
6.60 (d, J = 8.6 Hz, 2H), 4.39 – 4.31 (m, 2H), 3.62 – 3.56 (m, 2H), 3.52 (ddd, J = 13.8, 7.7, 2.3 
Hz, 2H), 3.30 – 3.22 (m, 2H), 2.01 – 1.80 (m, 4H), 1.79 – 1.65 (m, 4H).LCMS (ESI, +ve mode) 
expected m/z for C29H30NO4S [M+H]






 To a glass vial with septum was added 3-(piperidin-1-yl)propan-1-ol (18 mg, 5 Eq, 0.12 
mmol) and anhydrous DMF (0.5 mL). The vial was cooled in an ice-water bath and sodium 
hydride (12 mg, 12 Eq, 0.30 mmol) was added portionwise, then allowed to stir for 30 minutes 
while warming to room temperature. To the vial was then added (4-fluorophenyl)(6-hydroxy-2-
(4-hydroxyphenyl)benzo[b]thiophen-3-yl)methanone (9.0 mg, 1 Eq, 25 µmol) (the reaction turns 
deep blood-red) and the reaction was heated to 50 °C for 5 hours. The reaction was then cooled, 
quenched with water, acidified with TFA, and purified by reverse-phase chromatography (10-
100% methanol in water + 0.1% TFA). The collected fractions were concentrated and 
lyophilized to yield (6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)(4-(3-(piperidin-1-
yl)propoxy)phenyl)methanone 2,2,2-trifluoroacetate (12.64 mg, 85%) as a yellow solid. 
1H NMR (400 MHz, Methanol-d4) δ 7.71 (d, J = 8.9 Hz, 2H), 7.41 (d, J = 8.8 Hz, 1H), 7.26 (d, J 
= 2.3 Hz, 1H), 7.18 (d, J = 8.6 Hz, 2H), 6.89 – 6.80 (m, 3H), 6.62 (d, J = 8.8 Hz, 2H), 4.09 (t, J = 
5.7 Hz, 2H), 3.60 – 3.50 (m, 2H), 3.28 – 3.19 (m, 2H), 2.92 (td, J = 12.6, 3.0 Hz, 2H), 2.19 (dq, J 
= 11.4, 5.7 Hz, 2H), 2.00 – 1.90 (m, 2H), 1.88 – 1.66 (m, 3H), 1.50 (qt, J = 12.4, 3.8 Hz, 1H). 
LCMS (ESI, +ve mode) expected m/z for C29H29NO4S [M+H]








 To a glass vial with septum was added 2-(dimethylamino)ethan-1-ol (11 mg, 5 Eq, 0.12 
mmol) and anhydrous DMF (0.5 mL). The vial was cooled in an ice-water bath and sodium 
hydride (12 mg, 12 Eq, 0.30 mmol) was added portionwise, then allowed to stir for 30 minutes 
while warming to room temperature. To the vial was then added (4-fluorophenyl)(6-hydroxy-2-
(4-hydroxyphenyl)benzo[b]thiophen-3-yl)methanone (9.0 mg, 1 Eq, 25 µmol) (the reaction turns 
deep blood-red) and the reaction was heated to 50 °C for 5 hours. The reaction was then cooled, 
quenched with water, acidified with TFA, and purified by reverse-phase chromatography (10-
100% methanol in water + 0.1% TFA). The collected fractions were concentrated and 
lyophilized to yield (4-(2-(dimethylamino)ethoxy)phenyl)(6-hydroxy-2-(4-
hydroxyphenyl)benzo[b]thiophen-3-yl)methanone 2,2,2-trifluoroacetate (9.47 mg, 70%) as a 
yellow solid. 
1H NMR (400 MHz, Methanol-d4) δ 7.74 (d, J = 8.9 Hz, 2H), 7.43 (d, J = 8.8 Hz, 1H), 7.26 (d, J 
= 2.2 Hz, 1H), 7.17 (d, J = 8.7 Hz, 2H), 6.92 (d, J = 9.0 Hz, 2H), 6.87 (dd, J = 8.8, 2.3 Hz, 1H), 
6.61 (d, J = 8.6 Hz, 2H), 4.38 – 4.31 (m, 2H), 3.60 – 3.52 (m, 2H), 2.94 (s, 6H). 
LCMS (ESI, +ve mode) expected m/z for C25H24NO4S [M+H]








 To a glass vial with septum was added 2-(piperazin-1-yl)ethan-1-ol (16 mg, 5 Eq, 0.12 
mmol) and anhydrous DMF (0.5 mL). The vial was cooled in an ice-water bath and sodium 
hydride (12 mg, 12 Eq, 0.30 mmol) was added portionwise, then allowed to stir for 30 minutes 
while warming to room temperature. To the vial was then added (4-fluorophenyl)(6-hydroxy-2-
(4-hydroxyphenyl)benzo[b]thiophen-3-yl)methanone (9.0 mg, 1 Eq, 25 µmol)  (the reaction turns 
deep blood-red) and the reaction was heated to 50 °C for 5 hours. The reaction was then cooled, 
quenched with water, acidified with TFA, and purified by reverse-phase chromatography (10-
100% methanol in water + 0.1% TFA). The collected fractions were concentrated and 
lyophilized to yield (6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)(4-(2-(piperazin-1-
yl)ethoxy)phenyl)methanone 2,2,2-trifluoroacetate (12.04 mg, 83%) as a yellow solid. 
1H NMR (400 MHz, Methanol-d4) δ 7.72 (d, J = 8.8 Hz, 2H), 7.41 (d, J = 8.8 Hz, 1H), 7.26 (d, J 
= 2.2 Hz, 1H), 7.18 (d, J = 8.6 Hz, 2H), 6.91 – 6.83 (m, 3H), 6.62 (d, J = 8.6 Hz, 2H), 4.32 – 
4.24 (m, 2H), 3.46 – 3.38 (m, 4H), 3.30 – 3.23 (m, 4H). Note: 2H under residual methanol peak. 
LCMS (ESI, +ve mode) expected m/z for C27H27N2O4S[M+H]
+ 475.17, found 475.2 and 503.15 




 To a glass vial with septum was added 2-(pyrrolidin-1-yl)ethan-1-ol (14 mg, 5 Eq, 0.12 
mmol) and anhydrous DMF. The vial was cooled in an ice-water bath and sodium hydride (12 
mg, 12 Eq, 0.30 mmol) was added portionwise, then allowed to stir for 30 minutes while 
warming to room temperature. To the vial was then added (4-fluorophenyl)(6-hydroxy-2-(4-
hydroxyphenyl)benzo[b]thiophen-3-yl)methanone (9 mg, 1 Eq, 25 µmol)  (the reaction turns 
deep blood-red) and the reaction was heated to 50 °C for 5 hours. The reaction was then cooled, 
quenched with water, acidified with TFA, and purified by reverse-phase chromatography (10-
100% methanol in water + 0.1% TFA). The collected fractions were concentrated and 
lyophilized to yield (6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)(4-(2-(pyrrolidin-1-
yl)ethoxy)phenyl)methanone 2,2,2-trifluoroacetate (7.02 mg, 50%) as a yellow solid. 
1H NMR (400 MHz, Methanol-d4) δ 7.74 (d, J = 8.9 Hz, 2H), 7.44 (d, J = 8.8 Hz, 1H), 7.26 (d, J 
= 2.2 Hz, 1H), 7.17 (d, J = 8.6 Hz, 2H), 6.92 (d, J = 8.9 Hz, 2H), 6.87 (dd, J = 8.8, 2.3 Hz, 1H), 
6.61 (d, J = 8.6 Hz, 2H), 4.37 – 4.28 (m, 2H), 3.68 (s, 2H), 3.65 – 3.58 (m, 2H), 3.23 – 3.10 (m, 
2H), 2.23 – 1.94 (m, 4H). 
LCMS (ESI, +ve mode) expected m/z for C27H26NO4S [M+H]
+ 460.16, found 460.15 
UNC7159 
  
 To a 2-dram glass vial was added (4-fluorophenyl)(6-hydroxy-2-(4-
hydroxyphenyl)benzo[b]thiophen-3-yl)methanone (8.0 mg, 1 Eq, 22 µmol), piperazine (32 mg, 
17 Eq, 0.37 mmol), and DMSO (0.25 mL). The vial was capped and heated to 120 °C for a 4 
hour period. LCMS analysis of an aliquot indicated reaction completion. The reaction mixture 
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was diluted with 0.8 mL of water and purified by reverse-phase chromatography (10-100% 
methanol in water + 0.1% TFA), concentrated, and lyophilized to yield (6-hydroxy-2-(4-
hydroxyphenyl)benzo[b]thiophen-3-yl)(4-(piperazin-1-yl)phenyl)methanone 2,2,2-
trifluoroacetate (8.78 mg, 73%) as a yellow solid. 
1H NMR (400 MHz, Methanol-d4) δ 7.66 (d, J = 9.0 Hz, 2H), 7.35 (d, J = 8.8 Hz, 1H), 7.24 (d, J 
= 2.2 Hz, 1H), 7.18 (d, J = 8.6 Hz, 2H), 6.86 (d, J = 9.1 Hz, 2H), 6.83 (dd, J = 8.8, 2.3 Hz, 1H), 
6.61 (d, J = 8.6 Hz, 2H), 3.56 – 3.51 (m, 4H), 3.29 – 3.25 (m, 4H). 
LCMS (ESI, +ve mode) expected m/z for C25H23N2O3S [M+H]
+ 431.14, found 431.15 
HRMS (ESI, +ve mode) expected m/z for C25H23N2O3S [M+H]
+ 431.14239, found 431.14176 
UNC7265 
  
 To a vial containing (6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)(4-(3-
(piperidin-1-yl)propoxy)phenyl)methanone 2,2,2-trifluoroacetate (6.0 mg, 1 Eq, 10 µmol) was 
added THF (1 mL) and cooled in an ice-water bath. LiAlH4 (4.5 mg, 12 Eq, 0.12 mmol) was 
added cautiously and the reaction was allowed to come to room temperature with stirring. When 
LCMS of a quenched aliquot indicated complete conversion, the reaction was quenched with 1 
mL saturated sodium bicarbonate followed by 4 mL of 0.5 M Rochelle salt, diluted with ethyl 
acetate, and allowed to stir until 2 phases formed. The organic layer was separated, and the 
aqueous layer extracted twice more with ethyl acetate. The combined organic layers were 
washed once more with Rochelle salt, once with water, once with brine, then dried by passage 
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through a phase separator and concentrated to a yellow residue that was used without further 
purification or characterization. 
 To the vial containing the reduction product was added DCM (0.5 mL) and triethylsilane 
(1.5 mg, 2.1 µL, 1.3 Eq, 13 µmol) and cooled in an ice-water bath under nitrogen atmosphere. To 
the stirring solution was added TFA (0.25 mL) dropwise – formation of the benzylic cation was 
characterized by a blue color, which rapidly disappeared upon silane reduction. Upon reaction 
completion as indicated by LCMS, the solvents were removed in vacuo and the residue purified 
by reverse-phase chromatography (10-100% methanol in water + 0.1% TFA), concentrated, and 
lyophilized to yield 2-(4-hydroxyphenyl)-3-(4-(3-(piperidin-1-
yl)propoxy)benzyl)benzo[b]thiophen-6-ol 2,2,2-trifluoroacetate (4.22 mg, 72% over two 
steps) as a white solid. 
1H NMR (400 MHz, Methanol-d4) δ 7.29 – 7.24 (m, 3H), 7.16 (d, J = 2.3 Hz, 1H), 7.02 (d, J = 
8.6 Hz, 2H), 6.80 (d, J = 6.2 Hz, 2H), 6.78 (d, J = 6.2 Hz, 2H), 6.74 (dd, J = 8.7, 2.3 Hz, 1H), 
4.10 (s, 2H), 4.03 (t, J = 5.7 Hz, 2H), 3.96 (s, 1H, presumably OH), 3.60 – 3.50 (m, 2H), 3.27 – 
3.21 (m, 2H), 2.92 (td, J = 12.5, 3.0 Hz, 2H), 2.16 (dq, J = 11.3, 5.6 Hz, 2H), 1.99 – 1.89 (m, 
2H), 1.88 – 1.64 (m, 3H), 1.50 (qt, J = 12.4, 3.7 Hz, 1H). 
LCMS (ESI, +ve mode) expected m/z for C29H32NO3S [M+H]
+ 474.21, found 474.20 
UNC7267 
  
 To a vial containing (4-(2-(azepan-1-yl)ethoxy)phenyl)(6-hydroxy-2-(4-
hydroxyphenyl)benzo[b]thiophen-3-yl)methanone 2,2,2-trifluoroacetate (7.0 mg, 1 Eq, 12 µmol) 
was added THF (1 mL) and cooled in an ice-water bath. LiAlH4 (4.4 mg, 10 Eq, 0.12 mmol) was 
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added cautiously and the reaction was allowed to come to room temperature with stirring. When 
LCMS of a quenched aliquot indicated complete conversion, the reaction was quenched with 1 
mL saturated sodium bicarbonate followed by 4 mL of 0.5 M Rochelle salt, diluted with ethyl 
acetate, and allowed to stir until 2 phases formed. The organic layer was separated, and the 
aqueous layer extracted twice more with ethyl acetate. The combined organic layers were 
washed once more with Rochelle salt, once with water, once with brine, then dried by passage 
through a phase separator and concentrated to a yellow residue that was used without further 
purification or characterization. 
 To the vial containing the reduction product was added DCM (0.5 mL) and triethylsilane 
(1.8 mg, 2.4 µL, 1.3 Eq, 15 µmol) and cooled in an ice-water bath under nitrogen atmosphere. To 
the stirring solution was added TFA (250 µL) dropwise – formation of the benzylic cation was 
characterized by a blue color, which rapidly disappeared upon silane reduction. Upon reaction 
completion as indicated by LCMS, the solvents were removed in vacuo and the residue purified 
by reverse-phase chromatography (10-100% methanol in water + 0.1% TFA), concentrated, and 
lyophilized to yield 3-(4-(2-(azepan-1-yl)ethoxy)benzyl)-2-(4-hydroxyphenyl)benzo[b]thiophen-
6-ol 2,2,2-trifluoroacetate (4.12 mg, 60% over two steps) as a white solid.  
1H NMR (400 MHz, Methanol-d4) δ 7.29 – 7.24 (m, 3H), 7.17 (dd, J = 2.3, 0.5 Hz, 1H), 7.05 (d, 
J = 8.7 Hz, 2H), 6.87 (d, J = 8.7 Hz, 2H), 6.78 (d, J = 8.6 Hz, 2H), 6.73 (dd, J = 8.7, 2.3 Hz, 1H), 
4.31 – 4.24 (m, 2H), 4.12 (s, 2H), 3.61 – 3.46 (m, 4H), 3.33 – 3.29 (m, 2H), 2.01 – 1.80 (m, 4H), 
1.79 – 1.65 (m, 4H).  
LCMS (ESI, +ve mode) expected m/z for C29H32NO3S [M+H]






 To a dry flask was added 6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)(4-
(piperazin-1-yl)phenyl)methanone 2,2,2-trifluoroacetate (6.0 mg, 1 Eq, 11 µmol) and 
anhydrous THF (1 mL). The flask was cooled in an ice-water bath, and LiAlH4 (17 mg, 40 Eq, 
0.44 mmol) was added cautiously. The flask was then brought to room temperature, a water-
cooled condenser attached, and the reaction was heated at reflux under nitrogen atmosphere for 8 
hours. LC-MS analysis of a quenched aliquot indicated complete conversion to the alcohol. The 
reaction was cooled and quenched with 1 mL of saturated sodium bicarbonate followed by 4 mL 
of 0.5 M Rochelle salt and 5 mL of ethyl acetate and allowed to stir for 1 hour to achieve layer 
separation. The layers were separated, and the aqueous layer extracted a further 4 times with 
ethyl acetate. The combined organic layers were washed once more with Rochelle salt, once with 
water, and once with brine, then dried by filtration through a phase separator and concentrated to 
a yellowish residue that was used without further purification or characterization. 
 To a pear-shaped flask was added (6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-
yl)(4-(piperazin-1-yl)phenyl)methanone 2,2,2-trifluoroacetate (6.0 mg, 1 Eq, 11 µmol) in ethyl 
acetate, which was removed in vacuo to concentrate the starting material at the bottom of the 
flask (the starting alcohol does not dissolve in DCM). To the flask was added DCM (1 mL) and 
triethylsilane (32 mg, 44 µL, 25 Eq, 0.28 mmol), and the flask was cooled in an ice-water bath 
under nitrogen. To the stirring suspension was added TFA (500 µL) dropwise, taking care to 
wash down all sides of the flask, and upon complete addition the flask was swirled to solubilize 
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any leftover starting material. The cationic intermediate produced on TFA exposure is a deep, 
vivid blue, and silane reduction results in a pale peach color. The flask was left to stir for 4 hours 
with monitoring by LCMS. Upon reaction completion, the reaction was diluted with DCM, then 
concentrated on the rotary evaporator to a yellow-grey residue. Purification by reverse-phase 
chromatography (10-100% methanol in water + 0.1% TFA), concentration, and lyophilization 
yielded 2-(4-hydroxyphenyl)-3-(4-(piperazin-1-yl)benzyl)benzo[b]thiophen-6-ol 2,2,2-
trifluoroacetate (2.09 mg, 36% over two steps) as an off-white solid. 
1H NMR (400 MHz, Methanol-d4) δ 7.29 – 7.24 (m, 3H), 7.17 (d, J = 2.2 Hz, 1H), 7.03 (d, J = 
8.5 Hz, 2H), 6.89 (d, J = 8.7 Hz, 2H), 6.78 (d, J = 8.7 Hz, 2H), 6.74 (dd, J = 8.7, 2.3 Hz, 1H), 
4.10 (s, 2H). Note: piperazine protons do not appear. 
LCMS (ESI, +ve mode) expected m/z for C25H25N2O2S [M+H]











APPENDIX B: SULFATASE MULTIPLE SEQUENCE ALIGNMENT 
 
Loops 2 and 3 are annotated in red and blue, respectively. Residues used to generate rubric are in bolded purple. 
Conserved active site residues are boxed.  Secondary structural elements conserved between the enzymes are indicated 









































1auk    1  -------------------------------RPPNIVLIFADDLGYGDLGCY-------GHPSSTTPNLD   32 
1hdh    1  -------------------------------KRPNFLVIVADDLGFSDIGAF-------GG-EIATPNLD   31 
3ed4    1  --------------------------------QPNLVIIMADDLGYGDLATY-------GHQIVKTPNID   31 
6bia    1  -------------------------------QKPNIILIVADDLGYADVGFN-------GSKDIITPNID   32 
6USS    1  MNKKLIIPFALAPLAAPALQAQSQQSDGRMDTRPNIILFMVDDMGWQDTSLPFWTQKTHYNEVYETPNME   70 
4ug4    1  -------------------------GDPVTTGKPNILIIMVDQLNGKLFPDG-------PADFLHAPNLK   38 
5g2t    1  ----------------------------RQQEKPNFLIIQCDHLTQRVVGAY-------GQTQGCTLPID   35 
5g2v    1  -------------------------------KRPNIIFMMTDDHTTQAMSCY-------GGNLIQTPNMD   32 
6UST    1  -----------------------------MAVQPNFLFIFMDDMGWRDLACT-------GSTFYETPNID   34 
6hr5    1  -------------------------------EKPNIIFILTDDQRFDAIGYA-------GNKFVNTPEMD   32 
4upl    1  ------------------------------TAVMNILFIMFDQLRWDYLSCY-------GHKTLNTPHID   33 
4upi    1  --------------------------------NRNILWIMCDQLRFDYLSCY-------GHERLNTPNID   31 
2qzu    1  -----------------------GLQAQEKQPTPNLVFIMADQYRGDAIGCI-------GKEPVKTPHLD   40 
6j66    1  -------------------------------KKPNLLIVFPDEMRAHTLGFM-------NQDRSYTPNLN   32 
6hhm    1  -------------------------------SQPNVLVFYVDDLRA-ELGCY-------GSKTAITPNID   31 
AA:          ...............................PN......D.......................TP... 
SS:                                           eeeeee                           hh 
 
 
1auk   33  QLAAGGLRFTDFYVPVSL-XTPSRAALLTGRLPVRMGMYPGVLVPS------------------------   77 
1hdh   32  ALAIAGLRLTDFHTAST--XSPTRSMLLTGTDHHIAGIGTMAEALTP---------------ELEGKPG-   83 
3ed4   32  RLAQEGVKFTDYYAPAPL-SSPSRAGLLTGRMPFRTGIRSWIPSG-------------------------   75 
6bia   33  DLAKSGTSFSDAYVAHPF-CGPSRAALMTGRYPHKIGSQFNLPTRG------------------------   77 
6USS   71  RLAKQGVMFTQAYASSI--SSPTRCSLITGTNAARHRVTNWTYPKGQQTDRPSDVFNVADWNVNGVCQV-  137 
4ug4   39  ALAKRSARFHNNYTSSPL-CAPARASFMAGQLPSRTRVYDNA----------------------------   79 
5g2t   36  EVASRGVIFSNAYVGCPL-SQPSRAALWSGMMPHQTNVRSNSSEP-------------------------   79 
5g2v   33  RIANEGIRFDNCYAVNAL-SGPSRACILTGKFSHENGFTDNA----------------------------   73 
6UST   35  RLCRQGMVFANSYASCPV-CSPSRASYLTGQYPARLGVTDWIDMEGTSH----------PLRGKLIDAP-   92 
6hr5   33  KLAQQGTYFDHAIVTTPI-CAASRASLWTGLHERSHNFNFT-----------------------------   72 
4upl   34  RLAAKGVRFDRAYIQSPI-CGSSRMSTYTGRYVHSHGASWNG----------------------------   74 
4upi   32  KLAKRGVRFTNAYVQATVXCGPSRMSAYTGRYVRSHGSTQNG----------------------------   73 
2qzu   41  KLASEGINFTNAISSYPV-SSPARGMLMTGMYPIGSKVTGNCNS---------------------ETAP-   87 
6j66   33  KFAKESAVLKQAVSNFPL-XTPFRGMLMTGQYPYRNGIQGNSHT---------------------AMPGN   80 
6hhm   32  KLATEGVQFNKAYVQQAI-CAPSRMSTLTGLRPETLGIYSIFT---------------------------   73 
AA:        ..A..G..F............P.R....TG........................................ 
SS:        hhhh   eeeeeee      hhhhhhhhh                                          
 
β1 αA 








1auk   78  -----SRGGLPL--EEVTVAEVLAARGYLTGMAGKWHLGVGPEG----------------------AFLP  118 
1hdh   84  -----YEGHLNE--RVVALPELLREAGYQTLMAGKWHLGLKP------------------------EQTP  122 
3ed4   76  -----KDVALGR--NELTIANLLKAQGYDTAMMGKLHLNAGGDRTD--------------------QPQA  118 
6bia   78  -----SNVGVPT--DAKFISKLLNENNYFTGALGKWHMGDTP------------------------QHHP  116 
6USS  138  -----PNIDHTF--QATSLAEILKDNGYHTIHCGKAHFGAVNTP----------------------GESP  178 
4ug4   80  -------AEYQS--SIPTYAHHLRRAGYYTALSGKMHFVGP--------------------------DQL  114 
5g2t   80  ------VNTRLP-ENVPTLGSLFSESGYEAVHFGKTHDM----------------------------GSL  114 
5g2v   74  -------STFNG--DQQTFPKLLQQAGYQTAMIGKWHLISEP----------------------------  106 
6UST   93  -----YIKHLPE--GEYTIAQALKDAGYETWHVGKWHLGGRE-------------------------YYP  130 
6hr5   73  -------GNVREEYMNNAYPKLLKNNGYYTGFYGKYGVRYDNLE--------------------------  109 
4upl   75  -------IPLKV--GEMTMGDHLRAAGMGCWLVGKTHMRADEEG------------MARLGLEPDSLIGA  123 
4upi   74  -------IPLRV--GEPTLGDHLRDVGMRNVLIGKTHMRPDLDG------------MKRLGIDPDSEIGA  122 
2qzu   88  -----YGVELSQ--NARCWSDVLKDQGYNMGYIGKWHLDAPYKPYVDTYN-NRGKVAWNEW-----CPPE  144 
6j66   81  FGGKDFGIELKK--STRTWSDILKDQGYSMGYIGKWHLDTPEAPFIPSYNNPMEGRYWNDW-----TAPD  143 
6hhm   74  -----PLRSVHK--DVVSVPQLFKENGYKTVSIGKVYHHGTD----------------------------  108 
AA:        ......................L...GY.....GK.H................................. 
SS:                          hhhhhhh   eeeeee                                     
 
                                                            
 
1auk  119  --PHQGF-HRFLGIPYS----------HDQG----PCQNLTCFP---------------PATPCDGGCDQ  156 
1hdh  123  --HARGF-ERSFSLLPG----------AANH----YGFEPPYDE---------------STPR-----IL  155 
3ed4  119  --QDMGF-DYSLANTAG----------FVTD----ATLDNAKER---------------PRYG-------  149 
6bia  117  --NKRGF-DEYYGFLGG----------GHNYFPDQYQPQYKKQKAQ-------------GLKN------I  154 
6USS  179  --YHMGF-EVNIAGHAG----------GGLA----SYLGENNYG---------------NRTD-------  209 
4ug4  115  ----HGFEERLTTDIY-----------PADF----GWTPDYRKPGERIDWWYHNLGSVTGAGV------A  159 
5g2t  115  ----RGF-KHKEPVAKP----------FT------------------------------DPEF-------  132 
5g2v  107  ----QGF-DHWSILSGQ--------HEQGDY---------------------------------------  124 
6UST  131  ----DHF-GFDVNIGGC--------SWGHPH--------------------------------------E  149 
6hr5  110  --------SQFDEFESY----------NNRY---------------------------------------  122 
4upl  124  RVAECGF-DVFERDDGMLPEGPDGYYDPDG----------------------------------------  152 
4upi  123  RVGEGGF-DAFDRDDGVH------PTGYRKKEPA-----YNDYLRHAGFQAENPWEFWANSAEGKGGENQ  180 
2qzu  145  --RRHGF-DHWIAYGT-----------YDYHLK-------------------------------------  163 
6j66  144  --RRHGF-DFWYAYGT-----------YDKHLT-------------------------------------  162 
6hhm  109  --DKNQW-TNYFTKE------------PNTYNKPENIALLEQFK--------------------------  137 
AA:        .....GF............................................................... 










1auk   157  GLVPIPLL----------------------------------ANL----SVEAQPPWLPGLEARYMAFAH  188 
1hdh   156  KGTPALYV----------------------------------EDE----RYLDTLPEGFYSSDAFGDKLL  187 
3ed4   150  MVYPTGWL----------------------------------RNG----QPTP--RADKMSGEYVSSEVV  179 
6bia   155  FEYITPLE----------------------------------HNG----KEVK---ETQYITDALSREAV  183 
6USS   210  -GKPNPWF----------------------------------AVP----GLDKYWGTDTFVSEALTLEAI  240 
4ug4   160  EITN-----------------------------------------------------QMEYDDEVAFLAN  176 
5g2t   133  PVNN-----------------------------------------------------DSFLDVGTCEDAV  149 
5g2v   125  --YDPDFW----------------------------------EDG----KHIV---EKGYATDIITDKAI  151 
6UST   150  GYFSPYGI----------------------------------ETL----PEGP---EGEYLTDRITDEAV  178 
6hr5   123  --KDKRGY----------------------------------YYK----TINN---DTVHLTRYTGQQAI  149 
4upl   153  ----AKEYNKFLRAKGYESDNPWHDFANSGLDDEGNVQSGWFLKNATRPANIA---EEDSETPYLTSRAM  215 
4upi   181  SGWLLTHA----------------------------------DKP----ARVP---EEHSETAYMTRRAM  209 
2qzu   164  ----PMYW----------------------------------NTTAPRDSFYY---VNQWGPEYEASKAI  192 
6j66   163  ----PIYW----------------------------------TNETPRDQPIK---VNQWSPEHEADIAI  191 
6hhm   138  --KEGKKA----------------------------------NGPAFENADVA---DEAYKDGRAAKYAV  168 
AA:         ....................................................................A. 
SS:                                                                      hhhhhhhhh 
        
       
1auk   189  DLMADAQRQ-----DRPFFLYYASHHTHYPQ-FSGQSF--------------------------------  220 
1hdh   188  QYLKERDQ------SRPFFAYLPFSAPHWPL-QAPREI-----VEKYRGRYD--AGP-EALRQERLARLK  242 
3ed4   180  NWLDNKKD------SKPFFLYVAFTEVHSPL-ASPKKY-----LDMYSQYMS--AYQ-------------  222 
6bia   184  NFVDKAVNK-----KHPFFLYLAYNAPHTPL-QAKDED-----MAMFPNIKN------------------  224 
6USS   241  KALNHAKEY-----NQPFFLYMAHYAIHVPI-DKDKRF-----YQKYIDK--------------------  279 
4ug4   177  QKLYQLSRENDDESRRPWCLTVSFTHPHDPY-VARRKF-----WDLYEDCEH--LTP-EVGAI------P  231 
5g2t   150  AYLSNPP-------KEPFICIADFQNPHNICGFIGENAGVHTDRPISGPLP---ELP-DNFDV-----ED  203 
5g2v   152  NFLENRDK------NKPFCMMYHQKAPHRNW-MPAPRH-----LGIFNNTIF--PEP-ANLFD------D  200 
6UST   179  RLLKERKAGG---SRKPFYMNLCHYAVHTPI-QVKDED-----RERFEKKAR--EQG-LDQET-------  229 
6hr5   150  DFIDKNATN-----TQPFMLSLSFSAPHAEK---------------------------------------  175 
4upl   216  EFIEQQ--------TGPWCCHLSYIKPHWPY-IVPEPY-----ASMFGPEHV--QDV-VRSDS------E  262 
4upi   210  EFMEAA-EKD----GRPWCAHLSYIKPHWPY-IVPAPY-----HDMFGPDDV--KPA-VRSDE------E  259 
2qzu   193  EYINGQKDQ-----KQPFALVVSMNPPHTGYELVPDRY-----KEIYKDLDVEALCKGRPDI--------  244 
6j66   192  KYLRNENGHYR-DRDKPFTLVVSMNPPHSPYDQVPQKY-----LDKFDGETSRSLNT-RPNV--------  246 
6hhm   169  ETLKKLK-------NDKFIMFVGFSKPHLPF-NAPKKY-----WDLYDKNNFEI----PERK-------K  214 
AA:         ................PF.........H.......................................... 












1auk        ----------------------------------------------------------------------      
1hdh   243  ELGLVEADVEAHPVLALTREWEALEDEER-----------------------------------------  271 
3ed4   223  -----------------KQHPDLFYGDWA-----------------------------------------  234 
6bia        ----------------------------------------------------------------------      
6USS        ----------------------------------------------------------------------      
4ug4   232  LDEQDP-----HSQRIMLSCDY-----QNF----------------------------------------  251 
5g2t   204  WSNIPT-----PVQYICCSHR---RMTQAA----------------------------------------  225 
5g2v   201  YEGRGK-----AAREQDMSIE-----HTLTNDWDLKLLTREEMLKDTTNRLYSVYKRMPSEVQDKWDSAY  260 
6UST   230  ----------------ALVEGEFHHTEDKK----------------------------------------  243 
6hr5        ----------------------------------------------------------------------      
4upl        RQNAHP-----LFKAFMDTKVG----EAF-----------------------------------------  282 
4upi   260  LKAAHP-----LFKAMTEEVYS----RNF-----------------------------------------  279 
2qzu   245  --------------------------PAKG----------------------------------------  248 
6j66   247  --------------------------QWDQ----------------------------------------  250 
6hhm   215  PENMYR-----LAL-TNW-GELKGYHGIPND---------------------------------------  238 
AA:         ...................................................................... 
SS:                                                                                 
 
 
1auk   221  --------------------AERSGRGPFGDSLMELDAAVGTLMTAIGDLGLLEETLVIFTADNGPETM-  269 
1hdh   272  -------------------AKSARAMEVYAAMVERMDWNIGRVVDYLRRQGELDNTFVLFMSDNGAEGA-  321 
3ed4   235  -------------------DKPWRGVGEYYANISYLDAQVGKVLDKIKAMGEEDNTIVIFTSDNGPVTRE  285 
6bia   225  -----------------------KDRKTYAGMVYAVDRGVGKLVEALKKNNQYDNTLIVFMSDNGGKLSK  271 
6USS   280  --------------------GLTPKEAAYAALIEGMDKSLGDLMDWLDKNGEADNTIVIFMSDNGGLSS-  328 
4ug4   252  ---------------DVTEENVRRSRRAYFANISYLDEKVGELIDTLTRTRMLDDTLILFCSDHGDMLGE  306 
5g2t   226  ---------------HWNEENYRHYIAAFQHYTKMVSKQVDSVLKALYSTPAGRNTIVVIMADHGDGMAS  280 
5g2v   261  AQRIAEYRKGDLKGKALISWKYQQYMRDYLATVLAVDENIGRLLNYLEKIGELDNTIIVYTSDQGFFLGE  330 
6UST   244  --------------GRRVVRRVIQSDPSYAGMIWNLDQNIGRLLEALSECGEEENTVVVFTSDNGGLATS  299 
6hr5   176  ---------------------YQHSLKGYYRMISGIDLEIKKIRDKLKEKGVDKNTVIIVMGDNGYFLGE  224 
4upl   283  ----------------SRQEVRDAVIPAYMGLIKQADDQMGRLFKWLEDTGRMQDTMIVLTSDHGDFLGD  336 
4upi   280  ----------------ARDEVREKVIPAYMGLIKQIDDQLGQLFAFMQERGLDENTMIVFTADHGDYLGD  333 
2qzu   249  ---------------TEMGDYFRNNIRNYYACITGVDENVGRIIEALKQNNLFDNTIVVFTSDHGICMGA  303 
6j66   251  ---------------EYLEGYGPEYFKEYMAMVHGVDDQFGRIIDELDRLGLTEDTLVVFFSDHGCCMGS  305 
6hhm   239  ------------VEY-LDDNLTRDLIHGYHASISYVDAQVGKVMEALEALGLRKNTTVIFMSDHGYKIGE  295 
AA:         ............................Y.......D...G.....L........T......D.G..... 










1auk   270  -----RMSRG-------------------------------------GCSGLLRCGKG-TTYEGGVREPA  296 
1hdh   322  -----LLEAFPKFGPDLLGFLDRHYDNSLENIGRANSYVWYGPRWAQAATAPSRLYKA-FTTQGGIRVPA  385 
3ed4   286  ARKVYELNLA-------------------------------------GETDGLRGRKD-NLWEGGIRVPA  317 
6bia   272  G----------------------------------------------ANNFPLKAGKG-STQEGGFRVPM  294 
6USS   329  -----EPGWRD--------------------------------GKLHTQNSPLNSGKG-SAYEGGVREPM  360 
4ug4   307  R---------------------------------------------------GLWFKM-NFFEGSARVPL  324 
5g2t   281  H---------------------------------------------------RMVTKHISFYDEMTNVPF  299 
5g2v   331  H---------------------------------------------------GWFDKR-FMYEECQRMPL  348 
6UST   300  E-------------------------------------------GSPTCNLPASEGKG-WVYEGGTRVPL  325 
6hr5   225  R---------------------------------------------------QLAGKW-LMYDNSIRVPL  242 
4upl   337  H---------------------------------------------------WMGEKT-FFHDASTRVPL  354 
4upi   334  H---------------------------------------------------WMGEKY-LFYEAAAKVPL  351 
2qzu   304  H---------------------------------------------------ENAGKD-IFYEESMRIPM  321 
6j66   306  N---------------------------------------------------GKPTKN-VHYEEAMRIPM  323 
6hhm   296  Y---------------------------------------------------GAWCKH-SNEEIDVRVPL  313 
AA:         ........................................................K.........R.P. 




1auk   297  LAFW-PGH----IAPGVTH-ELASS-LDLLPTLAALAGAP--LPN---------VTLDGFDLSPLL-LGT  347 
1hdh   386  LVRY-PRL---SRQGAISH-AFATV-MDVTPTLLDLAGVR--HP-GKRWRGREIAEPRGRSWLGWL-SGE  445 
3ed4   318  IIKY-GKH---LPQGMVSD-TPVYG-LDWMPTLAKMMNFK--LPTD--------RTFDGESLVPVL-EQK  370 
6bia   295  LFHW-PKH---VPAGKRFS-HPVSA-LDLYPTFAALAGAK--VEEN--------QHLDGTNMWPAF-IKN  347 
6USS   361  IVRW-PGV---VKPDTKCD-KYLII-EDFYPSILEMAQVK--HYKT-------VQPIDGISFIPLL-KQT  414 
4ug4   325  MIAG-PGI---APG--LHL-TPTSN-LDVTPTLADLAGISLEEVR---------PWTDGVSLVPMV-NGV  376 
5g2t   300  IFAG-PGI---KQQKKPVDHLLTQPTLDLLPTLCDLAGIA--VPA----------EKAGISLAPTLRGEK  353 
5g2v   349  IIRY-PKA---IKAGSTSS-AISMN-VDFAPTFLDFAGVE--VP----------SDIQGASLKPVL-ENE  399 
6UST   326  IVKY-PGH---VAPGSRCD-VPVTT-PDFYPTFLELAGVP--QKSG--------IPIDGRSIVPLL-AGN  378 
6hr5   243  IVFD-PRV---NKHQDISE--MVLN-IDVTQTIADLAGVK--AP----------ESWQGKSLLPLV-KQE  292 
4upl   355  IIYD-PRPEADATRGSVCD-ALVES-IDLAPTFVEAAGGK--PAM---------HILEGESLIPIL-HGA  409 
4upi   352  IIYD-PSDKADATRGTVSD-ALVEM-IDLAPTFVDYAGGV--PPM---------HILEGKSLLPLL-HDD  406 
2qzu   322  ILSW-PDQ---IKPRKSDP-LMIAF-ADLYPTLLSMMGFSKEIP----------ETVQTFDLSNEV-LTG  374 
6j66   324  MFRW-PGK---LTP-RQDD-LLFSA-PDIYPTLFGLMGLEELIP----------DTVEGTNFAKTV-SGI  375 
6hhm   314  IVSRETSYK-GRVAGKTSD-ALVEN-VDIFPTLVELCGLE--GP-----------KTDGKSILQVI-DRP  366 
AA:         .....P.....................D..PT.....G....................G........... 
SS:         eee             ee    ee  hhhhhhhhhh                          hhhh     
αF αG 
β6 








1auk   348  GKS---PRQSLFFYPSYPDE-----------VRGVFAVRTGKYKAHFFTQGSAHSDTTADPACHASSSLT  403 
1hdh   446  TEA---AHDENTVTGWE--------------LFGMRAIRQGDWKAVYLPA------------------PV  480 
3ed4   371  ALK---REKPLIFGIDMPFQDD---------PTDEWAIRDGDWKMIIDRNN-------------------  409 
6bia   348  ENP--HKDEPIYALRHRKG-------------YSDAAIRMNQWKALKVNQ--------------------  382 
6USS   415  GDP---SKGRSLYWNFPNHWGNDG-----PGIGPTCTVRKGDWKLIYYYEN-------------------  457 
4ug4   377  ER-----TEPVLMEYAAEAS-----------YAPLVAIREGKWKYVYCAL--------------------  410 
5g2t   354  QKK---SHPYVVSEWHSEYEYV---------TTPGRMVRGPRYKYTHYLEG-------------------  392 
5g2v   400  GKTPADWRKAAYYHYYEYPAEHS--------VKRHYGIRTQDFKLIHFYND-------------------  442 
6UST   379  HMPERPVFWHYPH-----YGNQG--------GTPAASVVLGDYKYIEFFED-------------------  416 
6hr5   293  TSTI-SRDTILIEHLWDFEN-----------IPPSEGVRTEEWKYFRYVND-------------------  331 
4upl   410  RDHT--LRDHVICEYDFSASPIAHLNDISVRQAVMFMVADKNWKLIHFEAD-------------------  458 
4upi   407  DSSW--DRQYVFSELDYSNLPARLKLGRDIQDCRATMVFDGRYKLVEVMG--------------------  454 
2qzu   375  KNK---KDLVQPYYFVKFDNH----------ATGYRGLRTDRYTYAVHAT-----------------DGK  414 
6j66   376  EGD---TRPTSQLYTFMPYGGQ---------SYGRRGVRTDRYTLMIDRK-----------------IAK  416 
6hhm   367  NTP---WDQVATAVYARGK------------NIMGCTATDGEWRYTEWRD----------------AKTQ  405 
AA:         ...................................................................... 




1auk   404  AHEPPLLYDLSKDPGENYNLLG--ATPEVLQALKQLQL-LKAQLDAAVTF--------GPSQV-------  455 
1hdh   481  GPATWQLYDLARDPGEIHDLAD--SQPGKLAELIEH---WKRYVSE-TGVV-------------------  525 
3ed4   410  --KPKYLYNLKSDRYETLNLIGK-----KPDIEKQMYG-KFLKYKTDIDNDSLMKARGDKPEA-------  464 
6bia   383  --QPWQLFNIENDISEKHDVSKS-----NKALLTDMVR-EMEKWSW-DNQ---------QPSW------F  428 
6USS   458  --GKKELFNIPQDIGEKNNLAAQ-----HPDIVKHLSK-DLGNYLRKVGGQRP---SFKATGK-------  509 
4ug4   411  --DPEQLFDLEADPLELTNLAENPRGPVDQATLTAFRD-MRAAH-----WDM------EAFDAAVRESQA  466 
5g2t   393  --NGEELYDMKKDPGERKNLAKDPKYSKILAEHRALLD-DYITR---SKDDY-------RSLK-VDADPR  448 
5g2v   443  -IDEWEMYDMKADPREMNNIFGKAE---YAKKQKELMQ-LLEETQKQYKDND-------PDEKE------  494 
6UST   417  --GRGELYDLKADFSETNNICEN-----MPEMAARLRM-LLHGWQREVCARF-------PEVN-EAYGEV  470 
6hr5   332  -KTIEELYNIKKDPKEINNLIGKKK---YQNVAKALRE-KLDELIAKNSD--------------------  376 
4upl   459  --PRPMLFDLKNDPQELVDLGGDPA---HADVIAGMYD-KLFRWTRRQSQRT-------TRSE-EQLIAM  514 
4upi   455  --FAPILFDLEVDPDELKDLGRDPS---AEEVRQRLTS-ALDAWHRNTRQRI-------TKSD-AAYRAL  510 
2qzu   415  I-DNVILFDRTNDPHEMNNIASQ-----QLKLTHTFNR-QLKTWLEKTNDPF-------AQYIKL-----  465 
6j66   417  P-LTFVLHDNQNDPYQMTNIAND-----NQELIAQLIEKELIPWLELTGDPW-------RPTE-------  466 
6hhm   406  DILGAELYEHKNSLLSFKNLSGNTK---YKKEEARMKG-LLETQFPRNQGPF-------LQHDTP-----  459 
AA:         ......L.....D..E...................................................... 
SS:               eee                   hhhhhhhhhh hhhhhhhhh                       
αH 










1auk   456  -ARG---------------------EDPALQICCHPGC---------TPRPACCHCP  481 
1hdh        ---------------------------------------------------------      
3ed4   465  -VTWG----------------------------------------------------  468 
6bia   429  HETT--EGVNWRL-----------DAMPRFDKTFKT---------------------  451 
6USS   510  PCPWP------------------DEIK------------------------------  518 
4ug4   467  RRWV--VYEALRNGA-YYPWD----HQPLQKASERYMRNHMNLDTLEESKRYPRGE-  515 
5g2t   449  CR--------------NHTPGYPSHEGPGAREI------------------------  467 
5g2v        ---------------------------------------------------------      
6UST        ---------------------------------------------------------      
6hr5        ---------------------------------------------------------      
4upl   515  ------RTKSRKRGIVLGIYD----ENETPLELTVKYRDRKARPYKDYLKG------  555 
4upi   511  DPVLRESDPDLMAGVIIGYWD----EDEVEAEKRRIAR---------ILGEN-----  549 
2qzu        ---------------------------------------------------------      
6j66   467  ----------VPASV-AKAY-------------------------------------  475 
6hhm        ---------------------------------------------------------      
AA:         ......................................................... 
SS:                                                                    
 
 
 
